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In primary human monocyte-derived macrophages (MDM), HIV assembles on complex 
intracellular plasma membrane-connected compartments (IPMCs). Currently, it is 
unclear whether, in addition to assembly at IPMCs, HIV uses the cell surface of MDM, 
as viruses that bud at the cell surface may dissociate and be lost from the samples. As 
the endosomal sorting complex required for transport (ESCRT) machinery is required 
for the final scission events that release assembled virus from the plasma membrane, 
this question was addressed by depleting the ESCRT components Tsg101 and ALIX, or 
generating mutant HIV-1 strains defective in recruiting the ESCRT machinery, to arrest 
HIV budding and visualise all budding events. 
 
Using siRNA, ALIX and Tsg101 were depleted efficiently in MDM. Although the 
effects on virus release were minimal, Tsg101 had a greater effect than ALIX for HIV 
release in MDM. In the second approach, I generated mutants (HIV-1 PTAP−, YP−, 
PTAP−YP−, Δp6) defective in recruiting the ESCRT machinery, by mutating the 
sequences that bind Tsg101 and ALIX. The mutants were characterised on HEK 293T 
cells, and the release of PTAP−, PTAP−YP− and Δp6 was inhibited. Analysis by electron 
microscopy (EM) showed that the mutants indeed produced arrested viruses. As the 
mutants are defective in release, I developed a method to rescue HIV-1 PTAP− and 
PTAP−YP− viruses for infecting MDM. The cells were infected with the rescued 
mutants, and analysed using immunofluorescence and EM. By confocal microscopy, 
77% of the cells had viruses in the IPMCs. Using EM, immature viruses were found 
predominantly (97%) in the IPMCs. Estimates of membrane area revealed enrichment 
of HIV in the IPMCs. 
 
This study provides the first conclusive evidence that HIV is targeted to IPMCs in 
MDM. This may shield the virus from immune surveillance during virus assembly, with 
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1. General Introduction 
 
The Human Immunodeficiency Virus (HIV) is the causative agent of acquired 
immunodeficiency syndrome (AIDS), and T cells and macrophages are the main target 
cells for HIV infection in vivo. Although both cell types are infected in vivo, infection 
manifests significant differences in each cell type, and the relative contribution of each 
to pathogenesis remains unclear. One of the main differences is that macrophages can 
live for weeks, if not months, following infection (Watters et al., 2013). By contrast, 
productively infected T cells usually die within 48 hrs (Perelson et al., 1996). This had 
given rise to the view that macrophages may serve as viral reservoirs, a property that 
may be linked to the observation that HIV assembles on intracellular membranes in 
macrophages, but at the cell surface in T cells. The idea of HIV assembling in 
intracellular structures in macrophages has been evolving for more than two decades. 
Initially, the structures were thought to be part of the Golgi apparatus (Orenstein et al., 
1988), and later considered to be late endosomes (Raposo et al., 2002; Pelchen-
Matthews et al., 2003). The current view is that these structures are internally 
sequestered plasma membrane (PM) compartments that maintain contact with the cell 
surface (Deneka et al., 2007; Welsch et al., 2007; Bennett et al., 2009; Welsch et al., 
2011; Koppensteiner et al., 2012b; Pelchen-Matthews et al., 2012). However, it remains 
unclear whether HIV also buds at the cell surface, as any viruses budding at the cell 
surface would dissociate from cells and be lost from samples. To address this question, I 
established a system to arrest virus assembly during the budding process so that all 
budding events could be visualised. I then carried out detailed light and electron 
microscopy analyses to determine where HIV assembly occurs in infected macrophages.  
 
This chapter gives an overview of HIV/AIDS, currently one of the major global health 
issues, especially in developing countries, and particularly in Africa. The biology of 
HIV is reviewed in the context of its structure and the replication cycle. I have 
described in detail the cell machinery that HIV exploits to dissociate from host cells, the 
endosomal sorting complex required for transport (ESCRT), as this was the main tool 
used in this thesis to study HIV assembly in macrophages. An overview of the main 
target cells for HIV is given, with a detailed description of the compartments where 
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HIV assembles in macrophages. Finally, I describe the general pathogenesis of HIV in 
infected individuals.   
 
 HIV epidemiology  1.1
Globally, the number of people living with HIV was about 35.3 million in 2012, with an 
estimated 2.3 million new infections, showing a 33% decline in incidence from 2001 
(UNAIDS, November 2013). Sub-Saharan Africa is the epicentre of the HIV pandemic 
(Figure 1.1) (UNAIDS, 2014). In 2009, the region accounted for 68% of new infections, 
and 72% (1.3 million) of mortality from AIDS (UNAIDS, December 2010). Although 
southern Africa has only 2% of the world’s population, the sub-region has one-third of 
the global HIV infections (Novitsky and Essex, 2012), which has significantly lowered 
the life expectancy in the sub-region. Some countries in southern Africa have recorded 
very high HIV prevalence amongst pregnant women. For instance, in my home country 
Botswana, HIV prevalence amongst pregnant women was hovering around 33% 
between 2005 and 2009 (NACA, 2010).  
 
 
Figure 1.1: Global adult HIV prevalence in 2013.  
Taken from Kaiser Family Foundation, based on UNAIDS, The Gap Report, 2014. 
 
Unprotected heterosexual transmission is responsible for the majority of HIV cases, 
especially in sub-Saharan Africa. In Europe and America, the main route of 
transmission is unprotected homosexual sex between men, and needle sharing between 
intravenous drug users. In the absence of anti-retroviral therapy (ART), vertical 
transmission can also occur from infected mother to the unborn child, and during 
1"5%%(29%countries)%<1%%(75%countries)% 5"10%%(3%countries)% >10%%(9%countries)%NA%
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delivery or breast-feeding. High viral load in body fluids, as well as sexually 
transmitted diseases, increase the risk of HIV transmission (Maartens et al., 2014). 
 
 The origin and phylogenetic classification of HIV 1.2
HIV is a retrovirus that belongs to the Lentivirus genus. Its genome is composed of two 
copies of single-stranded RNA. During replication, a retroviral genome is reverse 
transcribed by the viral enzyme, reverse transcriptase (RT), to a double-stranded DNA, 
hence the family name Retroviridae. Currently, there are two types of HIVs: HIV-1 and 
HIV-2. These exhibit distinct biologic and epidemiologic attributes. HIV-1 has 
worldwide distributions whilst HIV-2 is mainly confined to West Africa (Gilbert et al., 
2003). The two types are believed to have entered the human host independently from 
different primate sources (Figure 1.2). Phylogenetic analysis has shown that HIV-1 is 
closely related to simian immunodeficiency viruses (SIVs) from chimpanzee (SIVcpz) 
and gorilla (SIVgor), whilst HIV-2 is related to SIV from sooty mangabeys (SIVsm) 
(Heeney et al., 2006; Hemelaar et al., 2011; Tebit and Arts, 2011; Peeters et al., 2014).  
 
Four classes of HIV-1 are recognised, namely M (major), O (outlying), N (new) and P, 
indicative of viruses having crossed into humans independently at least four times 
(Figure 1.2) (Renjifo and Essex, 2002; Ndung'u and Weiss, 2012; Peeters et al., 2014). 
HIV-2 on the other hand, crossed into humans at least nine times (Peeters et al., 2014). 
The HIV-1 M class is further sub-classified into nine major clades or subtypes: A-D, F-
H, J and K; plus viruses derived from the recombination of different clades, to generate 
what are known as circulating recombinant forms (CRFs) such as AE and AG, as well 
as the unique recombinant forms (URFs). A URF is found in only one individual, and 
becomes a CRF when it is transmitted to numerous people. CRFs are continually 
increasing as HIVs recombine and diversify. As of 2013, 58 CRFs and several URFs 
had been reported worldwide and they are responsible for 20% of all HIV infections 
globally (Lau and Wong, 2013). More than 90% of HIV-1 infections in the world are 
attributed to class M, with HIV-1C being the most predominant subtype, accounting for 
50% or more of all infections, particularly in Southern Africa, South America and India 
(Hemelaar et al., 2011; Lau and Wong, 2013). Classification of subtypes is based to a 
large extent on the 20-50% difference between envelope (env) nucleotide sequences 
(Wainberg, 2004). The high degree of HIV-1 diversity is partially linked to the lack of a 
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proofreading mechanism by the RT of the virus, which contributes to viral evolution. 
However, nucleotide sequences that code for inflexible core proteins, such as Gag, are 




Figure 1.2: Phylogenetic relationships of SIVs to HIVs. 
SIVs (SIVcpz, SIVgor, and SIVsm) crossed species from chimpanzees (cpz), gorillas (gor) and 
sooty mangabeys (sm) into the human population. Adapted from Tebit and Arts (2011).  
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 HIV-1 structure 1.3
HIV-1 is a double stranded RNA enveloped virus, with a genome composed of nine 
genes: gag, pol and env – for the structural proteins and essential enzymes; tat and rev – 
for the regulatory proteins; vif, vpr, vpu and nef – for the auxiliary proteins (Figure 






Figure 1.3: Organisation of the HIV-1 genome and mature particle. 
(A) Organisation of the HIV-1 genome. Protein coding regions are shown in different colours. 
CA, capsid; IN, integrase; MA, matrix; NC, nucleocapsid, PR, protease; RT, reverse 
transcriptase; SP, signal peptide. (B) The schematic representation of the mature HIV-1 
particle. The location of the viral proteins and genome are indicated. 
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A mature HIV-1 particle is about 130 nm in diameter (Briggs et al., 2004), and contains 
two copies of the viral RNA (~10,000 nucleotides in length) encapsulated in a conical 
capsid (p24) (Figure 1.3B). The virus has a lipid outer membrane derived from the host 
cell during virus assembly and budding. The inner leaflet of the lipid membrane is lined 
with the matrix protein (p17). The viral envelope glycoproteins are anchored into the 
lipid membrane of the virus. These glycoproteins are made up of a receptor binding 
subunit (gp120) that initiates viral entry into target cells, and a trans-membrane subunit 
(gp41) responsible for mediating fusion of the viral envelope with the host cell 
membrane.  
 
 HIV-1 replication cycle 1.4
Briefly (details are in later sections), HIV enters a cell through initial interactions 
between viral surface glycoproteins and cellular receptors, and subsequent fusion of the 
viral membrane with the host cell plasma membrane (PM). The viral core is then 
released into the host cytoplasm, where the viral genome undergoes reverse 
transcription and is eventually integrated into the host genome as a provirus. The 
integrated viral genome is transcribed upon transcription of the host genome. The 
mRNAs and genomic RNA are transported to the cytoplasm where mRNAs are 
translated into viral proteins. The virus assembles on the PM and becomes enwrapped in 
the membrane. The resulting “lollipop”-like structures dissociate from the plasma 
membrane to release new virions and complete the replication cycle. The HIV 
replication cycle can be interrupted at different stages using anti-retroviral drugs. The 
current classes of ART approved by the United States of America Food and Drug 
Administration include 25 drugs that target virus entry, membrane fusion, reverse 
transcription, integration, and maturation (Figure 1.4) (Maartens et al., 2014). Although 
these drugs cover many facets of the virus life, there remain stages that offer 
opportunities as new targets for development of novel therapeutic interventions. 
 





Figure 1.4: Schematic representation of the HIV-1 replication cycle.  
HIV binds to receptor (CD4) and co-receptor (CCR5 or CXCR4) molecules on the plasma 
membrane. The virus and plasma membranes fuse, releasing the virus core into the host cell, 
where it is reverse transcribed and the DNA is imported into the nucleus for integration into the 
host genome (brown boxes). Viral transcripts are produced from the integrated genome and 
exported out of the nucleus, to be translated on the endoplasmic reticulum or free ribosomes. 
Viral proteins (Gag in blue; Env in purple) and RNA are assembled at the plasma membrane. 
Finally, the Gag recruits host proteins (shown later in Figure 1.9) to facilitate the dissociation of 
virus particles from the host cell. EM images (J. Burden, LMCB) on the left depict different 
stages of virus assembly and maturation. The replication cycle stages that can currently be 
inhibited by approved anti-retroviral drugs are in italics and underlined. 
 
1.4.1 Virus entry  
Viruses are obligate intracellular parasites that completely depend on host cells for their 
reproduction. HIV-1 typically has about 14 Env spikes on its surface (Cosson, 1996). It 
is believed that HIV-1 redistributes Env into clusters during maturation, to compensate 
for the low Env content, which ultimately increases virus entry efficiency (Chojnacki et 
al., 2012). Virions with truncated Env C-terminal tail (CT) domain do not display Env 
clustering on mature virions, thereby reducing virus fusion and infectivity. HIV entry 
into target cells is partially mediated by hijacking cluster of differentiation 4 (CD4) 
molecules, co-receptors with the T cell receptor for recognising peptides bound to major 
histocompatibility complex class II (MHC-II) molecules on antigen presenting cells. 
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The virus attaches to CD4 on host cells through its Env subunit, gp120 (Figure 1.5). 
Structurally, gp120 is made up of five variable domains  (V1-5) interspersed with five 
constant domains (C1-5) (Checkley et al., 2011). Three of the conserved domains (C1, 
C3 and C4) are the main determinants of binding to CD4. CD4 binding causes 
conformational changes in Env that favour exposure of a co-receptor binding surface, at 
the base of the V3 loop of gp120.  
 
 
Figure 1.5: Schematic representation of HIV binding and fusion.  
During HIV entry, the viral Env binds CD4 molecules on the plasma membrane of target cells. 
Conformational changes in Env result in the engagement of the co-receptor, insertion of the 
fusion peptide and ultimately membrane fusion. Taken from Wilen et al. (2012). 
 
HIV-1 uses two chemokine receptors on the cell surface, as coreceptors: CCR5 
(CD195) and/or CXCR4 (CD184) depending on the virus strain. CCR5 and CXCR4 are 
seven-transmembrane G-protein coupled receptors involved in cell signalling (Alkhatib, 
2009). The natural ligand for CXCR4 is stromal-derived-factor-1 (Ghanem et al., 2014), 
whilst natural ligands for CCR5 include macrophage inflammatory proteins (MIP)-1α, 
MIP-1β, and RANTES (for Regulated-on-Activation, Normal T cell Expressed and 
Secreted) (Alkhatib et al., 1996). HIV strains are generally divided according to their 
co-receptor usage: X4 viruses use CXCR4, R5 viruses use CCR5, and R5X4 use both 
co-receptors (Wilen et al., 2012). An increase in the net positive charge of the V3 loop, 
favouring binding to the negatively charged CXCR4 surface, results in virus tropism 
change from R5 to X4 (Checkley et al., 2011). R5 viruses dominate early during 
infection, but a change to X4 viruses may occur late in the course of infection, in about 
50% of infected individuals (Regoes and Bonhoeffer, 2005). A switch from R5 tropism 
is very rare in HIV-1C infections compared to HIV-1B (Ndung'u et al., 2006; Lin et al., 
2011). The reasons for co-receptor switch are not entirely understood. 
The second step of virus ntry and the
first absolutely required for infection entails
binding of Env to its primary receptor, the
host protei CD4 (Maddon et al. 1986;McDou-
gal et al. 1986). Env is a heavily glycosylated
trimer of gp120 and gp41 heterodimers. The
gp120 subunit is responsible for receptor bind-
ing and gp120 contains five relatively conserved
domains (C1–C5) and five variable loops (V1–
V5), named for their relative genetic heteroge-
neity. Each of the variable regions is comprised
of a loop s ructure formed by a di ulfide bond at
its base, with the exception of V5. The variable
loops lie predominantly at the surface of
gp120 and play critical roles in immune evasion
and coreceptor binding, particularly the V3
loop (reviewed in Hartley et al. 2005). CD4 is
a member of the immunoglobulin superfamily
that normally functions to enhance T-cell re-
ceptor (TCR)-med ated sign ing. Env interacts
with the CD4 binding site (CD4bs) in gp120
(Kwong et al. 1998). Env binding to CD4 causes
rearrangements of V1/V2 and subsequently V3.
In addition, CD4 binding leads to formation
of the bridging sheet, a four-stranded b sheet
comprised of two double-stranded b sheets
that are spatially separated in the unliganded
state (Kwong et al. 1998; Chen et al. 2005).
The bridging sheet and repositioned V3 loop
play critical roles in the next step of virus entry,
coreceptor engagement.
The third st p of virus entry, coreceptor
binding, is widely thought to be the trigger
that activates the membrane fusion potential
of Env. HIV strains can be broadly classified
based on their coreceptor usage. Viruses that
use the chemokine receptor CCR5 are termed
R5 HIV, those that use CXCR4 are termed X4
HIV, and viruses that can use both coreceptors
are called R5X4 HIV (Berger et al. 1998). There
is no compelling evidence that coreceptors
other than CCR5 and CXCR4 play important
roles in supporting infection of HIV-1 in vivo.
With rare exception, only R5 and R5X4 viruses
are transmitted between individuals (Keele et al.
2008), likely owing to multiple imperfect but
overlapping host restrictions on X4 HIV trans-
mission (reviewed in Margolis and Shattock
2006). Interestingly, despite identification at
earlier time points and despite high levels of
CXCR4 expression on irculating HIV target
cells, X4 or even R5X4 HIV rarely predominate
until late in infection (Tersmette et al. 1989;
Schuitemaker et al. 1992; Connor et al. 1997).
In addition, X4 viruses are less common in clade
C HIVand SIV infection (Chen et al. 1998; Ping
et al. 1999; Cecilia et al. 2000; Huang et al.
2007). Several nonmutually exclusive models
may explain this. First, clade B Envs may be
different in their ability to adapt to CXCR4
tropism. Second, there may be differences in
clade B host biology. For instance, clade B hosts













igure 1.Overview of HIVentry. To deliver the viral payload into cells, HIV Env, comprised of gp120 and gp41
subunits (1), first attaches to the host cell, bindingCD4 (2). This causes conformational changes in Env, allowing
coreceptor binding, which is mediated in part by the V3 loop of Env (3). This initiates the membrane fusion
pr cess as the fusion peptide of gp41 inserts into t target me brane, followed by six-helix bundle formation
and complete membrane fusion (4).
C.B. Wilen et al.
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When gp120 is bound to the co-receptor, further conformational changes in gp41 
release the fusion peptide, allowing it to insert into the cell membrane, and forming a 
pre-hairpin structure. gp120 and gp41 then dissociate, and the pre-hairpin structure is 
transformed into a six-helix bundle, thereby promoting fusion of the viral and cell 
membranes and subsequent release of the viral core into the cytoplasm (Gallo et al., 
2003; Melikyan, 2008; Wilen et al., 2012). 
 
1.4.2 Transcription and nuclear export 
It is still debatable when uncoating of viral genome occurs; and uncoating, or at least 
partially, may be required for the formation of reverse transcription complex (RTC) 
(Arhel, 2010; Fassati, 2012; Ambrose and Aiken, 2014). The composition of this 
complex is not entirely clear, but in addition to viral components (Vpr, p24, IN, RT), 
the RTC contains host proteins believed to stabilise the complex (Konig et al., 2008; 
Fassati, 2012; Gaudin et al., 2013b). During reverse transcription, single-stranded 
positive sense RNA is converted to double-stranded DNA. Reverse transcription is 
primed by lysyl tRNA. The RTC contains RNA or RNA-DNA intermediates of reverse 
transcription. Subsequently, the RTC is converted to pre-integration complex that no 
longer contains the viral RNA, but provirus. The pre-integration complex is translocated 
to the nucleus where the provirus is integrated into the host DNA using the virus-
encoded enzyme, IN (Arhel, 2010).  
 
The productive phase of the HIV replication cycle, described as “late events” in Figure 
1.4, begins with the transcription of the integrated viral DNA. Transcription of the 
provirus is initiated at the 5’LTR by cellular RNA polymerase II, and is activated by 
HIV-1 Tat that binds to the bulge of TAR RNA, and recruits positive transcription 
elongation factor b (P-TEFb) [composed of cyclin T1 and cyclin- dependent kinase 9 
(Bres et al., 2008)], as well as other transcription factors (Karn and Stoltzfus, 2012). 
The generated transcripts fall into three major classes: 1) unspliced mRNAs for the Gag 
and GagPol polyproteins; 2) partially spliced mRNAs which are translated into the Env, 
Vif, Vpu and Vpr proteins; 3) multiply spliced mRNAs encoding the Rev, Tat and Nef 
proteins. Before transport to the cytoplasm, intron-containing viral mRNAs are first 
bound to Rev. Rev binds to a cis-acting RNA element, the Rev response element 
(RRE), which is found in the env gene of all unspliced and partially spliced HIV-1 
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RNAs (Freed, 2001; Freed, 2002). Then mRNA-bound Rev complexes with cellular 
chromatin maintenance-1 nuclear export receptor to form the viral ribonucleoprotein 




Translation takes place on the endoplasmic reticulum and on free ribosomes in the 
cytosol, leading to the synthesis of the viral accessory proteins, as well as the structural 
and enzyme polyprotein precursors. The Gag polyprotein precursor is synthesized on 
free ribosomes in the cytosol. The 3’ end of gag overlaps with the 5’ end of pol. During 
translation, a -1 frameshift signalled by UUUUUUA slippery sequence or ribosomal 
frameshift stimulatory signal, results in the production of a fused GagPol protein, and 
ultimately a Gag:GagPol ratio of 20:1 (Jacks et al., 1988; Pettit et al., 2005; Bell and 
Lever, 2013). The viral enzymes (protease, integrase and reverse transcriptase) are 
produced from the Pol polyprotein.  
 
Env is synthesised on the rough endoplasmic reticulum (RER) as a polyprotein 
precursor, gp160 (Checkley et al., 2011). Targeting of gp160 to the endoplasmic 
reticulum (ER) membrane is mediated by a signal sequence at the N-terminus of 
unprocessed Env. In the ER, gp160 is glycosylated with N-linked oligosaccharide side 
chains (Allan et al., 1985), and oligomerises mostly into trimers before it traffics to the 
Golgi and trans-Golgi network (Checkley et al., 2011). Addition of O-linked glycans 
occurs post-translationally during transport of Env through the Golgi.  Earlier studies 
indicate that gp160 is proteolytically cleaved by host cell proteases (furin or furin-like 
enzymes) in the Golgi, into gp120 and gp41, the subunits found in the mature fusion-
competent virions (Hallenberger et al., 1992; Checkley et al., 2011). However, it has 
been shown that depletion of Rab7a impairs gp160 processing. As Rab7a is involved in 
membrane trafficking through late endosomes (Brighouse et al., 2010), this suggests 
that either Env, or a protease, must traffic through late endosomes for gp160 processing 
(Caillet et al., 2011). Ultimately, the mature trimeric Env is trafficked to the PM to be 
incorporated into virions by mechanism(s) that are still poorly understood (Checkley et 
al., 2011; Tedbury and Freed, 2014).  
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 HIV assembly 1.5
HIV-1 Gag is the main structural protein that orchestrates the assembly and egress of 
virus or virus-like particles (VLPs) in cells. Gag is the only HIV-encoded protein that, 
when expressed alone, is able to produce non-infectious VLPs with the appearance of 
immature particles (Bieniasz, 2009). After synthesis, HIV-1 proteins and the full-length 
genome of the virus are trafficked to the PM where they are assembled into new virus 
particles. The assembly of HIV is driven primarily by elements within the Gag 
polyprotein, which include the membrane-targeting (M) domain found at the N-
terminus of Gag; the Gag-Gag interaction residues − the majority of which are found in 
the CA, with some in the NC; and the late assembly (L) domain, or p6, required for the 
dissociation of nascent virions from the host cell membrane (Fujii et al., 2007; Klein et 
al., 2007; Pincetic and Leis, 2009; Watts et al., 2009; Maldonado et al., 2014). These 
interactions will be discussed in more detail below. 
 
1.5.1 Gag assembly at the plasma membrane 
The MA domain of Gag (Figure 1.3) is co-translationally modified at the C-terminal 
end, by the addition of a myristoyl group. The myristoylated Gag is trafficked to the 
inner leaflet of the PM. Several host proteins, such as ATP binding cassette E1 ATPase, 
microtubule motor proteins, AP-3 adaptor complex, and small GTPases called ADP-
ribosylation factors, are implicated in the trafficking of Gag to the PM. The N-terminal 
myristoyl moiety and residues 17-31 on the highly basic region of the MA domain of 
Gag facilitate binding of the Gag polyprotein to phosphatidylinositol-4,5-bisphosphate 
[PI(4,5)P2]-rich PM (Yuan et al., 1993; Zhou et al., 1994; Ono et al., 2004; Saad et al., 
2006b; Chukkapalli et al., 2010). Upon binding of myristoylated MA domain (myrMA) 
to the PI(4,5)P2, a “myristoyl switch” occurs, whereby the myristoyl moiety, 
sequestered or concealed in a hydrophobic pocket in the MA domain of Gag, is exposed 
and inserted into the lipid bilayer. The inositol head group of PI(4,5)P2 also becomes 
exposed and the 2’ unsaturated fatty acid chain of the lipid molecule fits into the 
“empty” hydrophobic pocket of the MA domain. This leads to the formation of salt 
bridges with basic residues in the MA (Saad et al., 2006b). Therefore, PI(4,5)P2 
performs at least two functions in HIV-1 assembly: (i) triggering the myristoyl switch, 
and (ii) acting as an anchor for Gag polyprotein in the lipid bilayer.  
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The Gag polyprotein that accumulates at the PM induces membrane curvature, 
subsequently forming a spherical Gag shells with two-thirds complete Gag lattice before 
membrane scission and virus release (Carlson et al., 2008). Viruses with complete Gag 
lattice are not dissociated from the host cell. Virus release is discussed in detail in 
Section 1.5.4. 
 
1.5.2 Packaging of viral RNA  
The 5’ untranslated region (5’ UTR) of the HIV-1 genome has determinants for viral 
genome dimerization, and packaging of two copies of the full-length 9-kb viral RNA 
into the virions (Laughrea and Jette, 1994; Skripkin et al., 1994; Pallesen, 2011; 
Jalalirad et al., 2012; Seif et al., 2013). This region is composed of elements that 
include: the 5’ repeated region (5’R) made up of the trans-activator region (TAR) and 5’ 
polyadenylation signal [poly(A)]; the unique 5’ region (U5); the primer biding site 
(PBS), part of which is within the U5; the dimerisation initiation site (DIS); the splice 
donor (SD) and the packaging signal (PSI) (Pallesen, 2011; Seif et al., 2013). The PSI 
sequences are made up of a series of stem-loops (SL1 to SL4). Dimerisation is 
fascilitated by the SL1 (Laughrea and Jette, 1994; Skripkin et al., 1994; Jalalirad et al., 
2012).  
 
The initial interaction of the HIV genome and Gag, mediated through the highly basic 
region of MA and the zinc finger structure of the NC, occurs in the cytoplasm (Lu et al., 
2011; Sundquist and Krausslich, 2012; Chukkapalli et al., 2013). The zinc fingers are 
responsible for selecting unspliced viral genome (Lu et al., 2011). The HIV genome is 
recruited to the PM as a preformed dimer (Jouvenet et al., 2009). At the PM, the viral 
genome is encapsidated in the developing buds upon multimerisation of Gag. There are 
suggestions that binding of the viral RNA to Gag may also serve to regulate the 
interaction of Gag with the PM and targeting to the assembly site (Chukkapalli et al., 
2010; Chukkapalli et al., 2013; Kerviel et al., 2013). In addition to full-length viral 
genome, tRNA for reverse transcription initiation is also packaged, whilst other RNAs 
such as 28S rRNA may be packaged due to its abundance in the cytosol (Sundquist and 
Krausslich, 2012).  
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1.5.3 Incorporation of Env into virions 
The HIV-1 Env protein is trafficked through the secretory pathway to the PM 
independently of Gag. At the PM, Env has two fates: incorporation into virions by 
mechanism(s) that are poorly understood, or rapid internalisation in clathrin-coated pits 
through interactions with the clathrin adaptor protein AP2. Endocytosis may regulate 
the amount of Env that is exposed at the cell surface. On the cytoplasmic tail (CT) of 
Env gp41, two internalization motifs, di-leucine and GYxxØ motifs (where x is any 
amino acid; Ø is an amino acid with a bulky hydrophobic side chain) have been 
identified in HIV-1 and SIV (Sauter et al., 1996; Berlioz-Torrent et al., 1999; Bowers et 
al., 2000; Byland et al., 2007; Affranchino and Gonzalez, 2014). Although the full 
function of the GYxxØ motif is yet to be understood, experiments in a rhesus macaque 
simian model suggest it is crucial for pathogenesis. In this system, ΔGY viruses, in 
which the GY codons in the cytoplasmic domain of SIVmac239 were removed, virus 
levels became undetectable, and no pathogenesis was seen up to 140 weeks post-
inoculation with the virus (Fultz et al., 2001).  In a recent study, ΔGY-infected 
macaques showed a decline in peripheral blood CD4+ T cells, but at a slower rate 
compared to the SIVmac239-infected animals (Breed et al., 2013). Although the 
animals progressed to AIDS, the ΔGY mutation affected disease pathogenesis as there 
was no infection of macrophages or the central nervous system, and only transient 
infection of lamina propria1. Also, there was no evidence of microbial translocation. 
 
The CT of Env is thought to interact with the Gag in virions and restrict movement of 
Env on the surface of the virions (Muranyi et al., 2013; Roy et al., 2013). These two 
independent studies employed a form of super-resolution microscopy, stochastic optical 
reconstruction microscopy (STORM), to assess clustering of HIV Env on HeLa cells 
transfected with wild-type (WT) and mutant (ΔCT Env) proviruses. Analysis of the 
distribution of Gag and Env proteins revealed that Env lacking the cytoplasmic tail 
clustered indiscriminately throughout the PM, whilst WT Env primarily colocalised 
with Gag (Muranyi et al., 2013; Roy et al., 2013). These observations support a model 
                                                
1 A thin layer of loose connective tissue, or dense irregular connective tissue that lies beneath the 
epithelium, and together with the epithelium constitutes the mucosa. 
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for specific incorporation of Env into virions, mediated by interaction between Gag and 
Env (Cosson, 1996). Outside of Gag assembly sites, ΔCT Env formed larger clusters 
compared to WT Env clusters at similar sites, suggesting that the cytoplasmic domain 
may be modulating Env clustering. In addition to this model, other models have been 
proposed, which include passive incorporation, Gag-Env co-targeting, and indirect Env 
interaction (see Checkley et al., 2011; Tedbury and Freed, 2014, for reviews).  
 
1.5.4 Virus release 
Gag multimerises on the inner leaflet of the PM, hence forming a Gag shell and driving 
remodelling of the membrane. The time it takes to assemble an HIV particle has been 
estimated in HeLa cells, transfected with fluorescently labelled Gag, and analysed using 
wide-field and total internal reflection fluorescence microscopy (TIR-FM). By these 
methods, it was seen that on average it takes 8-9 min to assemble about 90% of VLPs, 
but this can vary from 4 to 20 min (Ivanchenko et al., 2009; Jouvenet et al., 2011). 
Nascent viral particles are separated from the plasma membrane by severing the 
membrane stalk that links them to the host cells. To accomplish this, retroviruses and 
other families of enveloped viruses (filoviruses, rhabdoviruses, and arenaviruses) have 
specific late (L) domain motifs to recruit host cell proteins that mediate topologically 
similar membrane scission processes, and these proteins are part of the endosomal 
sorting complex required for transport (ESCRT) machinery. Three such motifs have 
been identified: PPXY, P(T/S)AP and YPXnL [where X is any residue, and Xn is any 
sequence of n = 1–3 residues] (Freed, 2002). These motifs can appear in viruses as a 
single motif or in combinations (Figure 1.6). HIV-1 has two such motifs, PTAP and 
YPXnL, in the p6 subdomain of Gag (Figure 1.7). 
 
The ESCRT proteins were initially identified through a detailed morphological analysis 
of the data from several yeast genetic screens, that aimed at identifying the machinery 
involved in trafficking proteins to the vacuole, and including the vacuolar protein 
sorting (Vps) screen. One group of mutants gave similar morphology, dilate endosomal 
organelles that were subsequently termed class E mutants (Raymond et al., 1992). 
Members of this class were subsequently found conserved from archea to higher 
animals (Fujii et al., 2007; Samson and Bell, 2009). They function in various cellular 
processes such as the biogenesis of multivesicular bodies (MVBs), transcription 
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regulation, cytoskeletal dynamics, cytokinesis, and formation of microvesicles (Kamura 
et al., 2001; Slagsvold et al., 2006; Bieniasz, 2009; Samson and Bell, 2009; Wollert et 
al., 2009; Roxrud et al., 2010; Nabhan et al., 2012; Lin et al., 2013; Choudhuri et al., 
2014). Early in the new millennium, work from several laboratories simultaneously 
found that human homologues of several of these class E proteins are required for HIV 
formation (Garrus et al., 2001; Demirov et al., 2002a; Martin-Serrano et al., 2003; von 
Schwedler et al., 2003; Stuchell et al., 2004). 
 
 
Figure 1.6: Viral late domain motifs found in membrane-associated structural proteins of 
enveloped viruses.  
Motifs are coloured as follows: PT/SAP, red; PPXY, blue; YXXnL, green. From Pornillos et al. (2002). 
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Figure 1.7: HIV-1 Gag organisation. 
Amino acids sequence of the p6 subdomain of HIV-1 BaL strain. 
 
1.5.5 The ESCRT machinery and HIV budding 
Virus budding is topologically equivalent to abscission during cytokinesis and the 
formation of intralumenal vesicles in multivesicular bodies (MVB) biogenesis (Figure 
1.8). (Balasubramaniam and Freed, 2011; Henne et al., 2013). Other topologically 
equivalent processes recently identified, and that require the ESCRT machinery, include 
the arrestin domain containing protein-1 mediated formation and release of 
microvesicles at the plasma membrane (Nabhan et al., 2012), the release of T cell 
receptor enriched microvesicles at immunological synapses (Choudhuri et al., 2014), 
and PM wound repair (Jimenez et al., 2014). In these processes, the membrane scission 
machinery acts within the membrane neck, in contrast to the dynamin-mediated scission 
that facilitates the formation of clathrin-coated vesicles, whereby the scission machinery 
acts outside the membrane neck. 
 
 
Figure 1.8: Topologically equivalent membrane fission processes. 
Taken from Balasubramaniam and Freed, 2011. 
MA/p17 CA/p24 NC/p7 p6
LQSRPEPTAPPAPPEESFRFGEETTTPCQKQELIDKELYPLASLRSLFGNDPSSQ
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The ESCRT proteins are organised into five complexes (Table 1.1) that are recruited 
sequentially to sites where membrane scission processes occur (Votteler and Sundquist, 
2013; Van Engelenburg et al., 2014). In addition, there are a number of ESCRT-
associated proteins. The first three complexes, ESCRT-0, -I and -II, exist as preformed 
complexes in the cytosol, and they primarily interact with cargo or scaffolding proteins. 
These complexes recruit the fourth complex, ESCRT-III, which polymerises at 
membrane sites to constrict the membrane. The fifth complex is the AAA ATPase 
VPS4 and its co-factor lysosomal trafficking regulator interacting protein-5 (LIP5), 
which together further constrict the vesicle/bud neck, and/or disassemble ESCRT-III.  
 
Table 1.1:  A list of ESCRT/ESCRT-associated proteins that have been identified in yeast 
and their human homologues 




Hse1  STAM1/2  
      
ESCRT-I  
Vps23  Tsg101  
Vps28  Vps28  
Vps37 Vps37A-D  
Mvb12  Mvb12A, B  
—  UBAP1  
      
ESCRT-II  
Vps36  EAP45   
Vps22 EAP30  
Vps25  EAP20  
      
ESCRT-III  
Vps20  CHMP6  
Snf7  CHMP4A-D  
Vps24  CHMP3  
Vps2  CHMP2A, B  
Vps60  CHMP5  
Ist1 IST1 
Did2  CHMP1  
      
AAA ATPases  
Vps4  Vps4A and B  
—  Spastin  
      
ESCRT-associated proteins 
Vta1  LIP5  
Bro1 ALIX 
—  CEP55  
—  AuroraB  
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Studies of MVB biogenesis and cytokinesis have helped in the understanding of the 
membrane fission reactions that occur during the assembly of viruses, and vice versa. In 
MVB formation, the hepatocyte growth factor receptor substrate (Hrs) and signal 
transducing adaptor molecule (STAM), ESCRT-0 components, are recruited by 
ubiquitinated membrane proteins such as epidermal growth factor receptor, and 
cholesterol (Du et al., 2012; Schmidt and Teis, 2012). A PSAP motif in Hrs interacts 
directly with the ubiquitin-E2-like variant (UEV) domain of tumour susceptibility gene 
101 (Tsg10l), an ESCRT-I component (Pornillos et al., 2002). In cytokinesis, the 
centrosome protein 55 (CEP55) recruits Tsg101 (Carlton and Martin-Serrano, 2007). 
During virus budding, HIV-1 mimics Hrs or CEP55 by recruiting Tsg101. Tsg101 
(Vps23 in yeasts) exists with Vps28, Vps37 and Mvb12 as a stable cytosolic multi-
protein ESCRT-I complex (Martin-Serrano, 2007; Hurley and Hanson, 2010). However, 
an endosome specific ESCRT-I complex consisting of Tsg101, Vps37A, Vps28 and 
ubiquitin-associated protein 1 (UBAP1), has been identified (Stefani et al., 2011; 
Agromayor et al., 2012). Although UBAP1 plays a role in MVB sorting, it has no 
function in HIV budding or cytokinesis (Agromayor et al., 2012). A recent study 
suggests that Tsgl01 is recruited with Gag during VLP assembly, whilst the ESCRT 
components downstream in the pathway are recruited later and transiently (Bleck et al., 
2014). Mutations in the HIV-1 Gag PTAP motif, or the depletion of Tsg101 using RNA 
interference (RNAi), inhibit virus release and budding viruses remain tethered to the 
plasma membrane (Huang et al., 1995; Garrus et al., 2001).  
 
In HIV budding, the Gag p6-associated ESCRT-I is capable of directly engaging the 
ESCRT-III complex to catalyse membrane scission, without the ESCRT-II bridge. 
Although ESCRT-II is required for MVB formation, it is dispensable for HIV budding 
(Teis et al., 2010). ESCRT-III is also a multi-protein complex with at least 12 distinct 
but related subunits in mammals (Votteler and Sundquist, 2013). It is made up of the 
following core components of charged MVB proteins (CHMP) in humans, existing as 
monomers in the cytosol: CHMP6, CHMP4A-D, CHMP3, CHMP2A-B and CHMP5. In 
HIV-1 budding, some components of ESCRT-III are dispensable, except CHMP2 and 
CHMP4 (Morita et al., 2011; Weiss and Gottlinger, 2011) (Figure 1.9). Based on 
studies in yeast, the assembly of ESCRT-III is initiated by CHMP6, which nucleates the 
polymerisation of CHMP4. The CHMP4 polymer recruits CHMP3 to cap the complex 
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and engage CHMP2 that completes the assembly of ESCRT-III (Hurley and Hanson, 
2010; Schmidt and Teis, 2012). Although depleting CHMP6 does not inhibit HIV-1 
release (Morita et al., 2011), later work using purified proteins and giant unilamellar 
vesicles suggests that CHMP6 is required for recruiting downstream components of the 
ESCRT-III complex (Carlson and Hurley, 2012). Taken together, these studies suggest 
functional redundancy of ESCRT-III proteins under physiological conditions. 
 
 
Figure 1.9: Schematic representation of the functions of ESCRT proteins in HIV budding 
and MVB formation.  
Components of the ESCRT pathway are recruited sequentially. Double-headed arrows indicate 
direct protein-protein interactions. STAM, signal transducing adaptor molecule; Ub, ubiquitin. 
EAP, ELL (for 11-19 lysine-rich leukaemia gene)-associated protein. Adapted from 
Balasubramaniam and Freed, 2011. 
 
FIGURE 5. Schematic representation of topological equivalence of HIV-1 budding and release (A), MVB biogenesis (B), and cy-
tokinesis (C). D: the ESCRT machinery components implicated in HIV-1 budding and release. D was adapted from Ref. 71 and
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Several models, reviewed by Henne et al. (2013), have been proposed for the events that 
occur at the site of ESCRT-III polymerisation. A common feature for these models is 
that ESCRT-III accumulates at the neck outside of the bud or vesicle head, possibly 
forming filaments that assemble into helices or spirals (Hanson et al., 2008; Buchkovich 
et al., 2013). However, a diametrically opposite model has recently been proposed for 
HIV budding, where it was suggested that ESCRT-III and VPS4 accumulate in the virus 
bud (Van Engelenburg et al., 2014). Whilst this study provides an attractive model, it is 
unclear how much of what is observed is due to overexpression of the fluorescently 
tagged ESCRT proteins. On the contrary, when fluorescently tagged ESCRT-III 
proteins and VPS4 were stably expressed at endogenous levels, they were transiently 
recruited to the neck of the assembling particles prior to virus release (Bleck et al., 
2014), consistent with the previously proposed models. 
 
Understanding of the mechanism of membrane scission still remains elusive. Overall, it 
is believed that the electrostatic interactions of ESCRT-III filaments with the membrane 
of the virus/vesicle neck constrict the aperture. As the neck narrows to ~3 nm, a scission 
intermediate is spontaneously formed. Then VPS4 is rapidly and transiently recruited by 
CHMP2 to the scission complex, where it hydrolyses ATP thereby catalyzing 
membrane scission, and ultimately ESCRT components are disassembled and recycled 
(Hurley and Hanson, 2010; Adell and Teis, 2011; Jouvenet et al., 2011; Bleck et al., 
2014). The disassembly is the only known energy-requiring step in the ESCRT 
pathway, where ATP is hydrolysed to ADP and inorganic phosphate. Although VPS4 
has been suggested to act late during budding/vesiculation, new data suggest that it may 
also be involved early in the remodelling of membranes during MVB biogenesis and 
HIV budding (Adell et al., 2014; Cashikar et al., 2014). More studies are required to 
clarify aspects of the ESCRT pathway that are still obscure. 
 
Mutation of glutamate (E) to glutamine (Q) at position 228 of VPS4 generates a 
dominant negative VPS4, which is able to bind substrates but fails to hydrolyse ATP, 
thereby abolishing the catalytic activity of VPS4 (Babst et al., 1998). Overexpression of 
dominant negative VPS4 EQ in model cell lines results in the formation of enlarged 
endosomes, with cargo trapped at the surfaces of endosomes (Bishop and Woodman, 
2000). When overexpressed in HIV-1 infected cells, VPS4 EQ inhibits virus release 
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(Garrus et al., 2001). Collectively, these reports demonstrate the importance of VPS4 in 
these topologically related processes. 
 
Apoptosis linked gene-2 (ALG-2)-interacting protein X (ALIX) is an accessory protein 
that works in concert with other ESCRT components to mediate HIV release (Strack et 
al., 2003), and other membrane fission events such as MVB formation (Figure 1.9). It is 
made up of the Bro1, V-shaped and proline-rich domains (Fujii et al., 2007). The 
YPXnL motif of Gag binds the V-shaped domain of ALIX (Lee et al., 2007; Munshi et 
al., 2007). To engage ESCRT-III, the Bro1 domain of ALIX recruits CHMP4. CHMP4 
then recruits CHMP2 that binds VPS4. Mutations in the CHPM4-binding site on ALIX 
inhibit the ability of ALIX to support virus release (Fisher et al., 2007). In addition to 
binding Gag directly, ALIX is able to associate with Tsg101 (Strack et al., 2003) 
through its proline-rich domain. However, the Tsg101-ALIX interaction is not essential 
for virus budding, since the two proteins can be recruited independently to mediate 
membrane scission. Although HIV-1 has two late domain motifs, PTAP is the dominant 
motif because mutations in the PTAP motif severely reduce virus release in many cell 
systems, compared to mutations in the YPXnL motif (Demirov et al., 2002b; Fujii et al., 
2009). The interaction between YPXnL and ALIX may be weaker than the PTAP and 
Tsg101 interaction (Pincetic and Leis, 2009). Furthermore, endogenous levels of ALIX 
are not able to rescue defects in Tsg101 recruitment (Fujii et al., 2009). However, 
expression of higher levels of ALIX may compensate for the weak interaction, as 
overexpression of ALIX can rescue viruses with mutations in the PTAP motif (Carlton 
et al., 2008; Chung et al., 2008). 
 
1.5.6 Virus maturation 
During or immediately after scission of immature virus particles from the producer cell, 
Gag and Gag-Pol polyproteins are cleaved by the viral PR. The PR, synthesised as part 
of the Gag-Pol polyprotein (see section 1.4.3), dimerises during HIV assembly to 
become active (Lee et al., 2012b). Autocatalysis of PR releases the PR from the Gag-
Pol polyprotein. Through a positive feedback loop, the released PR is able to cleave 
more Gag-Pol, thereby liberating more PR together with RT and IN. The viral PR 
cleaves the Gag polyprotein into its sub-domains (Konnyu et al., 2013). Premature 
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activation of the PR can occur when Gag-Pol and Gag are highly expressed in cells 
(Carlson et al., 2010). 
 
The proteolytic cleavage of Gag proceeds sequentially (Figure 1.10) (Pettit et al., 1994; 
Bell and Lever, 2013). First, the Gag polyprotein is cleaved to produce p41 (MA-CA-
p2) and p15 (NC-p1-p6) processing intermediates. These are processed further to 
ultimately yield individual Gag subdomains as shown in Figure 1.10. Whereas the 
amino acid sequence is crucial for cleavage, context also plays an important role in 
determining the efficiency of this process. For instance, the binding of viral RNA to NC 
promotes Gag cleavage at the p1-p6 sites, but it does not affect the rate of cleavage at 
the p2-NC (Lee et al., 2012a). It is not clear how RNA binding promotes cleavage, 
however, it has been suggested that the RNA may serve as a cofactor for the PR, or 
promote some conformational change in the cleavage site in favour of the reaction (Lee 
et al., 2012a).  
 
Proteolytic processing of HIV-1 Gag results in mature virions characterised by 
structural and morphological changes (Ganser-Pornillos et al., 2008; Briggs and 
Krausslich, 2011). The cleavage of different sites is not equally important for virus 
morphology and infectivity. For example, in tissue culture, separation of NC and p1 
(SP2) is not essential for maturation and infectivity (de Marco et al., 2012). HIV-1 
mutants lacking SP2 are infectious to the same extent as WT virus, suggesting that SP2 
is dispensable in the replication cycle of HIV-1, at least in tissue culture. However, the 
failure to separate SP2 and p6 has detrimental effects to the virus, resulting in reduced 
infectivity and formation of a high proportion of irregular cores. Seemingly, the 
liberated p6 determines replicative capacity and morphogenesis of HIV-1 (de Marco et 
al., 2012). Once Gag has been cleaved, the CA reassembles to form the virus core seen 
in mature particles (Figure 1.3 and 1.10).  




Figure 1.10: Maturation of HIV-1 by proteolysis.  
(A) Sequential proteolytic processing of the Gag polyprotein (p55) shown in (a) to ultimately 
yield mature viral proteins shown in (e) (B) An immature virus particle with an electron dense 
Gag shell and translucent centre. (C) A mature virus particle with an electron dense core, 
produced from the proteolytic processing of Gag and the assembly of CA into a hexagonal 
lattice around the genomic RNA. Adapted from Bell and Lever (2013). 
 
 
 Target cells infected by HIV-1 1.6
HIV targets key immune system cells that typically express the CD4, CCR5 and/or 
CXCR4 molecules. These cells include a subset of T cells, macrophages, dendritic cells 
(DCs), and to a small extent monocytes. The physiological roles of these cells involve 
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1.6.1 T cells 
Early studies (in the 1980s) on the immunological parameters of HIV-infected 
individuals revealed that T cells were important in the pathogenesis of the infection. 
AIDS patients showed a decline in the population of Leu-3/OKT4 antigen-bearing T 
lymphocytes (CD4+ T cells), whilst the Leu-2/OKT8 antigen-bearing cells (CD8+ T 
cells) remained numerically normal so that their proportions relative to other T cells 
subpopulations were elevated (Schroff et al., 1983). Later, two laboratories 
independently identified CD4 molecules on T cells as essential for HIV entry into cells 
(Dalgleish et al., 1984; Klatzmann et al., 1984). However, CD4 molecules were not 
sufficient for entry as the virus could not infect non-human cells expressing the CD4 
molecule, and some HIV strains could infect activated T cells but poorly infect 
macrophages. This led to the hypothesis that a co-factor may be involved in HIV entry. 
The search for the co-factor(s) resulted in the discovery of the co-receptors 
CXCR4/fusin, which when co-expressed with CD4 on non-human cells, permitted HIV 
entry and replication, and virus entry could be blocked by an antibody against 
CXCR4/fusin (Feng et al., 1996). In addition, CCR5 was discovered and its role as a co-
factor for virus entry into macrophages was inhibited by its ligands, RANTES and MIP-
1α/β (Deng et al., 1996). CCR5 molecules are also expressed on CD4 T cells  (Moore et 
al., 1997). Genetic polymorphism in CCR5 has been reported, where a deletion of 32-bp 
in the second extracellular loop leads to the production of a truncated protein 
(CCR5Δ32) that fails to traffic to the plasma membrane (Samson et al., 1996). 
Individuals with homozygous CCR5Δ32 are resistant to HIV infection, and the 
frequency of this mutation increases amongst the Caucasians from the southern to 
northern parts of Europe (Galvani and Novembre, 2005; Sidoti et al., 2005; Faure and 
Royer-Carenzi, 2008). 
 
HIV infection is highly permissive in activated CD4+ T cells, compared to resting 
CD4+ T cells. Recent data show that inhibition of HIV replication in resting CD4+ cells 
is partially attributed to restriction by SAMHD1 (sterile alpha motif and HD domain-
containing protein-1) (Baldauf et al., 2012). SAMHD1 acts by depleting the available 
deoxynucleoside triphosphates (dNTPs), thereby starving the virus of a building block 
essential for reverse transcription (Lahouassa et al., 2012). Notably, resting CD4+ T 
cells express high levels of SAMHD1 (Baldauf et al., 2012). 
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Although CD4+ T cells are directly infected by free viruses, they can also be infected 
through cell-cell transmission of viruses from other T cells (Jolly and Sattentau, 2005), 
dendritic cells (DC) (Dong et al., 2007) or macrophages (Duncan et al., 2014; Giese and 
Marsh, 2014), through the so-called virological synapses (see Section 1.6.3).  
 
1.6.2 Macrophages 
Macrophages are terminally differentiated haematopoietic cells found in all tissues. 
They are related to dendritic cells in that they are derived from the same haematopoietic 
stem cells in the bone marrow (Figure 1.11) (Tsunetsugu-Yokota and Muhsen, 2013). 
Macrophages play key roles in both innate and acquired immunity (Geissmann et al., 
2010; Hashimoto et al., 2011). Tissue macrophages have a wide range of pathogen-
recognition receptors, which function in recognising, taking up and degrading microbes, 
foreign and damaged cells. Degraded peptides are presented on major histocompatibility 
(MHC) class II, important for antibody production. Macrophages also secrete cytokines 
to attract effector cells such as neutrophils. 
 
Monocytes are morphologically heterogeneous, and can be divided into three subsets 
according to differential expression of CD14 (a lipopolysaccharide receptor) and CD16 
(immunoglobulin gamma Fc region receptor III): classical CD14++CD16-, non-
classical CD14+CD16+, and intermediate CD14++CD16+ cells. The intermediate 
subset expresses higher levels of CCR5, and are therefore preferentially infected by 
HIV (Gorry and Ancuta, 2011). CD16+ cells constitute a small proportion of circulating 
monocytes (about 5%) (Coleman and Wu, 2009), therefore few monocytes are infected 
by HIV. The infected monocytes can disseminate infection to tissues where they 
migrate and differentiate into macrophages.  
 
In vivo, myeloid lineage cells can be infected with HIV-1 at two stages of 
differentiation: (1) as monocytes in the blood; and (2) as mature macrophages in tissues. 
HIV production in monocytes is inhibited at different stages of the replication cycle, 
including reverse transcription. For example, unlike macrophages, monocytes do not 
have a functional positive transcription elongation factor b (P-TEFb), required to 
complex with Tat on the 5’LTR of the integrated HIV provirus (Coleman and Wu, 
2009). Furthermore, monocytes are more refractory than macrophages to productive 
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HIV infection, because they express higher levels of SAMHD1 (Laguette et al., 2011). 
Since monocytes migrate to different tissues or anatomic sites, including the brain, 
kidneys, lungs and the gut-associated lymphoid tissues (GALT) where they differentiate 




Figure 1.11: Development of monocytes, macrophages and dendritic cells.  
Hematopoietic stem cells in the bone marrow differentiate into monocyte/macrophage and DC 
precursors (MDP), which can become monocytes (mono) or common DC precursors (CDP). 
The CDP differentiate to precursor DC (preDC) or plasmacytoid DC (pDC), which migrate to 
peripheral tissues through the blood. In both lymphoid and non-lymphoid tissues, preDC can 
become either of two types of conventional DC (cDC) with the indicated markers. Circulating 
monocytes are the source of macrophages (Mφ), Langerhans cells (LC) and microglia. LC 
precursors in the bone marrow can migrate to the skin. CD14+ monocytes can migrate to 
inflamed tissue and differentiate into either migratory monocyte-derived DC (MDDC) or 
inflammatory Mφ. Cells committed to become DC express the Fms-like tyrosine kinase (Flt3), 
whereas those that commit to monocytes/macrophages express macrophage-colony stimulating 
factor (M-CSF) receptor. Therefore, Flt3 ligand and M-CSF are key molecules for the 
differentiation and proliferation of DC and monocytes/macrophages, respectively. Taken from 
Tsunetsugu-Yokota and Muhsen (2013). 
“fmicb-04-00178” — 2013/7/5 — 20:51 — page 3 — #3
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FIGURE 1 | Development of mye id cells and lineage relationship
between DC subsets. Hematopoietic stem cells in the bone marrow
differentiate into monocyte/macrophage and DC precursor (MDP),
which commits to a distinct lineage cell, either becoming a monocyte
or common DC precursor (C ). CDP differentiates to preDC or pDC,
and migrates to the peripheral tissues through blood. In the lymphoid
or non-lymphoid tissues, preDC can become eith r of tw types of
cDC: CD1c+ DC and CD141+/XCR1+/CLEC9A+ DC, the latter of
which has hig cross-presenting activity. In t e blood, CD14+ or CD16+
monocytes are also circulating. Blood monocytes are source of macrophages
(Mφ), LC, and microglias. The other LC precursor in the bone marrow, was
also shown to migrate to the skin. Upon tissue inflammation, CD14+
monocytes migrate to the inflamed tissue and differentiate into either
migratory MDDC or infla mat ry Mφ. It is known that the cells committed
to become DC express Flt3, whereas those that commit to monocytes/
macrophages express M-CSF receptor. Therefore, Flt3L and M-CSF are key
molecules for differentiation and proliferation of DC and monocytes/
macr phages, respectivel .
MDDC which can regulate immune responses locally (Cheong
et al., 2010).
It is well-known that effector CD8+ T cells play an essential
role regarding protection against HIV/SIV infection (Appay et al.,
2008). Once infection primes in lymphoid organs,memory CD8+
T cells can act as effector cells by circulating in the blood, in order
tomigrate to infected tissues upon re-exposure, and quickly elimi-
nate infect d cells. The importance of long-term resident memory
CD8+T (TRM) cells has been highlighted with respect to efficacy
of the local memory response (Gebhardt and Mackay, 2012). By
utilizing an elegant mouse model of herpes simplex virus (HSV)
infection, memory CD8+ T cells were shown to be initiated in
extra-lymphoid tissues, independent of migratorymemory CD8+
T cells (Wakim et al., 2008). In this model, HSV-infected dor-
sal root ganglia (DRG) was surgically transplanted to naïve mice,
because DRG is known to be latently infected with HSV, after
acute virus resolution, and to be reactivated by surgical extraction.
Stimulation of these CD8+TRM cells was dependent on recruited
DC in the DRG, and CD4+T cell help was required. These CD8+
TRM cells represent a self-renewing and highly protective popula-
tion of memory T cells distinct from circulating memory CD8+ T
cells, and express CD103 which is known to be widely expressed
in non-lymphoid tissues (Gebhardt et al., 2009). Interestingly, a
study using intravital two-photon microscopy revealed that while
memory CD4+ T cells are trafficked rapidly, CD8+ TRM cells are
removing slowly in the riginal skin site dur ng HSV infection
(Gebhardt et al., 2011).
The functional properties of CD8+ TRM cells have just begun
to be elucidated in influenza virus infection. The innate antiviral
function of IFN-induced transmembrane protein 3 (IFTM3) was
first discovered by using RNA interference screening for factors
modifying influenza virus infection (Brass et al., 2009). The IFITM
family is: (1)made up of IFN-stimulated genes (ISGs) with diverse
biological functions, (2) comprises of multiply closed members of
four genes in both humans andmice, and (3) restricts various virus
infections at a site of viral fusion (Diamond and Farzan, 2012).
www.frontiersin.org July 2013 | Volume 4 | Article 178 | 3
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1.6.2.1 The role of macrophages in HIV pathogenesis 
Although monocytes/macrophages are target cells for HIV infection in vivo, their role in 
HIV pathogenesis remains unclear. Transmitted/founder viruses have been described as 
showing preference for T cells (Ochsenbauer et al., 2012), and the loss of T cells clearly 
plays a major role in the decline in immunological competence. However, compared to 
T cells, macrophages are resistant to the cytopathic effects of HIV, which makes them a 
viable reservoir for the virus. 
 
Macrophages may play a critical role in HIV infection of the brain. About 50% of adults 
with HIV infections, and on ART, have varying degree of HIV-associated 
neurocognitive disorders (HAND), including dementia (Heaton et al., 2010). HIV-
infected individuals on ART have increased chances of survival and this has been 
accompanied by an increased incidence of HAND (Gras and Kaul, 2010). Post-mortem 
analysis of brain tissues from patients who presented with dementia and died from 
AIDS showed HIV in macrophages (Koenig et al., 1986). Furthermore, the severity of 
dementia correlates with the amount of virus in perivascular macrophages and microglia 
(Glass et al., 1995). In SIV-infected rhesus macaques, transfused with fluorescein-
labelled peripheral blood mononuclear cells (PBMCs), SIV positive and dye-labelled 
monocytes have been detected in the brain, indicative of monocyte infiltration into the 
central nervous system (CNS) (Clay et al., 2007). The secretion of chemokines by 
macrophages in the brain results in a chemotactic gradient across the blood-brain 
barrier, which promotes the recruitment of more infected/uninfected monocytes and T-
cells. Furthermore, HIV in the CNS can evolve independently of circulating virus 
(Harrington et al., 2009), although it is unclear whether macrophages have a role to play 
in this evolution.  
 
The main role of macrophages is phagocytosis and the destruction of unwanted particles 
such as cell debris and microorganisms. However, HIV infection can impair the 
phagocytic capacity of macrophages, such as alveolar macrophages obtained from HIV 
infected individuals (Jambo et al., 2014). One study suggests that Nef is responsible for 
inhibiting phagocytosis in primary macrophages (Mazzolini et al., 2010). In this study, 
Nef deleted HIV-1 or wild-type HIV-1 strains were used to infect MDM, and Nef-GFP 
or GFP expression vectors were electroporated into the macrophages. To assess 
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phagocytosis, IgG- or complement-opsonised sheep red blood cells, and complement 
receptor 3 and Fc receptor (FcR) were added to the cells. The efficiency of phagocytosis 
was reduced to approximately 50% in cells with WT virus or Nef expression vector. In 
support of these findings, inhibition of phagocytosis by Nef has also been reported in a 
macrophage cell line (Cui et al., 2012). Nef down-modulates the cell surface expression 
of CD4 and MHC-I and II molecules, which protects infected cells from secondary 
infection and cytotoxic T-lymphocyte-mediated killing (Mangasarian et al., 1999; 
Marsh and Pelchen-Matthews, 2000; Herbein et al., 2010). This modulation may apply 
to other surface molecules, such as FcR, thereby negatively regulating the immune 
system to the advantage of HIV.  
 
1.6.2.2 Intracellular plasma membrane-connected compartments 
In infected macrophages, HIV-1 accumulates in intracellular compartments (Gartner et 
al., 1986). These were initially thought to be part of the Golgi apparatus (Orenstein et 
al., 1988), but later work on HIV assembly in macrophages suggested that these virus-
containing compartments could be of endosomal origin because they contain the 
tetraspanin CD63, a marker for late endosomes or MVBs (Raposo et al., 2002; Pelchen-
Matthews et al., 2003). There is now substantial and compelling evidence that the 
intracellular compartments where HIV assembles in macrophages (Figure 1.12) are 
intracellular plasma membrane-connected compartments (IPMCs) (Deneka et al., 2007; 
Jouve et al., 2007; Welsch et al., 2007; Bennett et al., 2009; Marsh et al., 2009; Welsch 
et al., 2011; Chu et al., 2012a; Gaudin et al., 2012; Pelchen-Matthews et al., 2012; Berre 
et al., 2013; Gaudin et al., 2013a; Mlcochova et al., 2013; Giese and Marsh, 2014; 
Mariani et al., 2014).  
 
1.6.2.3 Morphological and biochemical features of the IPMCs 
It has been demonstrated that the IPMCs are connected to the cell surface by labelling 
intact primary macrophages with the PM impermeable dye ruthenium red (RR) and 
analysing the cells by EM (Deneka et al., 2007; Welsch et al., 2007). The dye labelled 
the cell surface, the virus containing compartment membranes, as well as virus particles 
in the compartments, but it did not stain membranes of the cells’ internal organelles 
such as endosomes, the Golgi and mitochondria. There is also access of fluid-phase 
markers such as horseradish peroxidase and membrane dyes such as CellMask and FM 
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4-64 (Deneka et al., 2007; Mlcochova et al., 2013). Most importantly, conduits 
connecting the IPMCs to the cell surface were also revealed by EM studies (Deneka et 
al., 2007; Welsch et al., 2007; Bennett et al., 2009). Notably, the IPMCs have neutral 
pH, whilst late endosomes and lysosomes are acidic (Jouve et al., 2007), further 
indicating that the internal compartments are distinct from early and late endosome, as 
well as lysosomes.  
 
 
Figure 1.12: Epon EM of IPMC in an HIV-infected MDM.  
MDM with a group of virus containing compartments. Arrowheads point to narrow tubes 
connecting some pockets of the IPMC. Notably, virus particles or budding figures were not seen 
at the cell surface. Bar, 2 µm. Taken from Deneka et al. (2007). 
  
IPMCs are morphologically heterogeneous in shape and size. Several studies have 
shown that they are present in uninfected macrophages, and that the IPMCs expand in 
size upon accumulation of HIV-1 (Welsch et al., 2011; Pelchen-Matthews et al., 2012; 
Berre et al., 2013; Mlcochova et al., 2013; Giese and Marsh, 2014). Analysis of the 
IPMCs’ architecture showed that they are morphologically complex, with vacuole-like 
elements, as well as swirls of tightly apposed membranes, and sponge-like arrays 
(Deneka et al., 2007; Welsch et al., 2007; Pelchen-Matthews et al., 2012). Although 
these structures may appear to exist as different units in two-dimensional EM images, 
three-dimensional EM imaging of RR-labelled cells indicates that they may in fact 
belong to the same network of continuous membrane (Welsch et al., 2011). Immature 
virus profiles have been identified in IPMCs, and budding virus structures have been 
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seen on the limiting membranes of IPMCs showing that the virus can assemble here 
(Figure 1.13) (Deneka et al., 2007; Welsch et al., 2007). Recently, live-cell imaging of 
MDM labelled with various fluorescent markers or probes have revealed that the IPMCs 
are stable but dynamic structures (Gaudin et al., 2013a; Mlcochova et al., 2013).  
 
 
Figure 1.13:  Virus assembly compartments in MDM.  
The internal plasma membrane-connected compartments (IPMCs) where HIV assembles are 
morphologically complex, consisting of interconnected vacuole-like structures filled with viruses 
(V). HIV buds into the IPMC (magenta arrow). The green arrow points to an immature virus in 
the IPMC. L, lipid droplet. Scale bar, 1 µm. EM by A. Pelchen-Matthews. 
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Several markers that are found on the cell surface membranes of MDM have also been 
found on IPMCs. These include the tetraspanins CD9, CD81 and CD53 (Deneka et al., 
2007). In addition, IPMCs also contain the PM marker CD44 (Welsch et al., 2007; 
Pelchen-Matthews et al., 2012), a hyaluronic acid receptor that is incorporated into 
budding virions (Lawn et al., 2000; Chertova et al., 2006). In uninfected macrophages, 
the tetraspanin CD63 is associated with endosomes labelled with the lysosomal-
associated membrane protein 1 (LAMP-1) but is not detected in IPMCs. However, in 
HIV infected cells, CD63 accumulates in IPMCs and is incorporated into virions, 
suggesting that this marker cycles through the assembly compartments (Deneka et al., 
2007; Ruiz-Mateos et al., 2008; Marsh et al., 2009). IPMCs do not contain or they 
poorly label with early endosome antigen 1 (EEA-1), an early endosome marker, or 
LAMP-1 (Deneka et al., 2007; Marsh et al., 2009; Giese and Marsh, 2014). Moreover, 
IPMCs fail to label with 2x FYVE-GFP (double FYVE2 zinc finger domain fused to 
GFP) which binds phosphatidylinositol 3-phosphate that is predominantly on early 
endosomes and intralumenal vesicles of MVBs, further indicating that the 
compartments are not endosomal (Mlcochova et al., 2013). A recent study has shown 
that CD36, a multi-ligand scavenger receptor present on the surface of macrophages, is 
also present on the IPMCs of uninfected and infected cells (Berre et al., 2013).  
 
A prominent feature of IPMCs seen in EM is the presence of extensive electron dense 
coats on the cytoplasmic aspects of the membrane (Pelchen-Matthews et al., 2012). 
These are morphologically distinct to clathrin coats and do not label with anti-clathrin 
antibodies. Detailed screening experiments showed these structures have features in 
common with focal adhesions, that is, they contain the integrin complex 
CD18/CD11b/c, as well as the focal adhesion proteins paxillin, talin and vinculin often 
in close association with filamentous actin. Several investigations have revealed that the 
cytoskeleton and the focal adhesion complex proteins are important in maintaining the 
integrity of the IPMCs (Gaudin et al., 2012; Pelchen-Matthews et al., 2012; Mlcochova 
et al., 2013). Depletion of CD18 results in the dispersal of the usually compact IPMCs 
and disappearance of the electron-dense coats. However, virus release was not 
significantly affected (Pelchen-Matthews et al., 2012). The dispersed IPMC 
                                                
2Named after the four cysteine-rich in which it was initially identified: Fab 1, YOTB, Vac 1 (vesicle transport 
protein), and EEA1 (early endosome antigen 1). 
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morphology has also been observed when latrunculin is used to depolymerise actin in 
MDM, and this is paralleled by increased virus release (Mlcochova et al., 2013). 
Furthermore, microtubule networks have been implicated in the maintenance of IPMCs, 
whereby kinesin KIF3A was reported to drive the transport of IPMCs towards the cell 
surface, thus facilitating virus release from macrophages (Gaudin et al., 2012).  
 
It is currently controversial how IPMCs are formed (Chu et al., 2012a; Giese and 
Marsh, 2014). It has been suggested that the compartments form when HIV is tethered 
at the plasma membrane by tetherin/CD317/BST-2 (bone marrow stromal cell antigen 
2) and subsequently phagocytosed by the macrophages (Chu et al., 2012a), in support of 
a previous study (Jouvenet et al., 2006). Tetherin is a glycoprotein made up of a short 
N-terminal transmembrane domain, an extracellular coiled-coil domain, and a C-
terminal glycophosphatidylinositol lipid anchor (Malim and Bieniasz, 2012). It is 
interferon-α–inducible and can restrict several enveloped viruses by physically tethering 
newly assembled particles at the plasma membrane. However, HIV-1 has evolved to 
antagonise tetherin through its accessory protein, Vpu, which promotes proteasomal 
and/or lysosomal degradation of tetherin (Neil et al., 2008; Mangeat et al., 2009; Hotter 
et al., 2013; Venkatesh and Bieniasz, 2013). By using HIV-1 vpu mutants defective in 
counteracting tetherin, as well as depleting tetherin with siRNA, our group has 
demonstrated that tetherin is not required for the formation or maintenance of the 
IPMCs in primary human macrophages (Giese and Marsh, 2014). However, it is still not 
clear how IPMCs develop, nor the function of the compartment in infected cells. 
 
1.6.3 Dendritic cells 
Like macrophages, (DCs) are derived from haematopoietic progenitors and they reside 
in most lymphoid and non-lymphoid tissues (Section 1.6.2, Figure 1.11) (Geissmann et 
al., 2010; Hashimoto et al., 2011; Tsunetsugu-Yokota and Muhsen, 2013). DCs capture 
and present extracellular antigens to CD4+ T cells, and therefore initiate specific 
(adaptive) immune responses. For antigen presentation, DCs and CD4+ T cells form 
intimate supermolecular contacts called immunological synapses. (Dustin, 2014; 
Shimauchi and Piguet, 2014).  
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Although HIV infects DCs, these cells have low levels of CD4, CCR5 and CXCR4 
molecules for HIV binding (Wu and KewalRamani, 2006). Dendritic cells exhibit two 
mechanisms of HIV transmission: cis-infection where the cells are productively 
infected; and trans-infection where DC-SIGN (dendritic cell-specific intercellular 
adhesion molecule-3- grabbing non-integrin) molecules on the surface of DCs capture 
the virus from the extracellular milieu, and transmit it to uninfected CD4+ T cells, 
without becoming infected themselves (Turville et al., 2004). EM studies of DCs have 
revealed deep invaginations of the plasma membrane, containing numerous virus 
particles (Garcia et al., 2005; Felts et al., 2010). This compartmentalised virus can be 
transferred through intimate contacts, the so-called virological synapses (VS), between 
donor and target cells. Some authors use distinct names for the cell contacts depending 
on whether the donor cell is infected or not, as in the case of DCs (Figure 1.14). 
Contacts made between uninfected donor and target cells have been dubbed infectious 
synapses, whilst those made between infected donor and target cells have been named 
VS (Tan and Sattentau, 2013). 
 
 
Figure 1.14: Cell contacts that facilitate HIV transmission.  
(A) VS architecture (T cell). The primary signal for VS assembly is Env-CD4 binding. 
Subsequent stabilization is achieved by interactions between ICAM-1 and LFA-1. Virus buds at 
the interface and infects the target cell in a CD4-dependent manner. (B) Infectious synapse 
architecture (Dendritic cell). The synapse forms as cell adhesion molecules interact, resulting in 
release of mature HIV-1 virions from the surface-accessible virus-containing compartment into 
which mature HIV-1 particles were previously captured by various cell-surface molecules 
including DC-SIGN. (C) VS architecture (Monocyte-derived macrophage, MDM). DC-SIGN, 
dendritic cell-specific intercellular adhesion molecule-3- grabbing non-integrin; ICAM-1, 
intracellular adhesion molecule 1; LFA-1, lymphocyte function associated antigen 1. Taken from 
Schiffner et al. (2013) 
T. Schiffner et al. / Vaccine 31 (2013) 5789– 5797 5791
Fig. 2. (A) VS architecture (T cell). The primary signal for assembly is Env-CD4 binding. Subsequent stabilization is achieved by interactions between ICAM-1 and LFA-1.
Virus  buds at the interface and infects the target cell in a CD4-dependent manner. (B) IS architecture (Dendritic cell). The synapse forms as a result of cell–cell adhesion
molecule interactions, and results in release of mature HIV-1 virions from the temporary surface-accessible viral storage compartment into which mature HIV-1 particles were
previously captured by various cell-surface molecules including DC-SIGN. (C) VS architecture (Monocyte-derived macrophage, MDM).  The structure displayed is hypothetical
–  due to limited published data – but probably shares features of both the T cell VS and the DC IS [43]. HIV-1 is known to assemble into a virus-containing compartment in
macrophages and presumably relocates to the target cell synapse where transfer appears to be CD4-Env dependent [40].
In the context of prophylactic vaccine strategies which aim
to prevent mucosal transmission of HIV-1 with antibodies, it is
important to resolve whether cell-to-cell spread represents an anti-
body evasion mechanism: cell-to-cell spread has been implicated
in inter-host viral trans ission in the macaque model of SIV [46], in
initial mucosal viral amplification following transmission [47], and
in viral broadcasting throughout secondary immune tissues [44] –
all critical steps in establishing HIV-1 infection. However, the assays
currently used to evaluate neutralization activity employ cell-free
viral inocula. In fact, in the only instance of HIV-1 vaccine-induced
protection reported to date [48] protection did not correlate with
cell-free neutralization activity, although a correlation with non-
neutralizing anti-Env antibody titres was found [49].
The hypothesis that cell-to-cell spread is an HIV-1 antibody eva-
sion mechanism was suggested by early studies which found that
patient sera capable of neutralizing cell-free virus infection were
unable to neutralize infection in co-cultures of patient and donor
peripheral blood mononuclear cells (PBMC) over multiple rounds
of infection [38]. Today, with the accumulation of a large panel of
bNAbs there are more powerful and specific tools with which to
address this question. However, as we outline below, significant
uncertainty remains. In this review we briefly discuss recent find-
ings regarding mechanisms of cell-to-cell transmission at immune
cell infectious transfer structures termed virological synapses (VS)
and infectious synapses (IS) and then focus on the prospects for
neutralizing antibody blockade.
2. Synaptic infection mechanisms
In early studies using cell lines and lab-adapted viruses, cell–cell
fusion (syncytium formation) was identified as the principal mech-
anism of cell-to-cell transmission, although it subsequently became
obvious that syncytia occur much less frequently with primary cells
and primary (mainly CCR5-using) viruses [43]. It is now established
that HIV-1 cell-to-cell transmission occurs at structurally distinct
intercellular contact zones via VS [39] and IS [41]. Both types of
synapse require transient adhesive junctions between infected and
target cell [50] but they are differentiated by the infection status of
the donor cell: VS are formed by HIV-infected cells whereas IS are
formed by uninfected cells that have captured free HIV-1.
A canonical feature in VS formation is the binding of Env
expressed by the infected donor cell to CD4 on the target cell
[39] (Fig. 2A). The subsequent assembly is stabilized by adhe-
sion molecule interactions [50,51], and a macromolecular structure
assembles which is reminiscent of, but distinct from, the immuno-
logical synapse [52]. The secretory apparatus of the infected T cell
is hijacked by HIV-1 and polarizes to the cell–cell contact zone
[53]. It is possible for one infected T cell to assemble multiple VSs
with s veral target cells simultaneously (polysynapses) [54]. Addi-
tional mechanisms for directed retroviral cell-to-cell transfer have
been described, mainly comprising actin-dependent membrane
projections, such as nanotubes and filopodia, which permit virion
cell-membrane “surfing”, but remain dependent on host receptors
for fusion (reviewed previously [55]). Although the relative impor-
tance of these various mechanisms is unclear, VS-mediated transfer
of HIV-1 appears to be more efficient in vitro [56] and has been
observed in vivo [45].
In contrast to VS, IS are formed by uninfected cells that
harbour captured virus. Myeloid-lineage dendritic cells (mDC)
capture HIV-1 using a variety of receptors including the C-type
lectins Dendritic Cell-Specific Intercellular adhesion molecule-3-
Grabbing Non-integrin (DC-SIGN) [57], Siglec-1 [58] and heparan
sulphate proteoglycans [59], a process that does not substitute for
CD4/coreceptor engagement and so does not directly result in infec-
tion [60]. The adsorbed virions are maintained in an infectious state
within complex surface-connected plasma membrane invagina-
tions [61–64]. When the DC subsequently contacts an uninfected
target cell such as a CD4+ T cell, the surface bound virus becomes
liberated from its invaginated holding compartment and engages
receptors on the target cell resulting in infection (a process known
as trans-infection) [60] (Fig. 2B).
3. HIV-1 entry mechanisms
The conventional entry pathway for HIV-1 virions is receptor-
activated fusion at the target cell plasma membrane at neutral pH
[65]. However recent evidence suggests that cell-free viral fusion
can occur at either the plasma membrane or from within endo-
somal compartments (reviewed in [66]). It is unclear whether one
mode of entry dominates the other and whether the mode of entry
is cell-type dependent, but regardless of this the overall receptor
dependence and tropism of the virus appear equivalent [66].
In VS-mediated transfer models there are conflicting reports
regarding whether endocytic uptake of intact virions by the
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 HIV-1 pathogenesis 1.7
HIV-1 infections in humans has three distinct phases involving different pathogenic 
mechanisms: (1) acute/early infection; (2) chronic/asymptomatic infection; and (3) 
AIDS (Figure 1.15) (Simon and Ho, 2003; Maartens et al., 2014). The acute phase is 
observed in the first 2-3 weeks following infection. It is characterised by very high 
levels of viremia, and a transient but dramatic decline in the memory CD4+ T cells in 
the mucosal tissues. In both HIV and SIV early infections, the virus massively infects 
and depletes mucosal-associated lymphoid tissue (MALT) CD4+CCR5+ memory T 
cells (Derdeyn and Silvestri, 2005). The host then mounts a humoral immune response 
(sero-conversion), resulting in a decline in the viral load until it reaches a certain set 
point, and recovery in the CD4+ T cell count, which may differ between individuals and 
can be influenced by host factors and the virus genotype. A slow rate of lowering 
viremia and high viral set point are linked to higher level of proviral diversity in HIV-
1C gp120, from zero to 200 days following sero-conversion (Novitsky et al., 2009), 
which may impact on disease progression in the absence of therapy. 
 
The chronic infection phase that follows sero-conversion is characterised by a slow 
decline of CD4+ T cells in the peripheral blood. Chronic immune activation is believed 
to fuel the depletion of CD4+ T cells, thereby compromising host immunity. This 
depletion may be caused by (1) activated CD4+ T cells becoming new targets for HIV 
replication and cell death; and/or (2) disruption of cell cycle control, leading to 
activation-induced apoptosis. The chronic phase is variable, but generally long and 
asymptomatic. Chronic immune activation characterises progressive HIV infection, 
with circulating microbial products contributing to activation (Brenchley et al., 2006). 
The compromised immune system predisposes individuals to opportunistic infections, 
an aggregate of which may lead to death if untreated. It is the aggregate of these 
opportunistic infections and the decline in immunity that give rise to the clinical 
condition known as AIDS.  
 
There is variation in the rate of disease progression in HIV infected people. Generally, 
AIDS manifests itself within 10 years in most HIV positive people, whilst about 1-5% 
do not develop AIDS until after about 15 years or more (Carrington et al., 2001). Many 
factors act in concert to determine progression rate. In addition to viral attributes, host 
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factors are important in disease progression (Carrington et al., 2001; Arenzana-
Seisdedos and Parmentier, 2006). Though HIV is not a genetic disease, about 10% 
variation in disease progression in the United States, where HIV-1B is the predominant 
subtype, has been attributed to host genetics (O'Brien and Nelson, 2004). Therefore, 
both viral and host factors are important in the outcome of HIV-1 infections. 
 
 
Figure 1.15: The natural course of untreated HIV-1 infection, and changes after anti-
retroviral therapy (ART). 
(A) In response to HIV infection, the body initially produces non-neutralising antibodies and HIV-
specific CD4+ and CD8+ T cells, associated with a transient decline in HIV-1 RNA in the blood. 
(B) In the presence of ART, the viral load is reduced, with the subsequent recovery of the CD4+ 
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Currently, there is still no effective cure or vaccine for HIV infection. The most widely 
used treatment is a combination of three or more ART drugs that act on different viral 
targets, and that constitute what is known as highly active anti-retroviral therapy 
(HAART). The World Health Organisation recommends that individuals with CD4+ T 
cell count of ≤350 cells/mm3 of blood should be initiated on HAART even if they are 
asymptomatic, whilst anyone else who has AIDS defining clinical conditions should be 
put on HAART irrespective of the CD4+ T cell count (WHO, 2013). Worldwide, about 
12.9 million people received this treatment at the end of 2013, showing about 37% 
coverage of all the people who are living with HIV (UNAIDS, 2014). The aim of 
HAART is to reduce circulating virus (viral load) to undetectable levels, with the result 
that CD4+ T cell counts improve and disease progression is delayed. Despite the 
beneficial effects of the HAART, the emergence of drug-resistant HIV strains and drug 
toxicities are a great concern in the management of HIV infections (Doualla-Bell et al., 
2006; Novitsky et al., 2007; Wester et al., 2009; MacLeod et al., 2010; Wester et al., 
2010; Wester et al., 2012; Tourret et al., 2013). Thus, there is a continued need for new 
approaches to treat or prevent HIV replication. To this end, an increasing effort is being 
directed at understanding how HIV interacts with host cells, including macrophages, 
with the view that these might offer novel therapeutic targets. 
 
 
 Aims of this thesis 1.8
Several independent studies have shown that in macrophages HIV-1 buds into IPMCs. 
Currently it is not clear whether IPMCs are the only sites for HIV-1 assembly and 
budding in macrophages, or whether the cell surface is also used, as viruses that bud at 
the surface may dissociate (Figure 1.16) and be lost from the samples. Therefore, the 
main aim of this thesis was to examine in detail the sites where HIV assembles in 
primary human macrophages. This was achieved by modulating HIV-ESCRT 
interactions to arrest virus budding, thereby forming stable budding intermediates. The 
assembly sites for HIV-1 were then examined and quantitatively analysed to determine 
where HIV was enriched in macrophages.  
 




Figure 1.16: Schematic representation of HIV-1 budding in macrophages.  
Several reports show that HIV-1 can be targeted (green arrow) to the IPMCs. Currently it is not clear 
whether and how much HIV is also targeted (orange arrow) to the cell surface in macrophages.  
 
In Chapter 3, I investigated the requirement of the ESCRT machinery in HIV-1 budding 
in macrophages, as this has not been previously examined to any great extent in this cell 
type. Two approaches were used to achieve this: (1) using siRNA to deplete Tsg101 and 
ALIX in infected macrophages; (2) mutating the motifs that recruit Tsg101 and ALIX in 
HIV-1 Gag constructs or a full HIV-1 molecular clone. siRNA of the key ESCRT 
factors, Tsg101 and ALIX, had only limited effects on virus release. Therefore a second 
approach was developed, in which I disrupted the Gag-ESCRT interaction using HIV-1 
mutants defective in ESCRT recruitment. Specifically, I generated full-length molecular 
clones of HIV-1 R3A where the Tsg101 and ALIX recruiting motifs were mutated to 
generate HIV-1 R3A PTAP−, PTAP−YP− and Δp6. Inhibition of virus release was 
demonstrated biochemically in HEK 293T cells and in primary macrophages. This 
chapter therefore describes how I developed the tools that were later used to investigate 
HIV assembly in macrophages. 
 
Chapter 4 describes the morphological characterisation of these HIV mutants (HIV-1 
R3A PTAP−, PTAP−YP− and Δp6) in HEK 293T cells. I used electron microscopy 
approaches to analyse the budding of these virus mutants. The mutants showed only 
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HIV particle release. Furthermore, I developed approaches to rescue particle production 
for these mutants in order to produce infectious mutant virus stocks for the 
investigations in Chapter 5.  
 
In Chapter 5, macrophages were infected with the virus mutants. Infected cells were 
immuno-labelled for HIV-1 Gag and imaged by confocal microscopy so that virus 
distribution could be determined quantitatively. On 77% of cells, I could only detect 
virus budding into IPMCs. To analyse the location of HIV assembly at higher 
resolution, viruses were also visualised by EM. Infected cells were identified using 
correlative on-grid immuno-labelling, and the distribution of the immature viruses was 
determined. I found that 97% of the viruses were in the IPMCs. Two-dimensional 
stereology was employed to estimate the area of plasma membrane associated with the 
IPMCs and with the cell surface. This revealed that HIV was highly enriched in the 
IPMCs.  Together, the immunofluorescence and EM analyses demonstrate that in 
mature human MDMs, HIV-1 assembly is specifically targeted to IPMCs. 
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2. Materials and Methods 
 
 Antibodies and reagents 2.1
All chemicals were obtained from Sigma-Aldrich (Dorset, UK), media and supplements 
were obtained from Life Technologies (Paisley, UK), restriction enzymes and the DNA 
ladder were purchased from Promega (Southampton, UK), EM chemicals and supplies 
where procured from TAAB Laboratories (Reading, UK), unless otherwise specified. 
Tissue culture plasticware was obtained from Thermo Fisher Scientific (Cramlington, 
UK) or Techno Plastic Products AG (Trasadingen, Switzerland). 
 
Table 2.1: List of antibodies used in this thesis 








Anti-p24 (Kal-1) Mouse IgG1  Dako (Ely, UK)  
Anti-p24 (38:96K, ARP365) Mouse IgG1 NIBSC Centre for AIDS Reagents (South Mimms, UK)  
Anti-p24 (EF7, ARP366) Mouse IgG1 NIBSC Centre for AIDS Reagents (South Mimms, UK)  
Anti-p17 (4C9, ARP342) Mouse IgG2a NIBSC Centre for AIDS Reagents (South Mimms, UK)  
Anti-Nef (EH1) Mouse IgG1 Jim Hoxie, University of Pennsylvania, PA, USA 







Anti-Adaptin-γ Mouse BD Biosciences (Oxford, UK) 
Anti-ALIX Rabbit polyclonal 
Wes Sundquist (University of Utah, Salt Lake City, 
USA) 
Anti-CD195 Mouse anti-human BD Biosciences (Oxford, UK) 
Anti-CD14 Mouse anti-human BD Biosciences (Oxford, UK) 
Anti-CD4 Mouse anti-human BD Biosciences (Oxford, UK) 
Anti-CD3 Mouse anti-human BD Biosciences (Oxford, UK) 
Anti-CD44 (MEM-85) Mouse IgG2b Abcam (Cambridge, UK)  
Anti-Tsg101 (M-19) Goat IgG polyclonal  Santa Cruz Biotech. (Santa Cruz, USA) 











Anti-Mouse IgG1 (A488) Goat Life Technologies (Paisley, UK)  
Anti-Mouse IgG2a (A568, A594, A647) Goat Life Technologies (Paisley, UK)  
Anti-Mouse IgG2b (A568, A594, A647) Goat Life Technologies (Paisley, UK)  
Anti-Mouse IgG (H+L) Rabbit Rockland, Gilbertsville (PA, USA) 
Anti-mouse IgG (H+L) A488 Rabbit Life Technologies (Paisley, UK)  
Anti-Goat HRP Donkey  Santa Cruz Biotech. (Santa Cruz, USA) 
Anti-Mouse HRP Goat Thermo Fisher Scientific (Cramlington, UK)  
Anti-Rabbit HRP Goat  Thermo Fisher Scientific (Cramlington, UK)  
 
  




2.2.1 Cell lines 
HeLa cells were used to test small interfering RNA (siRNA) oligonucleotides before 
optimising the protein knockdown in primary human monocyte-derived macrophages 
(MDM). TZM-bl cells, a gift from J. Martin-Serrano (Kings College London, London, 
UK), were used to determine titres for virus stocks. The TZM-bl cells are a CXCR4-
positive HeLa cell clone engineered to express β-Galactosidase, CD4 and CCR5 (Platt 
et al., 1998; Wei et al., 2002). HEK 293T (ATCC, Teddington, UK) cells were used for 
testing expression of molecular clone constructs.  
 
To prepare new cultures, cells cryo-preserved in medium supplemented with 10% v/v 
dimethylsulfoxide (DMSO) and 20% v/v heat-inactivated foetal bovine serum (FBS) 
(PAA, Yeovil, UK) were retrieved from liquid nitrogen storage and thawed at 37°C. 
The cell suspension was added to 10 mL pre-warmed complete DMEM (that is, DMEM 
supplemented with 10% v/v FBS, 2 mM L-glutamine, 100 units/ml of penicillin and 
100 µg/ml of streptomycin), centrifuged at 500 g for 8 min, and then resuspended in 10 
mL medium. The suspension was plated in a 10-cm tissue culture dish and incubated at 
37°C, 5% CO2 until 70-80% confluency, before passage.  
 
Adherent cells were normally trypsinised in 1 mL 0.05% v/v trypsin-EDTA. Cells were 
maintained in complete DMEM. As HEK 239T cells have poor adhesion to tissue 
culture surfaces, for experiments, they were plated on surfaces coated with 0.01% w/v 
sterile tissue culture grade poly-L-lysine.  Poly-L-lysine is a polycation that enhances 
electrostatic interactions between negatively charged components of the cell membrane 
and the culture surface. The following tissue culture plate formats were used for both 
HEK 293T cells and HeLa cells: 6-well (4.2 x 105 cells/well in 3 mL medium), 12-well 
(0.75 x 105 cells/well in 500 µL) or 24-well (1.5 x 105 cells/well in 1mL).  
 
2.2.2 Preparation of macrophages 
Monocytes were isolated from peripheral blood mononuclear cells (PBMCs) by gelatine 
adherence and then differentiated to macrophages with macrophage-colony stimulating 
factor (M-CSF) and recombinant human interleukin-2 (IL-2), both purchased from 
R&D Systems (Abington, UK). PBMCs were isolated from buffy coats obtained from 
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healthy blood donors (National Blood Services, Essex, UK). The buffy coats (about 50 
mL) were mixed with PBS (Life Technologies, Paisley, UK) at a ratio of 1:1. The 
diluted buffy coats were overlaid on 15 mL Lymphoprep (Alere, Stockport, UK) in 50-
mL centrifuge tubes, and centrifuged at 930 g for 30 min at 20°C to separate 
components. The white PBMC layers were collected from the interface, washed in PBS 
and pelleted at 500 g for 8 minutes. The cells were resuspended in RPMI 1640 
supplemented with 10% v/v human serum (HS) and plated on 15-cm tissue culture 
dishes coated with 2% w/v gelatine. For the monocytes to adhere to the gelatine coating, 
the plates were incubated for 2 hrs at 37°C, 5% CO2. The plates were washed in RPMI 
1640 to remove unattached monocytes. Fresh RPMI with 10% v/v HS was added, and 
the plates were left to incubate overnight.  
 
The next day, cells from each donor were pooled into a 50-mL centrifuge tube, and 5 
mM EDTA (ethylenediaminetetraacetic acid) in PBS was added to plates to detach the 
remaining cells. The cells were then washed once in PBS by centrifugation as described 
above. Cells were resuspended in RPMI 1640 and enumerated using the Scepter 
automated counter (Millipore, Watford, UK). A small aliquot of the cells was set aside 
for routine analysis of the monocytes for surface markers CD4, CD3, CD14 and CCR5 
by flow cytometery (Figure 2.1). CD14 is a marker for monocytes, whilst CD3 is a 
maker for T cells. CD4 and CCR5 are the receptor and co-receptor, respectively, 
required for HIV binding and entry into cells.  
 
Prior to immunostaining, non-specific binding of antibodies to Fc receptors on the cells 
needed to be blocked. To this end, cells were maintained in FACS block (PBS, 1% v/v 
FBS, 0.05% v/v Na Azide, 6 µg/mL Human IgG) at 4°C for 30 min. A mixture of 
antibodies (90 µL FACS block, 45 µL anti-CD3-PerCP, 45 µL anti-CD4-FITC, 45 µL 
anti-CD14-APC, 45 µL anti-CCR5-PE) was prepared and 100 µL of the mixture was 
added to washed cells. Washes were performed in 100 µL FACS buffer (PBS, 1% v/v 
FBS, 0.01% v/v Na Azide) by centrifugation at 500 g. The cells were incubated on a 
shaker at 4°C for at least 1 hr. Washed cell were resuspended in FACS buffer for 
analysis with the FACSCalibur flow cytometer (BD Biosciences, Oxford, UK) and the 
FlowJo software (TreeStar, Ashland, USA) (Figure 2.1). 
 




Figure 2.1: A typical analysis of monocytes for cell surface markers.  
Monocytes were isolated from PBMCs and analysed for the expression of CD3, CD4, CCR5 and 
CD14.  The dot plot on the left shows gating on populations of T cells and monocytes labelled with 
antibodies coupled to different fluorochromes against the makers indicated on the axis of the 
histograms. The proportions of cells in the cell suspension are also indicated, for example, 49.6% of 
the cells were monocytes. The green curves show expression levels of the markers, whilst the black 
curves show unlabelled control cells.  
 
Different densities of cells were plated in tissue culture plates and dishes according to 
experimental requirements: 5x106 cells per 25 cm2 flasks; 2x106 cells per 6-well (9 
cm2); 1x106 cells per 12-well (3.8 cm2) and 0.4x106 cells per 24-well (1.9 cm2). Where 
required, coverslips were placed in the wells before seeding. The cells were incubated 
for 2 hrs at 37°C, and medium was changed to add RPMI 10% HS containing 10 ng/mL 
M-CSF and 5 ng/mL IL-2. The cultures were incubated for 2 days at 37°C before 
replacing the M-CSF-containing medium with RPMI 10% HS, and adhered monocytes 
were allowed to differentiate into monocyte-derived macrophages (MDM) until used for 
experiments, 7-8 days after isolation.  
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 Virus preparation 2.3
2.3.1 HIV-1 BaL WT 
HIV-1 BaL is an R-5 tropic strain, originally isolated from lung tissue of an HIV 
infected patient in 1986 (Gartner et al., 1986). The initial stock of the virus used in this 
thesis was obtained from R. Shattock, St. George’s Hospital, London, UK.  To make 
virus stocks, PBMC-grown HIV-1 BaL was used to inoculate MDM in 25 cm2 flasks. 
Culture supernatants were collected every 3 to 4 days, and cleared of cell debris by 
centrifugation at 500 g for 8 min. Virus aliquots were frozen and stored in liquid 
nitrogen until required.  
 
2.3.2 Determination of virus titres 
Infectious virus titres were measured on TZM-bl cells. The cells were seeded in 96-well 
plates at 2 x 104 cells/well in 100-µL complete DMEM, and grown overnight. The cells 
were infected by spinoculation (centrifugation at 1,300 g and 25°C for 2 hrs) with 100 
µL of serially diluted virus. Spinoculation enhances CD4-dependent binding of HIV-1 
to cells (O'Doherty et al., 2000). A virus stock of known titre (in focus forming units 
[FFU/mL]) was used as a standard. After 24 hrs of incubation of the infected cultures, 
the Galacto-Star Reporter Gene Assay System (Life Technologies, Paisley, UK) was 
used to quantify β-Galactosidase activity in cell lysates, according to the manufacturer’s 
instructions (Figure 2.2). The luminescence (expressed as relative light units [RLU]) 




Figure 2.2: A typical standard curve for the reference virus (HIV-1 BaL).  
The standard curve was used to calculate titres in newly prepared virus stocks. 
y = 1.3102x - 332851 
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 Infection of MDM with HIV-1 2.4
MDM in tissue culture plates were infected with HIV-1 WT and mutant viruses at 3 and 
6 focus forming units per cell (FFU/cell), respectively, by spinoculation and incubated 
for 24 hrs. The culture media were replaced with fresh media and incubated further, 




 siRNA transfections 2.5
To deplete the ESCRT/ESCRT-associated proteins, Tsg101 and ALIX, HIV-1-infected 
MDM were transfected with the respective siRNA, using LipofectamineTM RNAiMAX 
(Life Technologies, Paisley, UK) as the transfection reagent. To prepare the transfection 
complex, 60 nM of duplex siRNA oligonucleotides (Table 2.2) were mixed with 8 µL 
LipofectamineTM RNAiMAX in Opti-MEM reduced serum medium to a total volume of 
250 µL, for one well in a 12-well plate. Cultures were incubated at 37°C, 5% CO2. The 
virus and cells were harvested 6 days after siRNA transfection. I had determined that 
the proteins were optimally depleted on day 6, by setting up two parallel cultures 
transfected with either 60 or 90 nM of Tsg101 siRNA oligonucleotides per experiment, 
and incubating one set-up for 3 days, and other for 6 days. Protein levels were analysed 
by western blotting and quantified as shown in Figure 2.3. The optimal conditions for 
the depletion of Tsg101 were also optimal for ALIX depletion in MDM.  
 
Table 2.2: siRNA used to deplete Tsg101 and ALIX 
 
Sequences (5’ to 3’) Supplier 
Tsg101 
GCAUGUACGUCUUCUGUCCCGUAAA 











    




Figure 2.3: Optimisation of Tsg101 depletion in MDM.  
Different Tsg101 siRNA oligonucleotides (sequence ID numbers: A = HSS111013; and B = 
HSS186437) were tested in MDM at 60 and 90 nM. Two parallel experiments were set-up and 
incubated for 3 and 6 days each. The protein level was depleted when the transfection siRNA 
and RNAiMAX were used at a ratio of 30:4, and incubated for 6 days. Notably, the residual 
protein levels are still high on day 3 post-transfection, and this may be sufficient to support virus 
release and accumulation in the IPMCs before day 6.  
 
 
 Plasmid DNA transfections  2.6
In this thesis, introducing plasmid DNA into cell lines using the reagent-based 
transfection method is simply referred to as transfection. This method was used to 
transfect HEK 239T or HeLa cells with the constructs shown in Table 2.3. Cells were 
seeded a day prior to transfection. Briefly, plasmid DNA and FuGENE HD transfection 
reagent (Roche, Welwyn Garden City, UK) were mixed at a ratio of 1:3 [µg DNA:µl 
FuGENE HD] in OptiMEM to form transfection complexes, and incubated for 15 min 
at room temperature, before adding to cell cultures. Transfected cultures were incubated 




60 nM 90 nM 60 nM 90 nM 60 nM 60 nM 
HSS111013 HSS186437 HSS111013 HSS186437 
30:1 30:4 
3 days 36.62 52.86 41.91 55.3 31.61 35.7 
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Table 2.3: List of plasmids used in this thesis 
Name Obtained from 
pCMS28-mCh-Alix  J. Martin-Serrano (Kings College London, London, UK) 
pCR3.1 HA-Alix  J. Martin-Serrano (Kings College London, London, UK) 
pGag-EGFP WT and PTAP− Wesley Sundquist (University of Utah, Salt Lake City, USA) 
pGFP-VPS4 WT and EQ Adrian Isaacs (University College London, London, UK) 
pNL4.3-R3A WT Jim Hoxie (University of Pennsylvania, Philadelphia, USA) 
pNL4.3-R3A PTAP−, YP−, PTAP−YP−, & Δp6 This thesis 
pRK5GagBaL WT Marsh Lab, UCL 
pRK5GagBaL PTAP−, YP−, PTAP−YP− This thesis 
 
 Nucleofection/Electroporation 2.7
Nucleofection or electroporation is an instrument-based transfection method. The 
procedure was used to introduce plasmids into macrophages because this cell type is 
difficult to transfect using reagent-based methods (Stacey et al., 1993). Using an empty 
pmaxGFP vector, I had determined that the transfection efficacy of primary 
macrophages varied between 15 and 35% for cells from different blood donors.  
Monocytes were differentiated into macrophages for 14 days so that IPMCs can develop 
before electroporation (Pelchen-Matthews et al., 2012; Mlcochova et al., 2013). The 
cells were washed in PBS, incubated on ice to detach, resuspended in PBS and counted.  
The suspended cells (106 cells) were pelleted and, mixed with plasmid DNA (10 µg 
HIV-1 plasmid; 5 µg other plasmid DNA), and electroporated using the Amaxa Human 
Macrophage Nucleofector Kit and Amaxa Nucleofector II device (Lonza, Kent, UK). 
Electroporated cells were replated and incubated for 24 hrs at 37°C, 5% CO2.  
 
 Western blotting 2.8
Western blotting (or immunoblotting) was carried out to analyse cells for the expression 
of specific proteins. Cell cultures were washed in PBS and lysed in Laemmli sample 
buffer (Sigma-Aldrich, Dorset, UK). For viruses or virus-like particles (VLPs) released 
into culture supernatants, the medium was first centrifuged to pellet cell debris. To 
concentrate viruses or VLPs, the supernatant was overlaid on a 20% w/v sucrose 
cushion, and centrifuged at 100,000 g for 2 hrs at 4°C. The viruses or VLPs were lysed 
in Laemmli sample buffer. All lysates were heated at 95°C for 10 min, under β-
mercarptoethanol reducing conditions.  
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Proteins in lysates were resolved using sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). Separated proteins were transferred to an Immobilon-P 
polyvinylidene diflouride membrane (PVDF) (Millipore, Watford, UK) using the Trans-
Blot SD Semi-Dry Transfer Cell (Bio-Rad, Hemel Hempstead, UK). The blots were 
blocked with blocking buffer (PBS, 0.1% v/v Tween, 5% w/v milk powder [Premier 
Foods, St. Albans, UK]) for 1 hr at room temperature, and incubated overnight at 4°C 
with the appropriate primary antibodies. All antibodies were prepared in blocking 
buffer. The antibodies were washed off in 0.1% v/v Tween in PBS. The blots were 
incubated for 1 hr with Horseradish peroxidase (HRP)-conjugated secondary antibodies 
(Table 2.1) and washed off. Subsequently, membranes were incubated for 5 min in 
SuperSignal® West Dura Extended Duration Substrate (Thermo Scientific, Rockford, 
IL, USA), and chemiluminescence was detected using ImageQuant LAS400 mini (GE 
Healthcare UK Limited, Buckinghamshire, UK). Signal intensities were quantified 
using ImageJ software (Open Access).  
 
To quantify band signals on western blots, the integrated density (sum of the values of 
the pixels in the image or selection) was divided by the area (area of selection in square 
pixels), using ImageJ. HIV release efficiency was calculated using equations 1 and 2 for 
MDM and HEK 293T cells, respectively. The release efficiency of VLPs from HEK 
239T cells was calculated using equation 3.  
 
Equation 1 (for MDM): Virus  release  efficiency  (%) = p24c+ p24v+ p55v  p24c+ p55c+ p24v+ p55v   x  100% 
 
Where:  p24c is cell-associated p24  
  p55c is cell-associated p55 
p24v is virion p24 
  p55v is virion p55 
Because in macrophages HIV accumulates in IPMCs, viral p24 in cell lysates represents 
mature virus that is detached from the host membrane.  
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Equation 2 (for HEK 293T cells): Virus  release  efficiency  (%) = p24v+ p55v  p24c+ p55c+ p24v+ p55v   x  100% 
 
For the HIV-1 Δp6 mutant that produces a truncated Gag polyprotein, the p55Δp6 band 
was used for the calculations. 
 
Equation 3 (for HEK 293T cells): VLP  release  efficiency  (%) = p55vlp  p55c   x  100% 
 
Where:  p55vlp is VLP p55 
  p55c is cell-associated p55 
 
 
 Mutagenesis and subcloning 2.9
2.9.1 Site-directed mutagenesis  
To generate mutants of Gag or an HIV-1 full molecular clone, site-directed mutagenesis 
was performed using the QuikChange® Site-Directed Mutagenesis Kit (Agilent 
Technologies, Wokingham, UK) following the manufacturer’s instructions. Briefly, a 
50-µL polymerase chain reaction (PCR) was set up containing 20 ng template plasmid, 
100 ng/µL of each primer, high-fidelity PfuTurbo DNA polymerase, dNTPs, reaction 
buffer and nuclease-free sterile water. The PCR was performed in a Biometra T1 
Thermocycler (Thistle Scientific, Glasgow, UK) with the following conditions: a 30-sec 
denaturation step at 95°C, followed by 18 cycles of 95°C for 30 sec, 50°C for 1 min, 
and 68°C (1 min per kb length of plasmid). The reaction products were cooled down 
and held at 4°C. The parental double-stranded DNA was digested at 37°C for 1 hr with 
DpnI endonuclease, which targets methylated and hemimethylated DNA. E. coli XL10 
Gold Ultracompetent cells (Agilent Technologies, Wokingham, UK) were transformed 
with the mutated DNA plasmid.  
Materials	  and	  Methods	   Chapter	  2	  
 
 64 
2.9.2 Polymerase chain reaction 
To amplify fragments of plasmids for subcloning, PCR was carried out using Phusion 
polymerase (New England Biolabs, Hitchin, UK). The PCR reaction mixture contained 
10 pmol of each primer, dNTPs, Phusion HE buffer containing 1mM MgCl2, and 
Phusion Hot Start DNA Polymerase. The following PCR conditions were used: a 30-sec 
denaturation step at 98°C, followed by 30 cycles at 98°C for 10 sec (denaturation), 
60°C for 30 sec (annealing), 72°C for 30 sec per kb (extension), and a final extension 
for 10 min at 72°C. The reaction was held at 4°C. The products were purified using the 
QIAquick PCR Purification Kit (QIAGEN, Manchester, UK), according to the 
manufacturer’s instructions.  
 
2.9.3 Restriction enzyme digestion of DNA 
To generate inserts and vectors for subcloning, PCR products or DNA plasmids were 
digested with the appropriate restriction enzymes. Digestions were performed in a 20-
µL-reaction volume containing 1 µg DNA, 2 µL of 10X reaction buffer, 0.2 µL 
acetylated bovine serum albumin (10 µg/uL) supplied with the restriction enzyme, and 
nuclease free water. These were scaled up or down as required. The mixture was 
incubated at 37°C for 1-2 hrs.  
 
Digestion products were separated on 0.8% w/v agarose gels (Life Technologies, 
Paisley, UK) with 0.5 µg/mL of ethidium bromide (Life Technologies, Paisley, UK) in 
Tris-acetate-EDTA buffer (National Diagnostics, Atlanta, USA). The insert and vector 
DNA bands were cut and extracted from the gel using the QIAquick gel extraction kit 
(QIAGEN, Manchester, UK), according to the manufacturer’s instructions.  
 
2.9.4 Ligation  
To construct plasmids by subcloning, vectors and inserts made by restriction digestion 
were ligated at 1:3 molar ratio using the LigaFastTM Rapid DNA Ligation System 
(Promega, Southampton, UK). Ligation reactions consisted of 100 ng vector and 88 ng 
insert, mixed with 5 µL 2X Rapid ligation buffer and 3 units T4 DNA ligase. Reaction 
volumes were made up to 10 µL. The ligation products (2 µL) were used to transform 
XL10 Gold Ultracompetent cells.  
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2.9.5 Transformation of competent cells with DNA plasmids 
2.9.5.1 XL10 Gold Ultracompetent cells  
All plasmids, except the full molecular clone of HIV-1, were produced through the 
transformation of XL10 Gold Ultracompetent cells, according to the manufacturer’s 
instructions. Briefly, competent cells (100 µL) were added to pre-chilled 14-ml BD 
Falcon polypropylene round-bottom tubes on ice. 10 ng of plasmid DNA or 2 µL of 
ligation reaction was added to the cells on ice. The cells were incubated for 30 min on 
ice, and heat-pulsed in a water bath at 42°C for 30 sec. To stimulate the cells, SOC 
(Super Optimal broth with Catabolite repression) medium was added to the cells and 
incubated at 37°C for 1 hr, with shaking at 225-250 rpm. The transformation mixture  
(≤ 200 µL) was plated on Luria-Bertani (LB) agar (Sigma-Aldrich, Dorset, UK) 
containing the appropriate selection antibiotic, and incubated at 37°C for 16 hrs. 
Colonies were picked to inoculate LB broth (Sigma-Aldrich, Dorset, UK) supplemented 
with an appropriate antibiotic. The cultures were incubated at 37°C for 16 to 24 hrs.  
 
2.9.5.2 NEB 10-beta competent cells  
To produce HIV-1 full molecular clone plasmids for transfections, NEB 10-beta cells 
(New England Biolabs, Hitchin, UK) were transformed with HIV-1 plasmids from 
ligation reactions, following the manufacturer’s protocol. Briefly, DNA (2 µL) from 
HIV-1 R3A ligation reactions was added to 50 µL of cells in chilled 14-mL round-
bottom polypropylene tubes. The mixture was incubated on ice for 30 min, and then 
heat shocked (42°C for 30 sec). The cells were stimulated in SOC medium (30°C for 90 
min, shaking), plated on LB agar and incubated for 24 hrs at 30°C. Bacteria colonies 
were picked and grown in Terrific broth (Sigma-Aldrich, Dorset, UK). 
 
2.9.6 Purification of DNA plasmids 
DNA plasmids were purified from bacteria grown in broth on a small scale (5 mL) 
using the QIAprep MiniPrep kit, or on large scale (100 mL) using the Endofree Plasmid 
Maxi (QIAGEN, Manchester, UK). The plasmids were purified according to the 
manufacturer’s instructions, and quantified with the NanoDrop spectrophotometer 
(Thermo Fisher Scientific, Cramlington, UK). The plasmids were verified by restriction 
enzyme digestion, and/or DNA sequencing carried out through Source Bioscience 
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(Cambridge, UK) with the following platform: Applied Biosystems 3730xl using Big 
Dye Terminator v3. 
 
2.9.7 Generation of Gag mutants 
2.9.7.1 Native Gag BaL 
The pRK5GagBaL used in this study was derived from HIV-1 BaL by B. Kramer, a 
former PhD student in the Marsh Group. Primers (Table 2.4) PTAP_FWD and 
PTAP_REV were used to change the PTAP to LIRL, and YP_FWD and YP_REV were 
used to change the YP in the YPXnL motif to SR, using site-directed mutagenesis 
(Section 2.9.1), thereby generating single and double mutants: pRK5GagBaL PTAP−, 
YP− and PTAP−YP−. XL10 Gold Ultracompetent cells were transformed with the 
plasmids that were purified with Qiagen kits (Section 2.9.6). 
 
Table 2.4: Oligonucleotide sequences used for mutagenesis and regular PCR 
 
Sequences (5’ to 3’) Supplier 
Primers 
  
PTAP FWD TCAGAGCAGACCAGAGCTAATACGCCTACCAGCCCCACCAGAGG 
Sigma-Aldrich 
(Dorset, UK)  
 
PTAP REV CCTCTGGTGGGGCTGGTAGGCGTATTAGCTCTGGTCTGCTCTGA 
YP FWD CTGATAGACAAGGAACTGTCTCGTTTAGCTTCCCTCAGATCA 
YP REV TGATCTGAGGGAAGCTAAACGAGACAGTTCCTTGTCTATCAG 
YP_HXB2_FWD CCGATAGACAAGGAACTGTCTCGTTTAACTTCCCTCAGATCA 
YP_HXB2_REV TGATCTGAGGGAAGTTAAACGAGACAGTTCCTTGTCTATCGG 










R3A_YP FWD CGATAGACAAGGAACTGTCTCGTTTAGCTTCCCTCAGATC 
R3A _YP REV GATCTGAGGGAAGCTAAACGAGACAGTTCCTTGTCTATCG 
R3A_p6Del FWD CCCACAAGGGAAGGCCAGGGAATTTTTAACAGAGCAGACCAGA 
R3A_p6Del REV TCTGGTCTGCTCTGTTAAAAATTCCCTGGCCTTCCCTTGTGGG 
GAG1 (Fwd) CCGCCCCATTGACGCAAATGGGCGGTAGGCG 
GAG2 (Rev) CCCCCGCGGCCGCCTATTGTGACGAGGGGTCGTTGCC 
 
2.9.7.2 Codon-optimised Gag 
The codon-optimised GagGFP WT and PTAP− were gifts from Wes Sundquist 
(University of Utah, Salt Lake City) (Garrus et al., 2001), but the GagGFP WT was 
originally provided by Marylin Resh (Hermida-Matsumoto and Resh, 2000). To 
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generate codon-optimised Gag without the GFP tag (Figure 2.4), a forward primer 
(GAG1) (Table 2.4) was designed upstream of Gag, whilst the reverse primer was 
designed downstream of Gag (GAG2) but upstream of the GFP tag (Table 2.4), with the 
inclusion of sequences that would introduce a stop codon and NotI restriction site at the 
end of Gag. The Gag fragment (WT or PTAP−) in the pGagGFP plasmid was amplified 
by PCR to generate Gag without the GFP tag, PCR products were purified and digested 
with XhoI and NotI restriction enzymes. Similarly, the pGagGFP was digested with 
XhoI and NotI restriction enzymes to remove the GagGFP, thereby generating the 
pCMV vector backbone. The vector and inserts were ligated with LigaFast reagents 
(Section 2.9.4). The ligation reaction was used to transform XL10 Gold Ultracompetent 
cells, and the plasmids were purified (Section 2.9.6) and verified by restriction enzyme 
digestion (Figure 2.5). 
 
 
Figure 2.4: Schematic representation for the generation of pCMVGag constructs.  
(1) A Gag fragment (WT or PTAP−) in the pGagEGFP plasmid was amplified by PCR to generate 
Gag without GFP. (2) The purified Gag PCR product was digested with XhoI and NotI restriction 
enzymes to generate an insert. In parallel, pGagGFP was digested with the same enzymes to 
remove the GagGFP, thereby generating a vector that was named pCMV. (3) The Gag fragment was 
subcloned into the pCMV, generating a new plasmid, the pCMVGag (WT or PTAP−). Site-directed 
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To generate other mutants, primers (YP_HXB2_FWD and YP_HXB2_REV) were 
designed and used to mutate the pCMVGag WT and PTAP− to pCMVGag YP− and 
PTAP−YP, respectively, following the site-directed mutagenesis procedure described 
above. Plasmids were purified as above. 
 
  
Figure 2.5: Restriction analysis of pCMVGag to verify plasmids. 
Six plasmids were digested with either EcoRI and ApaI (E/A), or NdeI and NotI (N/N) pairs of 
restriction enzymes, and loaded in alternating lanes of an 0.8% agarose gel. Enzyme pairs, E/A or 
N/N, are shown at the bottom of lanes for the first two plasmids. Plasmids 1 and 4-6 have the 
expected digestion fragments for pCMVGag, whilst plasmids 2 and 3 have bands similar to digesting 
pGagGFP WT, which was originally used to generate the vector. 1 kbp DNA ladder was used (first 
and last lanes). 
 
2.9.8 Generation of HIV-1 R3A mutants 
HIV-1 R3A is a chimeric virus derived from the backbone of the NL4.3 molecular clone 
and env from the R3A strain (Meissner et al., 2004). Its plasmid, pNL4.3-R3A, was 
digested with EcoRI and ApaI restriction enzymes, to generate an insert with the entire 
p6 subdomain for subcloning. The digests were separated on agarose gel. The 
EcoRI/ApaI DNA fragment was extracted from the gel and quantified. Similarly, the 
cloning vector pEGFP-N1 was digested with EcoRI and ApaI restriction enzymes, run 
on an agarose gel, extracted, purified and the DNA quantified.  
 
Ligation of the insert (EcoRI/ApaI fragment) and vector (pEGFP-N1) was carried out to 
generate a carrier plasmid (Figure 2.6). XL10 Gold Ultracompetent cells were 
transformed with the carrier plasmid. The plasmid was purified, and verified by 
restriction digestion. Mutagenesis was performed on the carrier plasmid, mutating the 
PTAP to LIRL (primers: R3A_PTAP FWD and R3A_PTAP REV), and YP to SR 
−	  250 −	  500 
−	  1000 −	  1500 −	  2,000 
−	  3,000 −	  4,000 −	  6,000 
−	  10,000 
	  	  	  bp 
pCMVGag PTAP
− pCMVGag  
WT 
“pGagGFP WT” 
1 2 3 4 5 6 
E/A 
N/N E/A N/N 
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(primer: R3A_YP FWD and R3A_YP REV). To truncate the p6 subdomain, 
R3A_p6Del FWD and R3A_p6Del REV primers were used to introduce a stop codon at 
the beginning of the p6 subdomain. XL10-Gold Ultra-competent cells were transformed 
with the mutagenesis products. DNA plasmids were purified and sequenced to confirm 
the mutations.  
 
 
Figure 2.6: Schematic representation of how the HIV-1 R3A mutants were generated.  
(1) Plasmids pEGFP-N1 and pNL4.3-R3A (WT Gag in red) were digested with EcoRI and ApaI 
restriction enzymes. The EcoRI/ApaI fragment from pNL4.3-R3A contained the entire p6 subdomain. 
(2) The fragment was subcloned into the EcoRI/ApaI digested site of pEGFP-N1. (3) The new 
plasmid, carrying the EcoRI/ApaI fragment from pNL4.3-R3A (hereafter, called “carrier plasmid”) was 
mutagenised at the PTAP and YP residues. Alternatively, a stop codon was introduced at the 
beginning of p6. Mutants are represented in yellow. (4) The mutagenised carrier plasmids were 
digested to excise the EcoRI/ApaI fragments. (5) These fragments were used to substitute for the 
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To generate pNL4.3-R3A YP−, PTAP−, PTAP−YP− and Δp6 mutants, the mutated 
carrier plasmids were digested with the EcoRI and ApaI restriction enzymes to generate 
inserts for substituting similar fragments in the pNL4.3-R3A WT. Here, ligation of the 
insert and vector was carried out using T4 DNA ligase reagents from NEB. Each 
ligation reaction contained 2 µL of 10X T4 DNA ligase buffer, 50 ng vector DNA, 17 
ng insert DNA, 1 µL T4 DNA ligase. The reaction was made up to a final volume of 20 
µL with nuclease free water, and then incubated at room temperature for 20 min before 
transformation of NEB 10-beta competent cells. Purified plasmids were confirmed by 
restriction enzyme digestion. 
 
 Production of HIV-1 R3A mutant viruses 2.10
To develop and optimise the production of infectious HIV-1 R3A viruses, two methods 
were explored: (1) co-transfection of HIV-1 R3A PTAP− with ALIX expression vectors; 
and (2) co-transfection of HIV-1 R3A PTAP− with codon-optimised Gag WT 
expression vectors. HEK 293T cells (4.2 x 105 cells/well) were seeded in a 6-well plate, 
incubated at 37°C and 5% CO2 and transfected the following day. Transfection 
complexes were prepared in OptiMEM at a ratio of 1:3 [ng:µL] of DNA:FuGENE 
reagent. The pEGFP-N1 was used to normalise the plasmid concentration in the 
complexes. The complexes were added to the cultures, and incubated for 24 hrs. The 
virus and cells were harvested after 24 hrs, and analysed by western blotting. From 
these experiments, I determined the optimal conditions required for the production of 
infectious virus. 
  
To make stocks of infectious HIV-1 R3A mutants (PTAP− or PTAP−YP−), HEK 293T 
cells were seeded in a T80 flask at 5 x 105 cells/ml in 20 mL of complete DMEM 
medium. Next day, the cells were transfected with pNL4.3-R3A PTAP− or PTAP−YP− 
(30 µg), and pCMVGag WT (2.5 µg), complexed with FuGENE HD. After 48 hrs, the 
culture supernatants were pre-cleared by centrifugation and filtered through 0.2-µm-
pore membrane. The viruses were concentrated by ultracentrifugation through a 20% 
w/v sucrose cushion, resuspended in RPMI 1640, and stored in liquid nitrogen. Virus 
titres were determined by titration on TZM-bl cells (Section 2.3.2). 
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 Immunofluorescence (IF) microscopy 2.11
Whole cells (MDM or cell lines) on coverslips were fixed in 4% w/v paraformaldehyde 
(PFA), washed and free aldehyde groups were quenched in 50 mM NH4Cl in PBS. The 
cells were permeabilised for 20 min with 0.1% v/v Triton X-100 in blocking buffer (6 
mg/mL purified human IgG and 0.5% w/v BSA in PBS) for MDM or 0.1% v/v Triton-
X100 in wash buffer (0.5% w/v BSA in PBS) for cell lines. As MDM express Fc 
receptors (Guilliams et al., 2014) that would non-specifically bind IgG antibodies, 
human IgG was used to block the Fc receptors. Cells were incubated in primary 
antibodies for an hour, washed and incubated in the respective secondary antibodies 
(Table 2.1) for 45 min to 1 hr in the dark. Nuclei were stained with 0.5 µg/mL Hoechst 
33258 (Life Technologies, Paisley, UK) prepared in PBS, and the coverslips were 
mounted in Mowiol  (2.4 g Mowiol 40-88, 6 g Glycerol, 12 ml Tris [0.2 M], 6 ml H2O) 
on glass slides. Slides were kept at 4°C for at least 2 hrs before imaging on the confocal 
microscope. Confocal images were acquired with a Leica TCS SP3 confocal 
microscope, 63x oil objective and Leica LAS AF Software (Leica Microsystems, 
Milton Keynes, UK). Images were processed using ImageJ and assembled manually 
into montages using Adobe Illustrator CS4.  
 
Semi-thin sections on glass slides (see Section 2.12, below) were quenched in 50 mM 
glycine/50 mM NH4Cl in PBS, permeabilised for 6 minutes in 0.1% v/v TX-100 in 
PBS, and labelled with antibodies prepared in 1% w/v BSA in PBS. Nuclei were stained 
with 0.5 µg/mL Hoechst 33258, and the slides were mounted in Mowiol. Sections were 
examined with an Axioskop microscope (Carl Zeiss, Hertfordshire, UK). Images were 
recorded with charge-coupled device camera (Orca-ER; Hamamatsu), controlled by 
OPENLAB 5.0.2 software (Improvision, Perkin Elmer), and processed (adjusting 
brightness and contrast; assembling montages) using Adobe Photoshop CS4. 
 
 Preparation of cells for cryo-sectioning 2.12
For some of morphological studies by IF and EM, cells were prepared for cryo-
sectioning by first adding an equal volume of pre-warmed double strength fixative (8% 
w/v PFA in 0.1 M sodium phosphate buffer, pH 7.4) into the culture medium. After 10 
min at 37°C, the fixative was replaced with single-strength fixative (4% w/v PFA in 0.1 
M sodium phosphate buffer, pH 7.4) for 2 hrs. Fixed cells were either stored in 0.2% 
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w/v PFA storage fixative for later processing or washed with 20 mM glycine in PBS, 
pelleted and embedded in 12% w/v gelatine. The samples were infiltrated with 2.3 M 
sucrose, a cryo-protectant, before freezing in liquid nitrogen. Sample processing and 
subsequent procedures were performed with help from Annegret Pelchen-Matthews 
who carried out all the cryo-sectioning. Semi-thin sections (500 nm) were cut and 
supported in 2.3 M sucrose on slides to be used for IF, whilst ultra-thin (50 nm) sections 
were cut and supported in 1:1 mixture of 2.3 M sucrose 2% and methyl cellulose, on 
formvar-coated regular or H6 finder grids (Agar Scientific, Essex, UK) for EM (Slot 
and Geuze, 2007). We worked together to immunolabel and image cryo-sections for IF 
and EM.  
 
 EM immunolabelling 2.13
The Tokuyasu EM method was used for immunolocalisation of viral antigens on cells 
(Deneka et al., 2007; Pelchen-Matthews and Marsh, 2007; Slot and Geuze, 2007). Cryo-
sections (~50 nm) were incubated on melted 2% w/v gelatine at 37°C. They were 
subsequently quenched in 50 mM glycine/50 mM NH4Cl for 15 min. Washed 
specimens were stained for 1 hr with primary antibodies prepared in 2% w/v BSA/0.2% 
BSA-c in PBS. BSA-c (Aurion, Wageningen, The Netherlands) is acetylated BSA that 
is linearised to increase the net negative charge of BSA, thereby further preventing non-
specific binding of antibodies to the specimens. Where primary mouse IgG1 monoclonal 
antibodies were used, sections were incubated with a rabbit anti-mouse bridging 
antibody (Rockland, Gilbertsville, PA, USA) before labelling with Protein A-gold 
(PAG) (The EM Lab, Utrecht University, The Netherlands). PAG does not recognise all 
classes of IgG such as those raised in mouse or goat (Bendayan and Garzon, 1988), 
therefore a bridging antibody is required. Where double labelling was performed, the 
first primary antibody and PAG labelling were followed by fixing in 1% w/v 
glutaraldehyde, and staining with the second antibody reagent and PAG of a different 
size (Pelchen-Matthews et al., 2012). Sections were stained in neutral uranyl acetate 
(filtered through a 0.2 µm filter) and embedded in uranyl acetate (filtered through a 
0.2 µm filter) in 2% methylcellulose (1:9; v/v). Specimens were examined with a FEI 
T12 Tecnai Spirit transmission EM (FEI Tecnai, Eindhoven, The Netherlands).  Images 
were taken with Morada 11 megapixel digital camera (Olympus Soft Imaging 
Solutions), and processed with Adobe Photoshop CS4. 
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For correlative light and electron microscopy (CLEM), cell sections on H6 finder grids 
were labelled with a primary antibody followed by a fluorescently tagged bridging 
antibody (rabbit anti-mouse A488), before labelling with PAG and fixing with 1% w/v 
glutaraldehyde. The sections were incubated with Hoechst 33258 to stain the nuclei, 
mounted in 50% v/v glycerol in H2O for examination with an Axioskop microscope, 
and imaged, ensuring that the finder grid was also imaged to record coordinates of the 
labelled cells, so that they could be found at the electron microscope. After imaging, the 
grids were recovered and washed. As above, sections were stained with neutral uranyl 
acetate, examined by transmission EM, imaged, and the images were processed as 
above. 
 
 EM of Epon-embedded cells 2.14
HEK 293T cells were fixed for 30 min in a solution of 1.5% w/v glutaraldehyde and 4% 
w/v PFA prepared in 0.1 M sodium cacodylate buffer (pH 7.4), post-fixed in reduced 
osmium (1.5% w/v potassium ferricyanide, 1% w/v osmium tetroxide) at 4°C for 1 hr, 
and treated with 1% w/v tannic acid in 0.05 M sodium cacodylate for 45 min in the 
dark. The cells were further treated with 1% w/v sodium sulphate in 0.05 M sodium 
cacodylate (pH 7.4), and dehydrated sequentially in 70%, 90% and 100% ethanol. The 
cells were incubated in 50% v/v propylene oxide (PO) and 50% Epon 812 resin of 
medium hardness, before embedding in Epon 812 resin. J. Burden performed 
subsequent steps involving sectioning, staining and imaging of the specimens. The 
specimens were stained in uranyl acetate and examined using the transmission EM, 
imaged and processed as above (Section 2.13).  
 
 Analysis of budding morphologies 2.15
To determine the morphologies of budding particles quantitatively, EM images were 
analysed using the iTEM software (Olympus Soft Imaging Solutions). I estimated three 
parameters: the angle of Gag incorporation into the bud; the height of the bud from the 
cell surface; and the angle of bud closure (Figure 2.7A). The angle of Gag incorporation 
was measured by extrapolating a circle and measuring, from the centre of the circle, the 
angle enclosing the Gag layer. Bud height was measured from the base of a bud 
(including the virus stalk where present) – a base line was drawn to touch both side of 
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the plasma membrane at the bud opening into the cytosol (or the lower part of the stalk 
where present). To measure the angle of bud closure, an isosceles3 triangle was 
extrapolated within the bud, with the base touching both sides of the plasma membrane 
at the bud opening. In practice, the three parameters followed closely (Figure 2.7B). In 
particular (i) and (ii) measure the same parameter, albeit in a different way, and 
therefore they mirrored each other. As (i) was easiest to analyse for large numbers of 





       Cumulative number of budding figures 
 
Figure 2.7: Quantitative analysis of morphology of virus budding profiles.  
(A) The three measurements (explained in Section 2.15) taken on arrested virus profiles. (B) 
The measurements were compared graphically for one mutant (HIV-1 R3A PTAP−). Angles of 
Gag incorporation data mirrored angles of bud closure.  
  
                                                
3 An isosceles triangle has two equal sides and two equal angles. For analysis, the equal angles were 
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 Stereology of cell profiles 2.16
High-magnification (23,000x or 30,000x) EM images were processed and aligned using 
Adobe Photoshop. Virus profiles were counted on multiple aligned images using the 
counter tool in Photoshop. To segment the IPMCs and cell surfaces on cell profiles, 
different colours of the brush tool were used to trace the plasma membrane (PM) on the 
high-resolution images. Segmented cell profiles were printed on A3 paper, and equi-
distant (1-cm apart) straight lines were drawn across the images. The intersections of 
the lines with the PM-segmenting lines were counted and used to estimate the area of 
PM (West, 2012) (see details in Chapter 5). 
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3. The ESCRT Machinery is Required for HIV-1 
Release from Monocyte-derived Macrophages 
 
 Introduction 3.1
HIV-1 assembly is orchestrated by the Gag protein, the sequence and structure of which 
facilitate targeting, membrane binding multimerisation and the recruitment of factors 
required for membrane fission (see General introduction, Section 1.5.4). The virus has 
two late (L) domain motifs in the p6 subdomain of Gag, PTAP and YPXnL, which 
recruit ESCRT pathway proteins and mediate virus release (Huang et al., 1995; Garrus 
et al., 2001; Strack et al., 2003; Dussupt et al., 2009; Fujii et al., 2009; Im et al., 2010; 
Sundquist and Krausslich, 2012).  The PTAP motif recruits Tsg101, a component of the 
ESCRT-I complex; and the YPXnL motif, located downstream of the PTAP amino acid 
residues, recruits ALIX, an ESCRT accessory protein. These two proteins can mediate 
virus release independently; therefore, the virus does not need to recruit both (Fujii et 
al., 2009). Gag-bound ALIX, and/or ESCRT-I, then engages the ESCRT-III 
components that are assembled sequentially, to constrict the plasma membrane and 
finally the VPS4-LIP5 complex is recruited to catalyse the disassembly and recycling of 
ESCRT components, resulting in membrane fission to release virions from the host cell 
(Jouvenet et al., 2011).  
 
The role of Tsg101 and ALIX in HIV release has been studied extensively in T cells 
and model cell lines, but has not been investigated to a great extent in primary 
monocyte-derived macrophages (Demirov et al., 2002b; Fujii et al., 2009; Gaudin et al., 
2012). Therefore, the work described in this chapter aimed to establish whether 
Tsg101/ESCRT-I and/or ALIX play a similar role to that described in model cell lines. 
To determine the respective roles of ESCRT proteins in HIV-1 assembly in MDM, 
siRNA was used to deplete Tsg101 and ALIX in infected cells. The effects of the 
knockdowns were investigated either individually or in combination. Overall, 
downregulating Tsg101 and ALIX had only minimal inhibitory effects on HIV release 
in MDM, although the effect of Tsg101 depletion was greater than that of ALIX 
depletion.  
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To further investigate the role of ESCRT complexes in HIV assembly in primary 
macrophages, Gag mutants defective in Tsg101 and ALIX recruitment were generated 
by site-directed mutagenesis. Although a native Gag could not be expressed in MDM, a 
codon-optimised Gag was expressed. However, the ESCRT-recruitment defective 
mutants in codon-optimised Gag were released to the same extent as the WT in MDM. 
VPS4 is required at the end of ESCRT pathways, and accordingly the dominant 
negative VPS4 EQ inhibited the release of codon-optimised Gag and a full molecular 
clone of HIV-1 (HIV-1 R3A WT) in MDM, indicating that the ESCRT machinery is 
indeed required for HIV release in MDM. Therefore, proviral HIV-clones were 
generated, in which the PTAP and/or YPXnL motifs were mutated, or the entire p6 
subdomain was deleted. When these mutants were characterised in HEK 293T cells by 
western blotting (WB), their release was impaired. Most importantly, the release of the 
mutants was inhibited in MDM, and a greater effect was observed when the Tsg101 
recruiting motif (PTAP) was absent, compared to the absence of the ALIX recruiting 
motif (YPXnL). Therefore, the data presented in this chapter show that the ESCRT 
machinery is required for HIV release from primary macrophages, and that Tsg101 is 
more important than ALIX in mediating virus release in primary macrophages.  
 
 Results  3.2
3.2.1 Characterisation of primary MDM cultures 
To analyse HIV-1 assembly in macrophages, monocytes from blood packs were used to 
generate primary macrophages. This study aims to mimic the in vivo system as close as 
possible, and it has been reported that macrophage cell lines such at U937, Mono Mac 
or THP-1 do not reflect all the properties of primary MDM (Cassol et al., 2006). The 
monocytes were isolated from peripheral blood mononuclear cells (PBMCs), and 
differentiated into macrophages in the presence of M-CSF and IL-2 cytokines. 
Monocytes were characterised by analysing cell surface markers CD4, CD14 and CCR5 
by flow cytometer (see Materials and Methods, Section 2.2.2). CD14 is widely used as a 
marker for monocytes/macrophages (Jersmann, 2005). It was also important to confirm 
the expression of CCR5 on cells that would be infected with HIV, to avoid the 
possibility of using cells from a homozygous CCR5Δ32 individual. The deletion of 32 
bp in the second extracellular loop of CCR5 leads to the production of a truncated 
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protein that fails to traffic to the plasma membrane, thereby conferring resistance to 
HIV-1 infection (Samson et al., 1996).  
 
3.2.2 Downregulation of Tsg101 expression in MDM 
Depletion of endogenous Tsg101 by siRNA has been shown to significantly impair 
HIV-1 release in HEK 293T cells (Garrus et al., 2001), so I tested whether 
downregulating the expression of Tsg101 in MDM would similarly inhibit virus release. 
For these experiments, I followed the schema shown in Figure 3.1A. MDM were 
infected with HIV-1 BaL strain, an R5-tropic virus originally isolated from the lung 
tissue of a child with AIDS and characterised in 1986 (Gartner et al., 1986). The 
infected cells were treated with either control or Tsg101 siRNA 24 hrs later (see 
Materials and Methods, Section 2.5). The experiments were performed in duplicate for 
cells from multiple blood donors. Cell and virus lysates were analysed by SDS-PAGE 
and western blotting. 
 
The levels of Tsg101 in MDM were depleted for six days, as I had determined that the 
lowest levels were achieved on day six post-siRNA treatments (Materials and Methods, 
Figure 2.3). Cell lysates were analysed for Tsg101 depletion, using voltage-dependent 
anion-selective channel protein 1 (VDAC-1) as a loading control (Figure 3.1B). Tsg101 
was depleted very efficiently and reproducibly to about 15 ± 7% in MDM from eight 
blood donors. In four experiments where the effect of Tsg101 depletion on virus 
production and release was assessed, Tsg101 was reduced to 17 ± 6%. As macrophages 
are post-mitotic, there was no cytopathic effects associated with block to cytokinesis in 
Tsg101 knockdowns, as noted from the loading control, and this is consistent with a 
recent report (Gaudin et al., 2012). To look at the effects of Tsg101 depletion on virus 
production and release, cell lysates were analysed for the viral protein Gag, by assessing 
the unprocessed and processed forms of the protein, with adaptin-γ as the loading 
control for these samples. Accumulation of Gag processing intermediates (see Chapter 
1, Figure 1.10), such as p41, was noted for the Tsg101-depleted cultures compared to 
the control siRNA. A delay in scission may lead to inefficient proteolysis in the 
unscissioned buds, and hence the accumulation of processing intermediates. The p55 
protein is unprocessed Gag polyprotein, whilst the p24 (CA) protein found in mature 
virus is one of the end products of p55 proteolysis. The p24 is not normally seen in cell 
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lysates, but these are samples from macrophages, which contain mature virus in the 
IPMCs. The p24 levels were not conspicuously reduced in virions and cell lysates of the 
Tsg101-depleted cultures. Although, Tsg101 was efficiently reduced (17 ± 6%; n = 4), 
the virus release efficiency remained at 76 ± 7%, suggesting that the loss of 
Tsg101/ESCRT-I had only a modest effect on virus release (Figure 3.1C). 
 
 
Figure 3.1: Depletion of Tsg101 has a modest effect on virus release in MDM.  
(A) Experimental set-up of the siRNA knockdown in MDM. On day 0, which corresponds to the 7th or 8th 
day of cell culture post monocyte isolation, cells were infected with HIV-1 BaL (3 FFU). 24 hrs post-
infection, duplicate culture wells per donor were transfected with siRNA. The virus released during the 24-
hr window (days 6 to 7) was collected and concentrated by ultracentrifugation. The virus pellets and cells 
were lysed in Laemmli buffer, and analysed by western blotting. (B) Antibodies against Tsg101, VDAC-1, 
p24/55 and adaptin-γ were used to probe the WB. (C) A table summarising quantitative data from Tsg101 
RNAi experiments. To analyse WB, unsaturated band signal intensities were quantified using ImageJ. 
Virus release efficiencies were calculated using equation No. 1 in Materials and Methods, Section 2.8. A 
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3.2.3 Downregulation of ALIX expression in MDM 
The ESCRT accessory protein, ALIX, can be recruited independently to Gag by the p6 
subdomain of HIV, to facilitate virus release. ALIX has several distinct domains, one of 
which is a proline-rich region that has a PSAP motif that can bind Tsg101. However, a 
functional PSAP motif is not essential for ALIX to mediate virus release (Fisher et al., 
2007), which attests to the functional autonomy of Tsg101 and ALIX in HIV release. 
Overexpression of ALIX in HEK 293T cells can rescue virus mutants defective in 
recruiting Tsg101 (Usami et al., 2007; Carlton et al., 2008; Sette et al., 2010). Thus 
ALIX can facilitate ESCRT-III recruitment either directly or through ESCRT-I.  
 
To assess the effect of ALIX on virus release in macrophages, ALIX siRNA 
oligonucleotides were transfected into HIV-1-infected macrophages, following the same 
protocol used for knockdown of Tsg101 (Figure 3.1A). Cells treated with ALIX siRNA 
were comparable to control siRNA-treated cells: that is, there was no obvious 
cytotoxicity or cell rounding and detachment due to reduced ALIX levels. As before, 
the virions and cells lysates were analysed for levels of ALIX and HIV-1 BaL proteins 
by WB. On the representative WB (Figure 3.2A), ALIX was efficiently depleted to 
almost undetectable levels. ALIX was reduced to 5 ± 5% in cells from ten blood donors. 
Depleting ALIX had only a small effect on the cell-associated p24, as well as on the 
virion-associated p55 and p24, suggesting only a small disruption of virus release. Four 
out of ten samples were further analysed for the corresponding effect on virus release as 
shown in Figure 3.2B. In these four samples, the average ALIX level was 7 ± 6%. Here, 
the average virus release was about 92 ± 5%, despite the very efficient depletion of 
ALIX. These data suggest that ALIX has only minimal effects on virus release in 
macrophages. Therefore, it appears Tsg101/ESCRT-I is probably the main ESCRT 
protein that is directly recruited by Gag to mediate membrane fission in MDM, as in 
other cells (Fujii et al., 2009). Collectively, these data show that the downregulation of 
Tsg101 or ALIX, individually, does not significantly impact on virus release in this 
system, albeit Tsg101 may have a stronger role.  
 
 




Figure 3.2: Knockdown of ALIX by RNAi had a minimal effect on virus release.  
(A) WB for ALIX knockdown in MDM. HIV infection and ALIX depletion were carried out as 
described in Figure 3.1. Blots for cell lysates were probed with either anti-ALIX or HIV-1 Gag 
p24/55, using anti-VDAC-1 and anti-adaptin-γ, respectively, as loading controls. ALIX was 
depleted to almost undetectable levels. The reduced ALIX level had a small effect on virus 
release. (B) A summary of results from four experiments. ALIX was reproducibly reduced to 
near undetectable levels compared to control siRNA treatment. However, there was only a 
small effect on virus release.   
 
3.2.4 Double knockdown of Tsg101 and ALIX in MDM 
As shown above, depleting Tsg101 and ALIX, individually, produced only small effects 
on virus release, despite the efficient reduction in the levels of the proteins after siRNA 
treatments. Because the two proteins act independently in membrane scission events, it 
is possible that one may compensate for the absence of the other. Alternatively, the low 
levels of residual proteins may be sufficient to mediate scission of the membrane stalks 
connecting virions to host cells. Therefore, additional experiments were performed 
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where both proteins were downregulated together. This was conducted on cells from 
three blood donors. Following the experimental set-up in Figure 3.1, siRNA 
oligonucleotides for ALIX and Tsg101 were co-transfected into HIV-1 BaL-infected 
macrophages. This was followed by media changes on the fourth and sixth days post-
infection. The media from day six were collected and released virus particles pelleted 
by ultracentrifugation. Virions and cells were lysed and analysed by WB to determine 
the effect of the double knockdown.  
 
 
Figure 3.3: Depletion Tsg101 and ALIX in MDM has an additive effect on virus release.  
(A) The experimental set up in Figure 3.1 was followed to perform the double knockdown. A 
representative WB for cells depleted of Tsg101 and ALIX. Antibodies against ALIX, Tsg101 and 
p24/55 were used to analyse blots for virions and cell-associated proteins. Both ALIX and 
Tsg101 were efficiently depleted, with minimal effect on HIV release. (B) A summary of the 
quantitation of the knockdown levels and release efficiencies for cells from three blood donors.  
 
As with depleting Tsg101 and ALIX individually, depleting the two proteins 
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reduced to approximately 14 ± 5%, whilst Tsg101 was reduced to about 24 ± 11% 
(Figure 3.3B). The depletion was not as efficient as in single knockdown (KD) 
experiments, where the proteins were depleted to about 16 and 7% for Tsg101 and 
ALIX, respectively (Figure 3.1 and Figure 3.2). The average virus release efficiency for 
the double KD was 71 ± 9 %, which was less than the 76 and 92% for the single KD of 
Tsg101 and ALIX, respectively. Although, depletion of each protein in the double KD 
was not as efficient as in the single KDs, virus release efficiency was slightly lower than 
in any of the single KDs (particularly, Tsg101), suggesting some possible synergistic 
effect in the double KD, but the difference between the means was not statistically 
significant for the Tsg101 and double KDs (Figure 3.4).   
 
 
Figure 3.4: Comparison of virus release efficiencies for the single and double KDs of 
Tsg101 and ALIX.  
The difference between the average virus release efficiencies for cells depleted of ALIX and 
Tsg101 were statistically significant. When the two proteins were depleted together and 
compared to depleting Tsg101 alone, the difference was not significant. The means were 
compared statistically using unpaired t-test (P < 0.05). 
 
The small effect that the KDs have on virus release raises the question whether Tsg101 
and ALIX are important for HIV release in macrophages, or whether indeed the ESCRT 
pathway is important. Secondly, if either of the two proteins is important, then the small 
effect could be attributed to the difficulties in transfecting siRNAs into a small number 
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of infected cells. In this scenario, this approach would not be sufficient to study virus 
formation in MDM, which is the ultimate goal of this thesis. 
 
3.2.5 Mutagenesis of the ESCRT interacting motifs in the HIV-1 p6 
domain 
Although HIV release has been shown to depend on the ESCRT complexes (Garrus et 
al., 2001; Stuchell et al., 2004; Fujii et al., 2009), siRNA of the two ESCRT/ESCRT-
associated proteins Tsg101 and ALIX, individually or together, did not have big effects 
on HIV-1 BaL release in MDM. As an alternative approach, the ESCRT interacting 
motifs within HIV-1 BaL Gag (GagBaL) were inactivated by site-directed mutagenesis. I 
took advantage of the fact that Gag, the main structural protein of HIV, can be 
expressed without other viral genes, and can orchestrate assembly and release of non-
infectious VLPs that morphologically resemble immature virus particles (Bieniasz, 
2009). The plasmid pRK5GagBaL (generated by Beatrice Kramer), carrying native 
GagBaL, was used to generate the mutants. The PTAP residues were changed to LIRL, 
whilst the YP residues in the YPXnL motif were changed to SR (Demirov et al., 2002b; 
Dussupt et al., 2009). Single (PTAP−; YP−) and double (PTAP−YP−) mutants were 
generated (Figure 3.5A).  
 
To test whether the mutations inhibited GagBaL VLP release, I first transiently expressed 
the pRK5GagBaL constructs in HEK 293T cells, testing two molecular clones for each 
mutant. The proteins were analysed by WB (Figure 3.5B). The top panel of the WB 
shows that there were similar levels of Gag polyproteins in cells transfected with WT 
and the L domain mutants. Notably, there was variation in the mobility of mutants 
bearing the LIRL mutation, consistent with published data (Demirov et al., 2002b). The 
amount of VLPs released into medium of cells transfected with the mutants was almost 
undetectable for the GagBaL PTAP− and PTAP−YP− mutants, 2.9 and 2.4%, 
respectively.The GagBaL YP− mutants also had impaired particle release, 14.4%. These 
data are in agreement with published data (Fujii et al., 2009; Sette et al., 2010).  
 




Figure 3.5: Mutagenesis of pRK5GagBaL and expression of the mutants in HEK 293T cells. 
(A) Organisation of the gag open-reading frame. The amino acid sequences for the p6 subdomain 
are shown below. In the WT, the Tsg101 and ALIX binding motif, the PTAP and YPXnL, respectively, 
are highlighted in green. Three mutants were generated by mutagenesis of the ESCRT binding 
motifs. For each named mutant, the corresponding amino acid changes are indicated in red. (B) 
Cells were transfected with 2 µg of the indicated construct, and two clones were tested for each 
mutant. Cultures were harvested after 48 hrs of incubation. Purified VLPs and cells were lysed and 
analysed by WB. As two clones were tested for each mutant, the average release efficiencies for the 
VLPs could be determined. All mutants were defective in release from cells, as shown by the weak 
Gag signal on the VLP blot. The PTAP and double mutants show more severe defects compared to 
the YP mutant. Release efficiencies (R.E.) are indicated below the blot. 
 
3.2.6 Native GagBaL is not expressed in MDM  
Since the release of GagBaL mutants was inhibited in HEK 293T cells, I introduced these 
mutants into MDM by electroporation. A vector expressing GFP only, pmaxGFP, was 
used as a positive control for the procedure. Electroporation is the application of short 
and intense electric pulses to trigger formation of transient hydrophilic pores in the 
plasma membrane and nucleus such that plasmid DNA can be delivered into the cell 
(Stacey et al., 1993; Pehlivanova et al., 2012). Electroporation was a method of choice 
to transfect macrophages because these cells are difficult to transfect using reagent-
based transfection methods. Duplicate experiments were set up so that one could be 
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experiment were fixed and analysed whilst those in the 48-hr set-up did not survive. 
Fixed cells were stained with antibodies against Gag and CD44, and examined by 
confocal microscopy. Although, GFP expressed efficiently from the pmaxGFP (24% 
positive cells), none of the cells transfected with pRK5GagBaL WT or the mutants could 
be stained by anti-Gag antibodies, suggesting that they were not expressed. I also tested 
the role of different expression vectors and found that pRK5 is best (Appendix, Figure 
8.1). 
 
To investigate why GagBaL was not expressed in MDM, several control experiments 
were performed.  First, as a control for the Gag staining procedure, HeLa cells were 
transfected with either GagBaL WT or PTAP−. When expressed, GagBaL does label with 
the antibodies used against p55 (Figure 3.6 A, B). The second and third controls 
involved electroporating MDM (see Materials and Methods, Section 2.7) with the 
following plasmids: pGagGFP WT containing codon-optimised Gag (Hermida-
Matsumoto and Resh, 2000); or pcDNA3.1Nef that contained Nef, another HIV protein. 
These were performed in parallel with pRK5GagBaL WT electroporation. The codon-
optimised pGagGFP has previously been expressed in MDM by electroporation 
(Mlcochova et al., 2013). The discrepancy in expression between the native GagBaL and 
codon-optimised GagGFP arises from the fact that the gag in the former has a high AU 
content, which makes its transcripts unstable. In an HIV-1 full molecular clone, the HIV 
accessory protein Rev is expressed and it binds to the RRE in the gag RNA to help 
stabilise it. Nef expression, on the other hand, is Rev-independent (Freed, 2001; Freed, 
2002). In a codon-optimised Gag, site-directed mutagenesis has been used to inactivate 
sequences that hinder expression (Schwartz et al., 1992a; Schneider et al., 1997; 
Kotsopoulou et al., 2000). Analysis of the electroporated cells showed that although 
native Nef and codon-optimised GagGFP were expressed (Figure 3.6C, D), the native 
GagBaL was not expressed in MDM. The proportion of cells expressing Nef was 14%, 
tested on cells from one donor only, whilst GagGFP expression was variable (6 and 
38%) between MDM from two blood donors.  
 




Figure 3.6: Immunofluorescence staining for the expression control experiments.  
(A and B) Images of HeLa cells transfected with either pRK5GagBaL WT or PTAP−. Cells were 
incubated for 48 hrs post-transfection, fixed and immuno-stained for HIV Gag p24/55 and CD44. 
Single confocal sections were acquired. (C and D) MDM were electroporated with constructs 
expressing Nef or codon-optimised GagGFP. The cells were incubated for 24 hrs and then 
fixed. Cells electroporated with the Nef plasmid were immuno-stained for Nef and CD44 (C), 
whilst GagGFP-electroporated cells were immuno-stained for CD44 only (D). In D, the 
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Collectively, these data demonstrate that GagBaL can be expressed in HeLa cells, but not 
in macrophages. This is likely because the high AU content make its transcripts 
unstable in macrophages. This could be overcome by codon-optimisation or co-
expression of Rev. 
 
3.2.7 Codon-optimised Gag can be expressed in MDM 
I have shown that codon-optimised GagGFP could be expressed in macrophages by 
electroporation (Figure 3.6D). However, GagGFP produces aberrant particles or 
budding profiles, because GFP imposes steric interference on Gag packaging (Pornillos 
et al., 2003; Larson et al., 2005; Pelchen-Matthews and Marsh, 2007). To remove the 
GFP, I designed primers to amplify the codon-optimised Gag fragment of the 
pGagGFP, with the simultaneous introduction of a stop codon and a restriction site at 
the end of the p6 subdomain. The Gag fragment was re-cloned into the pCMV vector to 
generate pCMVGag (see Materials and Methods, Section 2.9.7). This procedure was 
repeated for the pGagGFP PTAP−. The pCMVGag WT and PTAP− were further 
changed by site-directed mutagenesis, to generate Gag YP− and PTAP−YP− mutants. 
 
The pCMVGag constructs were transfected into HEK 239T cells to test their 
expression. Cells and VLPs were harvested after 24 hrs, and analysed as before (Figure 
3.7A). Good expression of the WT and mutants was observed. The quantitation in 
Figure 3.7B shows release efficiencies of about 62, 18 and 4% for YP−, PTAP− and 
PTAP−YP− mutants, respectively. This severe release defect observed when the PTAP 
residues were mutated is in agreement with Tsg101 having a stronger effect on HIV-1 
release in many cell systems. Mutating the YP sequences to disrupt ALIX recruitment 
had a smaller effect compared to the PTAP mutations, while combining the mutations 
had an additive effect on VLP release in HEK 293T cells, consistent with data from a 
previous study (Fujii et al., 2009). Deleting the entire p6 subdomain, that has both the 
Tsg101 and ALIX binding sequences, has been shown to have a stronger effect than 
deleting the Tsg101-recruiting motif alone (Demirov et al., 2002b), suggesting an 
additive effect.  
 
 





Figure 3.7: Biochemical characterisation of pCMVGag in HEK 293T cells.  
(A) Cells were transfected with 2 µg of the indicated construct and incubated for 24 hrs. VLPs 
and cell lysates were analysed by WB. Mutants were less efficiently released compared to the 
WT, but severe effects were observed for the mutations on Tsg101 recruiting motif, PTAP, with 
almost undetectable p55 protein. (B) The p55 band signal intensities on WB were used to 
estimate the release efficiencies of VLPs, using equation No. 3 in Materials and Methods, 
Section 2.8. 
 
As the pCMVGag constructs worked in HEK 293T cells, their expression was also 
tested in macrophages. MDMs were electroporated to deliver plasmid DNA into the 
cells, and then incubated for 24 hrs. Examination of cell lysates by WB revealed that the 
constructs were expressed, and that bands for the p55 were present in the cell lysates. 
The WB for VLPs showed that pCMVGag PTAP− and PTAP−YP− mutants were 
released almost as efficiently as the WT (Figure 3.8A, B). Based on RNAi experiments 
in MDM (Figure 3.1 to 3.3), I had anticipated that the mutations would have a stronger 
inhibitory effect on the release of VLPs. Quantitative analysis showed release 
efficiencies of 95 ± 0.4% and 85 ± 17.1% for the PTAP− and PTAP−YP− mutants, 
respectively. Therefore, this warranted further investigation to establish the requirement 
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Figure 3.8: Biochemical characterisation of pCMVGag in MDM.  
(A) The expression of pCMVGag constructs was examined by electroporation into MDM. After 
24 hrs of incubation, VLPs and cells were harvested and lysed. Blots were probed with anti-
p24/55 and -VDAC-1. Mutants were released almost to the same extent as the WT. (B) Results 
for cells from two donors were quantified and illustrated on the graph shown here.  
 
3.2.8 Inhibition of HIV release with dominant negative GFP-VPS4  
VPS4 is thought to be required at the end of the ESCRT pathway, recruited by the 
ESCRT-III complex to catalyse membrane fission (Votteler and Sundquist, 2013). It 
does this by converting the energy of ATP hydrolysis into mechanical work. Changing 
the VPS4 glutamic acid (E) at position 228 to glutamine (Q) blocks ATP hydrolysis, 
thereby abolishing the catalytic activity of substrate-bound VPS4 (Bishop and 
Woodman, 2000). Irrespective of the motif used to recruit the ESCRT proteins to 
budding sites, the VPS4 complex is ultimately recruited to the site of assembly and this 
recruitment is essential for ESCRT-dependent virus release. To further investigate the 
involvement of the ESCRT pathway in HIV release in macrophages, I exploited the 
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In many cell lines, expression of VPS4 EQ results in the formation of endosomes with 
aberrant morphology characterised by enlarged vacuoles, reminiscent of the so-called 
class E aberrant endosomes (Bishop and Woodman, 2000). To verify this phenotype, 
GFP-VPS4 WT, or the dominant negative (GFP-VPS4 EQ), were transiently expressed 
in HEK 293T cells. As VPS4 EQ has been shown to affect endosome morphology, cells 
were stained for an endosome marker, the tetraspanin CD63 (Kobayashi et al., 2000). 
Cells expressing GFP-VPS4 WT had small CD63 puncta in the cytosol, whereas cells 
with the dominant negative GFP-VPS4 EQ, had swollen doughnut-shaped vacuoles 
with CD63 co-localising with GFP-VPS4 EQ on the perimeter (Figure 3.9A, B). CD63 
is found on lumenal vesicles because that is where it is sorted from the perimeter 
membrane. These data suggested that the GFP-VPS4 EQ does inhibit disassembly and 
recycling of ESCRT components, and should therefore also disrupt HIV release (Garrus 
et al., 2001). 
 
 
Figure 3.9: Expression of GFP-VPS4 in HEK 293T cells.  
(A) GFP-VPS4 WT was transiently expressed in HEK 239T cells. The cells were fixed 24 hrs 
after incubation, and immuno-stained with anti-CD63, a late endosome marker. Hoechst was 
used to label the nuclei. Single optical section images of the cells were acquired by confocal 
microscopy. (B) As in A, but with cells expressing an ATP-hydrolysis defective mutant, GFP-
VPS4 EQ. The insets are the enlarged snapshot of the boxed areas in the images, showing the 
swollen endosomes. Arrows show some examples of enlarged CD63-labelled vesicles that also 
contain the GFP-VPS4 EQ.  
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To determine whether the ESCRT pathway is involved in HIV assembly in MDM, cells 
were co-electroporated with pCMVGag WT and either pGFP-VPS4A WT or EQ. In 
parallel, MDM were also electroporated with the pCMVGag WT and PTAP−YP−. Cell 
cultures were harvested after 24 hrs and analysed by WB (Figure 3.10A). In cells co-
electroporated with pCMVGag WT and pGFP-VPS4 EQ, there was a clear reduction in 
the amount of released virus compared to cells with pCMVGag WT and pGFP-VPS4, 
although there was less Gag synthesis in VPS4 EQ-treated cells. Similar to the data in 




Figure 3.10: Co-expression of pCMVGag and pGFP-VPS4 in MDM.  
(A) Cells were (co-)electroporated with 1 µg of the indicated vector(s). Total DNA was 
normalised to 2 µg with pEGFP-N1 empty vector in a 12-well plate. Cell cultures were incubated 
for 24 hrs, and then harvested. VLPs and cell lysates were analysed biochemically by WB. As 
before, anti-p24/55 and anti-VDAC-1 were used to probe membranes for proteins. Cells treated 
with GFP-VPS4 EQ had impaired VLP release, with a p55 signal that was barely above 
background. (B) Quantitation of the VLP release efficiency, where treatments are either 
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To determine the extent of the inhibition by GFP-VPS4 EQ, the release efficiencies of 
VLPs for the treatments were quantified and compared to either the pCMVGag WT 
electroporation or pCMVGag WT + pGFP-VPS4 WT co-electroporation (Figure 3.10). 
The average virus release efficiency for the pGFP-VPS4 EQ-treated cells was 42 ± 9% 
relative to the pGFP-VPS4 WT treatment. The release of Gag PTAP−YP− compared to 
the Gag WT was 99 ± 5%, consistent with the unexpected data in Figure 3.10. However, 





Figure 3.11: Co-expression of pNL4.3-R3A and pGFP-VPS4 in MDM.  
Cells were co-electroporated with HIV-1 R3A provirus. Virus released into medium was 
harvested by ultracentrifugation through sucrose. Pelleted virus, and cells, were lysed in sample 
buffer and examined by WB. Anti-p24/55 was used to stain membranes for viral proteins, and 
adaptin-γ was used as a loading control.  
 
When MDM were electroporated with codon-optimised Gag constructs with mutations 
that have been shown to inhibit ESCRT recruitment, unexpected results were observed 
(Figures 3.7 and 3.10). However, the dominant negative GFP-VPS4 EQ was able to 
inhibit VLP release, showing that the ESCRT system is required for HIV-1 release in 
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provirus (pNL4.3-R3A WT). The provirus was co-electroporated with either pGFP-
VPS4 WT or EQ and analysed by WB (Figure 3.11). Relative to the loading control, 
Gag expression was the same in all lanes. Analysis of the virion-associated Gag showed 
that mature virus is produced in cells with the HIV-1 WT alone or with the HIV-1 WT 
and VPS4 WT. When cells were co-electroporated with pNL4.3-R3A WT and pGFP-
VPS4 EQ, the Gag was almost undetectable in the virion fractions, consistent with the 
notion that VPS4 EQ inhibits HIV release (Garrus et al., 2001). Taken together, these 
data demonstrate that the ESCRT pathway is important for HIV release in macrophages, 
and suggests that a better approach to studying HIV-1 assembly in MDM would be to 
use a full molecular clone of HIV. 
 
3.2.9 The generation of full-length release defective HIV-1  
The plasmid construct pNL4.3-R3A WT (14.8 kb in size) was used to generate HIV 
provirus mutants defective in recruiting the ESCRT machinery. The pNL4.3-R3A, is 
derived from the backbone of NL4.3 strain and the envelope gene (env) from the R3A 
strain (Meissner et al., 2004). 
 
 
Figure 3.12: Schematic representation of the HIV-1 NL4.3-R3A Gag polyprotein. 
The amino acid sequence of the p6 subdomain in the WT is shown with the Tsg101 and ALIX 
binding motifs, PTAP and YPLSTSL, respectively, highlighted in green. The dashes in the 
sequences for mutants (PTAP−, YP−, PTAP−YP−) denote amino acids identical to the WT. 
Changed sequences are shown in red. A red asterisk denotes the stop codon at the beginning 
Δp6.  
 
It is difficult to carry out site-directed mutagenesis on plasmids larger than 10 kb. 
Therefore, I used an alternative approach to generate HIV-1 R3A mutants. WT provirus 
was digested with restriction enzymes to cut out a 3.7-kb fragment containing the entire 
B. HIV-1 R3A Gag:
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p6 subdomain of Gag (see Materials and Methods, Section 2.9.8). The fragment was 
subcloned into the pEGFP-N1 backbone, generating an 8.4-kb plasmid.  Site-directed 
mutagenesis was then carried out on the p6 subdomain to change the PTAP sequence to 
LIRL, and YP to SR, individually or in combination: YP−, PTAP− and PTAP−YP−. To 
delete the entire p6 subdomain, a stop codon was introduced at the beginning of the p6 
subdomain. The mutagenised fragments were re-cloned into the pNL4.3-R3A, replacing 
the similar wild-type fragment, to generate HIV-1 R3A YP−, PTAP−, PTAP−YP− and 
Δp6 mutants (Figure 3.12). 
 
3.2.10 Characterisation of the HIV-1 R3A mutants in HEK 293T cells by WB 
Mutating the PTAP to LIRL and YP to SR, respectively, or deleting the entire p6 in 
HIV-1 Gag, inhibited the release of VLPs in HEK 293T cells (Figure 3.5 and 3.7). To 
determine whether the full molecular clone HIV-1 R3A with the same mutations in Gag 
were defective in release, mutants were transfected into HEK 293T cells, and the 
cultures were harvested after 24 hrs of incubation. Virions released into the media and 
cell-associated virus proteins were resolved on SDS-PAGE gels and analysed by WB 
(Figure 3.13A). This revealed similar levels of the Gag polyprotein in the cell lysates, 
indicating that the mutations did not affect Gag synthesis. The characteristic mobility 
shift of the p55 band when PTAP is changed to LIRL was observed, similar to mutation 
in the Gag only construct (Figure 3.5). Notably, the 52 amino acid deletion to generate 
the Δp6 resulted in the lower molecular weight band Gag polyprotein (55Δp6), about 49 
kb. A hallmark for mutagenesis of the p6 in HIV-1 is an increase in the levels of Gag 
processing intermediates, such as p41, in cell lysates (Huang et al., 1995; Demirov et 
al., 2002b). This was seen for the PTAP−, PTAP−YP− and Δp6 constructs. 
 
Analysis of the released viruses is shown in the lower panel of Figure 3.13A. The p24 
bands in the virion-associated Gag were hardly detectable for the PTAP−, PTAP−YP− 
and Δp6 mutants, which behave as expected. In addition, p55 and p55Δp6 bands were 
observed for the mutants, suggesting the presence of some unprocessed proteins, which 
could imply sheared immature particles, microvesicles or cell debris in the media. 
However, the fact that the band signals were stronger for the WT and YP−, than they 
were for the PTAP−, PTAP−YP− and Δp6, is indicative of impaired release of these later 
mutants.  





Figure 3.13: Immunoblotting of R3A mutants expressed in HEK 293T cells.  
(A) Cells were transfected with the indicated pNL4.3-R3A constructs, and incubated for 24 hrs. 
Virions released into the media were purified by ultracentrifugation on 20% sucrose cushions. 
Virus pellets and cells were lysed in sample buffer under reducing conditions, loaded on 10% 
SDS-PAGE gels, and blotted onto PVDF membranes. The membranes were probed with 
antibodies against viral p24/55 or the loading control adaptin-γ. Bands were visualised using the 
ImageQuant imaging system. (B) Band signal intensities were quantified using ImageJ to 
determine virus release efficiency, first using either virus p55 (or p55Δp6) plus p24, and/or virus 
p24 only. Virus release efficiencies ± SD were determined for two experiments, using equation 
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To determine the virus release efficiencies, band intensities were measured for two 
independent experiments. The release efficiencies for the mutants were determined for 
virus p55 (or p55Δp6) plus p24 (Figure 3.13B, blue bars). As the p55 (or p55Δp6) 
bands may imply contamination, their inclusion in the quantitations may elevate virus 
release efficiencies for the mutants. The p24 represents released mature virus particles 
and was thus used as a more reliable measure of virus release efficiencies. Using the 
p24 levels in virions, the average release efficiency for the YP− mutant was 82.0 ± 
2.4%, showing that this mutation had only a minimal effect on HIV release. The release 
efficiencies for the PTAP−, PTAP−YP− and Δp6 mutants were 8.3 ± 4.2, 11.1 ± 2.7 and 
8.4 ± 3.7%, respectively. These data are consistent with the notion that the Tsg101-
binding site (PTAP) is more important than the ALIX-binding site for HIV-1 release.  
 
3.2.11 Characterisation of the HIV-1 R3A mutants in MDM by WB 
To determine whether the release of the HIV-1 R3A mutants was also inhibited in 
MDM, cells were electroporated with the proviruses (see Materials and Methods, 
Section 2.7). The viruses and cells were harvested 24-hrs post-electroporation and 
analysed by WB (Figure 3.14A). The representative blot shows that it was not always 
easy to get equal amounts of expression for the proviruses. Electroporation stresses cells 
and they may not recover fully following the procedure, as most cultures showed 
reduced cell viability. Longer incubations of cultures (48 hrs) increased cell death. 
Nevertheless, examination of the WB shows that the p55 (or p55Δp6) bands for the 
R3A PTAP− and Δp6 mutants were stronger in the cell lysates, consistent with increased 
accumulation of unprocessed Gag when virus scission is hindered. There was reduced 
virion-associated p24 in the medium for the PTAP− and Δp6 mutants, suggesting virus 
release was inhibited.  
 
Estimates of virus release are shown in Figure 3.14B. The PTAP− and Δp6 mutants were 
inhibited to similar levels, with release efficiencies of about 37.4 and 37.1%, 
respectively, compared to the YP− mutant that had 71.4% release efficiency. This is the 
same trend as in HEK 293T cells. Furthermore, these data again show that mutations in 
the Tsgl01 binding motif, have a profound inhibitory effect on virus release in MDM, 
compared to mutating the ALIX recruiting motif. Most importantly, the mutants work in 
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Figure 3.14: Biochemical analysis of virus release efficiency from MDM.  
(A) Fourteen-day old MDM were electroporated with the respective constructs and incubated for 24 
hrs. Virus was purified from the culture medium by ultracentrifugation on a 20% sucrose cushion. 
The virus pellet and cells were lysed in sample buffer. Lysates were analysed by SDS-PAGE 
separation and western blotting. The WB is a representative from three experiments. (B) Virus 
proteins were quantified on WB to determine the amount of virus released into the medium relative to 
total virus that was in the cell culture. The virus release efficiency ± SD is for three experiments. 
 
 Discussion 3.3
HIV-1 is targeted to the plasma membrane where it assembles. To complete the 
assembly process, the virus uses its late domain motifs in Gag, PTAP and YPXnL, to 
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and virus release. Depleting ESCRT pathway proteins, using dominant negative forms 
of the proteins, or mutating the late domain motifs, all disrupt HIV release (Garrus et 
al., 2001; von Schwedler et al., 2003; Fujii et al., 2009; Sette et al., 2010). In the first 
approach, I used Tsg101 and ALIX siRNA to knockdown the proteins individually or 
together in HIV-infected MDM. Though the proteins were efficiently depleted, there 
was little effect on virus release. As an alternative approach to the RNAi, the late 
domain motifs, PTAP and YPXnL, were mutated in the native GagBaL expression 
plasmid, generating single and double mutants to disrupt recruitment of Tsg101 and 
ALIX, respectively.  The release of the mutants was efficiently inhibited in HEK 293T 
cells. When introduced into MDM by electroporation, the native GagBaL WT and 
mutants were not expressed. However, when codon-optimised Gag mutants were 
expressed in MDM, they were unexpectedly released. To address this, the activity of 
VPS4 was inhibited using a dominant negative form, the VPS4 EQ. When the VPS4 EQ 
plasmid was co-transfected with either codon-optimised Gag or HIV-1 provirus 
plasmids, the release of VLPs or virions was inhibited, indicating the involvement of 
the ESCRT pathway in HIV-1 assembly in MDM. A dual tropic provirus, HIV-1 R3A 
provirus, was used to generate mutants (PTAP− PTAP−YP− and Δp6) that are defective 
in recruiting the ESCRT machinery. The mutants were characterised by WB on HEK 
293T cells, where their release was found to be impaired. The release of these mutants 
was also defective in MDM, as determined by WB analysis of electroporated cultures. 
 
In order to disrupt ESCRT recruitment in infected MDM, the cells were transfected with 
siRNA to Tsg101 and ALIX. Individually, these proteins were depleted to very low 
levels, with ALIX being almost undetectable on average (Figures 3.1 and 3.2). Despite 
the efficient knockdown of Tsg101 or ALIX, the corresponding virus release was high, 
76% and 92%, respectively. When the two proteins were depleted together, virus release 
was 71%, which still showed a small inhibitory effect, given the good levels of 
knockdowns. As both the single and double knockdowns had only small effects on 
blocking virus release, it was likely that the majority of the infected cells escaped 
siRNA transfection, or that residual levels of the proteins were enough to mediate virus 
release. During the course of this study, two reports showed that when Tsg101 is 
depleted in MDM with nearly 100% infection by VSV-G pseudotyped HIV-1, about 30-
40% of p24 levels for the mature virions is detected in the culture supernatants (Gaudin 
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et al., 2012; Berre et al., 2013). That level of infection cannot be achieved using the 
physiological route of infecting macrophages with HIV-1. The best infection level I 
achieved in experiments with MDM was about 30%. It is possible that in my study 
infected MDM were difficult to transfect with siRNA, which probably did not matter in 
the two studies above if 100% of cells were infected. In the current study, protein 
depletions were optimal on the sixth day after siRNA transfections. It is possible that 
the virus that is detected was produced and stored in the IPMCs whilst Tsg101 and 
ALIX levels were progressively being depleted during the incubation period of the 
cultures. Therefore, the virus released may have come from the IPMC reservoir.  
  
As an alternative to siRNA studies, I decided to mutate the ESCRT interaction motifs, 
PTAP and YPXnL, in a native Gag plasmid, pRK5GagBaL, to generate Gag defective in 
recruiting the ESCRT machinery. The mutants were all severely defective in the release 
of VLPs (Figure 3.5).  However, the pRK5GagBaL constructs were not expressed in 
MDM during a 24-hr incubation, while a 48-hr incubation of the macrophages severely 
reduced the number of adhered viable cells as assessed by culture observations and 
trypan blue staining. Electroporation can be toxic to cells and it has been reported that 
in cells that survive, some cellular functions may be altered (Stacey et al., 1993). 
Temporary re-arrangement of the actin cytoskeleton has been reported in electroporated 
cells (Pehlivanova et al., 2012), which may affect adherence of macrophages in tissue 
culture, resulting in the loss of cells during fixing and staining. 
 
The high AU content of unspliced native gag transcripts makes them inherently 
unstable, especially in primary human cells. Rev binding to these unspliced transcripts 
is required to help stabilise and export them out of the nucleus (Schwartz et al., 1992a; 
Schwartz et al., 1992b; Nguyen et al., 2004). In the current study, the native GagBaL was 
expressed without Rev, and therefore its transcripts may have been destroyed before 
translation in MDM. As an alternative to the native Gag, a codon-optimised GagGFP 
plasmid was electroporated into MDM, and in this case the Gag protein was expressed 
(Figure 3.6). However, several studies have demonstrated that GFP-tagged Gag forms 
aberrant particles or budding profiles that are larger and more heterogeneous in size, 
characterised by discontinuous Gag layers (Pornillos et al., 2003; Larson et al., 2005; 
Pelchen-Matthews and Marsh, 2007). Therefore, untagged codon-optimised Gag WT 
ESCRT	  Requirement	  for	  HIV-­‐1	  Release	  from	  Macrophages	   Chapter	  3	  
 
 101 
and mutants were generated from the codon-optimised GagGFP constructs. In HEK 
293T cells, the Gag PTAP−YP− showed the strongest inhibitory effect on the release of 
VLPs, followed by Gag PTAP−, while Gag YP− was weakly inhibited (Figure 3.7). 
These data agree with the notion that Tsg101 predominantly facilitates HIV-1 release in 
many cell systems (Demirov et al., 2002b; Fujii et al., 2009). However, when the 
codon-optimised Gag WT and mutants were tested in MDM, they were released almost 
to the same extent as the Gag WT (Figure 3.8). The expectation was that deleting the 
ESCRT-recruiting motifs in Gag would have a stronger inhibitory effect on the release 
of VLPs, compared to using RNAi to disrupt the recruitment. It is possible that 
electroporated cells released some microvesicles that pelleted during ultracentrifugation 
of culture medium to harvest VLPs. 
 
I exploited the ability of a dominant negative VPS4 EQ to inhibit virus budding (Garrus 
et al., 2001; von Schwedler et al., 2003) by first co-electroporating MDM with VPS4 
EQ and Gag WT plasmids. The dominant negative VPS4 inhibited the release of Gag 
(Figure 3.10), showing that the ESCRT pathway is important for the release of VLPs. 
Next, HIV-1 provirus pNL4.3-R3A was co-electroporated, with either the pGFP-VPS4 
EQ or WT into MDM, to test ESCRT requirement with a full virus clone. When 
analysed by WB, the dominant negative markedly blocked HIV release to almost 
undetectable levels (Figure 3.11), indicating that the ESCRT pathway is required for 
HIV-1 release in MDM, in agreement with recent studies (Gaudin et al., 2012; Berre et 
al., 2013). As electroporated MDM did not survive incubations beyond 24 hrs, using 
infectious virus with mutations in the PTAP and YPXnL motifs to infect cell was 
required for studying assembly in MDM. 
 
Mutagenesis was carried out on the HIV-1 R3A strain, changing the PTAP motif that 
recruits Tsg101 to LIRL, and the YP residues within the ALIX-recruiting motif to SR. 
In addition, a stop codon was introduced at the beginning of p6, thus deleting the entire 
p6 subdomain and removing the binding sites for both Tsg101 and ALIX. However, it 
has been reported that ALIX can also bind the NC, but to mediate virus release it 
cooperates with late domain motifs (Dussupt et al., 2009).  The mutagenesis was 
designed such that the reading frame for pol was not affected, so that functional viral 
protease would be produced (Demirov et al., 2002b; Votteler et al., 2009; Watanabe et 
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al., 2013). In HEK 293T cells, the mutants were released less efficiently compared to 
the WT (Figure 3.13), as determined from the p24 in the virions. The p24 protein is 
only detectable in mature virions whose Gag polyprotein has undergone proteolytic 
cleavage. In addition, p55 (or p55Δp6) was present in virus lysates for the mutants, 
perhaps a result of shearing off of the immature particles (see Chapter 4 Discussion). 
Severe release defects were observed in mutants that did not have Tsg101 recruiting 
motif, consistent with previous reports showing that Tsgl01 is more important than 
ALIX for HIV release in many cell systems (Demirov et al., 2002b; Fujii et al., 2009). 
 
The HIV-1 R3A mutants were tested in MDM, and analysis of their expression by WB 
showed that the release of PTAP− and Δp6 viruses was impaired (Figure 3.14). Unlike 
cell lines, primary cells such as MDM are difficult to transfect using reagent-based 
methods (Dokka et al., 2000). Therefore, proviruses were introduced into MDM by 
electroporation (also called nucleofection). Although this method works for MDM, it 
has some undesirable effects on the cells. Poor cell adherence, which varied from donor 
to donor, was noticeable, and this could be attributed to the disturbance of the 
cytoskeleton caused by electroporation (Pehlivanova et al., 2012). The plasmids used 
for electroporation were of high purity and endotoxin-free, although hypothetically, the 
large plasmid size (14.8 kb) may also be responsible for low transfection levels, 
compared to smaller plasmids (<10 kb). It is possible that transient pores generated in 
the membranes during electroporation were not large enough to accommodate big 
plasmids. Therefore, I developed a method to rescue infectious release-defective 
mutants in HEK 293T cells (see Chapter 4), in order to infect MDM with the mutants.  
 
In this chapter, I have shown the efficient depletion of ESCRT/ESCRT associated 
proteins in MDM by RNAi, and that this resulted in about 30% inhibition of virus 
release at most, which would not be sufficient for the intended morphology studies in 
macrophages. However, it emerged in these studies that Tsg101 is more important than 
ALIX for HIV release in macrophages, as in many cell systems.  In the second approach 
to disrupt ESCRT recruitment, mutants defective in binding the ESCRT proteins were 
generated in Gag constructs, native Gag or codon-optimised Gag. In HEK 293T cells 
the mutants behaved as expected, showing a bigger inhibition effect with mutations in 
the Tsg101 recruiting motif, than in the ALIX recruiting motif. An additive effect was 
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seen when the two mutations were combined. In MDM, the effect of the mutations was 
not seen as mutants were released to the same extent as the WT. However, using the 
dominant negative VPS4 EQ demonstrated that the ESCRT pathway is indeed required 
for HIV release in macrophages. Therefore, I used an HIV-1 full molecular clone with 
mutations that disrupted Tsg101 and ALIX recruitment, and the release of HIV-1 R3A 
PTAP− and Δp6 viruses was inhibited in MDM, showing that indeed the ESCRT 
machinery is required for virus release in MDM. The morphologies of the mutants will 
be described in Chapter 4. 
 
 
“… I have discovered the secret that, after c l imbing a great h i l l ,  one only f inds 
that there are many more h i l ls to c l imb.”  
Nelson Rol ih lah la Mandela 
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4. Characterisation of HIV-1 Full Molecular Clones 
Defective in Recruiting ESCRT Components 
 
 Introduction 4.1
Late in the assembly of HIV-1, the late domain sequences of HIV Gag, PTAP and 
YPXnL, recruit the ESCRT pathway proteins, Tsg101 and ALIX, respectively (Carlton 
and Martin-Serrano, 2007; Martin-Serrano and Marsh, 2007; Carlton et al., 2008; 
Sundquist and Krausslich, 2012). The engaged Tsg101 or ALIX bind to the ESCRT-III 
complexes, which in turn recruit the VPS4 ATPase to catalyse the disassembly and 
recycling of the ESCRT proteins. This facilitates fission of the membrane stalk 
connecting nascent virions to host cells.  Inhibiting the ESCRT pathway impairs HIV 
release (Demirov et al., 2002b; Pornillos et al., 2003; Fujii et al., 2009; Sundquist and 
Krausslich, 2012) (see General introduction, Section 1.5.5). 
 
In chapter 3, I depleted the ESCRT machinery components Tsg101 and ALIX, to 
investigate their importance in the assembly of HIV-1 in primary macrophages, but 
there was modest inhibition of virus release despite the efficient depletion of the 
proteins. However, mutagenesis of Gag in a full-molecular clone of HIV-1, in which the 
PTAP and/or YPXnL motifs were mutated, or the entire p6 subdomain was deleted, 
significantly inhibited HIV-1 release in HEK 293T cells and primary macrophages. As 
my approach to verifying the site of HIV assembly in primary macrophages required the 
formation of stable, arrested, budding intermediates, I set out to initially verify the 
phenotype of the mutants in HEK 293T cells by immunofluorescence and electron 
microscopy methods. Semi-thin sections, of HEK 293T cells transfected with the HIV-1 
R3A WT and mutants (PTAP−, PTAP−YP− and Δp6), were immuno-stained and 
examined by fluorescence microscopy, revealing that the mutants produced immature 
viruses at the cell surface. To visualise the viruses, ultra-thin sections were examined 
using EM. Cells transfected with proviruses containing the late domain mutations 
showed accumulations of immature particles or arrested buds with the “lollipop” 
configuration that have been described previously (Garrus et al., 2001; von Schwedler 
et al., 2003; Carlson et al., 2008). As biochemical studies show that viruses were not 
released to the media (Chapter 3, Figure 3.13), these viruses were assessed to be 
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budding arrested. I therefore developed protocols in order to rescue the release-
defective viruses so that they could be used to infect primary macrophages for the 
analysis of the virus distributions at the IPMCs and cell surface, as will be described in 
Chapter 5. 
 
 Results  4.2
4.2.1 Morphological characterisation of HIV-1 R3A mutants in HEK 293T 
cells 
4.2.1.1 Screening transfected cells by immunofluorescence  
The analysis of the HIV-1 R3A mutants by immunoblotting showed that the release of 
PTAP−, PTAP−YP− and Δp6 was significantly impaired (Chapter 3, Figure 3.13). 
Therefore, I wanted to check whether the mutants actually produced arrested HIV-1 
budding profiles, which needs EM. HEK 293T cells were transfected with the HIV-1 
R3A WT, YP−, PTAP− and Δp6 proviruses and incubated for 24 hrs. Fixed cells were 
processed for EM. Initially, semi-thin sections of the transfected HEK 293T cells were 
screened by IF to determine transfection levels and locate infected cells. The sections 
were immuno-stained with anti-p24/55 in combination with anti-p17. The anti-p24/55 
antibodies recognise both the unprocessed Gag polyprotein (seen as diffuse cytoplasmic 
staining), as well as the processed CA protein p24 in virus, which gives a punctate 
labelling pattern at the cell surface. The anti-p17 antibody 4C9 binds to a short amino 
acid sequence at the extreme C-terminus of the MA portion of Gag at the PR cleavage 
site, and as a result only binds to the processed p17 MA of mature viruses. This 
monoclonal antibody can therefore be used to identify mature virus particles. The 
immuno-stained sections were examined by fluorescence microscopy (see Materials and 
Methods, Section 2.11).  
 
The p24/55 labelling on cells transfected with HIV-1 R3A WT showed diffuse cytosolic 
staining, presumably of unassembled Gag polyprotein, as well as puncta at the cell 
surface (Figure 4.1A). Notably, these puncta also labelled with the p17 antibody, 
suggesting that they were mature particles that had recently budded from the cells. 
Examination of the HIV-1 R3A PTAP− and Δp6 mutants in Figure 4.1B and C revealed 
that, on many cells, the cell surface was decorated with puncta that labelled with anti-
p24/55 antibody, but not with anti-p17. Occasionally, cells with bright p24/55 cytosolic 
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staining also had a continuous layer of p17 labelling that bordered the PM. Examples of 
these cells are marked with an asterisk on Figure 4.1B and C. The presence of cleaved 
p17 at the plasma may be due to the viral protease (PR) being auto-activated as Gag-Pol 
accumulates at the PM. It has been reported that the viral PR can be activated before 
scission when Gag is overexpressed (Carlson et al., 2010). These results demonstrate 
that the PTAP− and Δp6 mutants show a staining pattern characteristic of immature 
particles, which is consistent with the impaired release observed in the WB data 
presented in Chapter 3, Figure 3.13. 
 
 
Figure 4.1: Analysis of the expression of HIV-1 R3A WT and mutants in HEK 293T cells by IF. 
The cells were transfected with the indicated proviruses, incubated for 24 hrs and then fixed. Semi-
thin cryo-sections (0.5 µm) were double immuno-stained with anti-p24/55 (38:96K and EF7) and anti-
p17 (4C9) (A to C). (A) Mature viruses co-stain with p24/p55 (green puncta; selected examples 
shown by arrowheads) and p17 (red puncta). (B, C) Immature viruses labelled with p24/p55 (green 
puncta) only. In cells with high expression of Gag, the viral protease is prematurely activated to 
cleave Gag, and the cells then label with anti-p17 (cell with yellow asterisk). Scale bars, 10 µm. 
 
4.2.1.2 Ultra-structural analysis by EM  
Immunofluorescence screening of transfected cells showed that the mutants did not 
produce virus puncta that labelled with the p17 antibody, suggesting that virus 
maturation might be impaired (Figure 4.1). To assess whether the mutants were 
arrested, the same samples were analysed by EM. Ultra-thin cryo-sections were labelled 
with either the anti-p24/55 or -p17 (4C9) antibodies, and protein A gold (PAG). Gold 
binds to the secondary antibody, which is in turn bound to the primary antibody. It 
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creates electron dense spots, allowing for identification of the structure labelled by the 
primary antibody. For HIV-1 R3A WT, it was difficult to find virus particles, 
presumably because they were released into the culture medium and, therefore, lost 
from the specimens. Viruses were so rare that they could only be located and identified 
because of the antibody label (Figure 4.2A, B). When they were found, the p24 staining 
was observed over the virus particles, sometimes near visible cores, while the p17 
staining was on the periphery of the particles adjacent to the lipid membrane (explained 
in Figure 4.2 legend). The morphology of these viruses shows that they are indeed 
mature particles that have been detached from the cell membrane, in support of the IF 
data (Figure 4.1).  
 
Figure 4.2: Ultra-structure of HIV-1 R3A WT and mutants in HEK 293T cells.  
Immunolabelling of cryo-sections from HEK 293T cells transfected with the indicated HIV-1 R3A 
proviruses. Ultra-thin sections (50 nm) were immunolabelled with either p24/55/PAG10 (images on 
the left) or p17/PAG10 (on the right). (A, B) HIV-1 R3A WT mature viruses label with anti-p24/55 or 
p17. For p24, the gold labelling is over the centre of the virus particles, while p17 staining is near the 
outer membrane (within 20 nm of the outer membrane, consistent with two layers of antibodies i.e. 
p17 / rabbit anti-mouse / PAG10). Buds and mature virus particles are indicated with black, and white 
arrowheads, respectively. (C to F) HIV-1 R3A PTAP− and Δp6 virus profiles are immature and 
arrested budding intermediates observed at the cell surface, and labelled with anti-p24/55, but not 
with anti-p17. Scale bars, 100 nm. 
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For the PTAP− and Δp6 mutants, numerous arrested budding profiles were observed. 
These had electron-dense Gag layers under the bud membrane as described elsewhere 
(von Schwedler et al., 2003), and were predominantly labelled with anti-p24/55 
antibodies. On many of the cells, there was no labelling with anti-p17 antibody (Figure 
4.2D and F), in agreement with the IF data. These EM images confirm that both the 
PTAP− and Δp6 mutants were arrested late in budding, as expected for ESCRT 
recruitment deficiency.  
 
4.2.1.3 Ultra-structural analysis by Epon EM  
Most of the previous studies that examined the ultra-structure of arrested budding HIV 
used plastic embedding EM (Garrus et al., 2001; von Schwedler et al., 2003; Dussupt et 
al., 2009). Therefore, classical Epon embedding EM was used to further characterise the 
mutants in HEK 239T cells. Compared to gelatine-embedded and cryo-sectioned 
specimens, Epon-embedded cells have clearer morphology, due the use of osmium 
tetroxide to enhance membrane contrast. However, the harsh fixation steps and 
dehydration used for Epon EM destroys many antigens on the specimens, making them 
generally unsuitable for immuno-labelling. 
 
To analyse the morphology of viruses by Epon EM, HEK 293T cells were transfected 
with the proviruses HIV-1 R3A WT, PTAP−, PTAP−YP− and Δp6. The cells were fixed 
and embedded in Epon (Materials and Methods, Section 2.14). As observed in immuno-
EM, it was difficult to locate virus particles on the WT-transfected cells. Occasionally, a 
few virus particles were seen, trapped between adjacent cells. Where sectioned 
equatorially, they typically had electron dense cores, indicative of the mature HIV 
phenotype (Figure 4.3A and A’). These images show that most of the WT virus is 
released, in agreement with the WB results. Examination of cells transfected with HIV-
1 R3A PTAP−, PTAP−YP− and Δp6 showed arrested budding profiles decorating the 
surface of cells (Figure 4.3B and B’). The buds had a prominent Gag layer of immature 
non-cleaved Gag. A range of morphologies was observed, including shallow buds, the 
arrested “lollipops” that have been described previously, as well as some duplexes or 
rosettes (Figure 4.3B to D). These morphologies were only rarely observed on WT 
transfected cells presumably because they are transient intermediates of assembly. 




Figure 4.3: Epon-EM of HEK 293T cells transfected with HIV-1 R3A plasmids. 
The cells were transfected with the indicated plasmids, incubated for 24 hrs, then fixed and Epon-
embedded. Sections (70 nm) were examined by transmission EM. (A) Mature WT particles (selected 
examples indicated by arrowheads on A’) are trapped between the PMs of adjacent cells. (B-E) PTAP−  
(B), PTAP− YP−  (C) and Δp6 (D, E) budding profiles decorate the cell surface. (B) Overview of a typical cell 
with buds. In (B’-E), budding structures are shown at higher magnification. (B) A single shallow bud is 
indicated with an arrowhead. Some duplex buds are shown with an arrow. (C, E) The budding profiles that 
did not have visible connections to the plasma membrane appear as released immature particles. 
Asterisks are on the electron dense layer formed by non-cleaved immature Gag layers, whilst arrowheads 
point to the bi-layer membrane derived from cells. (D) The arrowheads point to virus stalks. Scale bars: A, 
2 µm; A’, 250 nm; B, 5 µm; B’, 100 nm; B”, 500 nm; C, 100 nm; D, 200 nm; E, 100nm. 
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The examination of R3A PTAP− and PTAP−YP− virus profiles revealed that many had 
fairly shallow bud morphology, while most Δp6 budding profiles appeared more 
spherical (compare Figure 4.3B’ and D). Where there were no visible connections to the 
PM, virus profiles appeared as released immature and spherical or dumbbell-shaped 
particles, with a thick Gag layer (Figure 4.3C and E), and this was particularly common 
with the Δp6. The average width of the bud opening (at the base where they were 
connected to the PM), or membrane stalks where present, was about 140 nm for 
PTAP−YP− or PTAP−, and about 75 nm for Δp6. The narrow stalks on Δp6 meant that 
the membrane connections were not always captured within the section (typically 70 
nm). These narrower stalks could be more susceptible to shearing off from the cell 
membrane, which may explain the higher levels of virion-associated Gag (p55Δp6) for 
the Δp6 mutant, compared to p55 for PTAP− or PTAP−YP− in the WB experiments (see 
Chapter 3, Figure 3.13). Given that most WT particles are released and therefore lost 
from cells, the fact that the mutant particles were easily found in the specimens 
suggested that they remained attached to the host cells.  
 
To follow up the differences, I counted virus profiles on EM images, and classified the 
profiles into mature and immature. The immature profiles were further subdivided into 
profiles connected to, and those without visible connections to, the PM. This was 
carried out for the HIV-1 R3AWT, and PTAP−, PTAP−YP− and Δp6 mutants. A total of 
1,301 profiles were analysed (Figure 4.4). Although a small number of profiles were 
found for the WT, a high proportion of those (74%) were mature. For the PTAP− and 
PTAP−YP− mutants, more that 80% of the profiles were connected to the PM, whilst 
only 40% of the Δp6 profiles had visible connections. The data are consistent with the 
notion that the width of the membrane stalks may influence what is observed as 
connected or not connected to the plasma membrane, and therefore, data on ultra-thin 
sections need to be interpreted with caution.  
 




Figure 4.4: Estimating the proportions of virus profiles connected to host cells. 
For each provirus used to transfect HEK 293T cells, virus figures were counted on EM images 
and scored as immature and mature. Immature figures were divided further into those 
connected to, and those without any visible connections to, the PM. The proportions for each 
category were determined per virus construct. 
 
As noted above, the PTAP− and PTAP−YP− arrested virus profiles appeared shallower 
than those for the Δp6. To quantitatively analyse the dimensions for the budding 
virions, a set of measurements were taken for each bud profile (illustrated and described 
in Materials and Methods, Section 2.15): (i) the angle of Gag incorporation, (ii) the bud 
height, and (iii) the angle of bud closure. For this analysis, only HIV bud structures 
showing membrane continuity with the producer cell were measured. To analyse the 
budding morphology for the PTAP−, PTAP−YP− and Δp6 mutants, the angle of Gag 
incorporation was measured on a total of 256 virus profiles. There was no significant 
difference between the averages for the angle of Gag incorporation for the PTAP− 
(180.3 ± 55.1°) and PTAP−YP− (176.3 ± 57.1°). However, the average for the Δp6 
(266.9 ± 54.4°) was significantly different to that of the PTAP− or PTAP−YP− mutants 
(Figure 4.5B). Additionally, the radii of any buds ≥180° were measured for each 
mutant: PTAP− (71.6 ± 4.1); PTAP−YP− (69.7 ± 4.3); and Δp6 (67.6 ± 4.1), and were 
found to be similar, indicating that the mutations did not affect the size of the virus 
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Figure 4.5: Quantitative analysis of the morphology of virus budding profiles.  
The angle of Gag incorporation was measured by extrapolating a circle, and measuring from the 
centre of the circle, an angle enclosing the Gag layer (see Materials and Methods, Figure 2.7A). 
Statistical analyses were performed using the unpaired t-test at p<0.05. 
 
Taken together, the EM observations together with biochemical analysis in Chapter 3, 
Figure 3.13, show directly that in HEK 293T cells, budding intermediates accumulate 
for PTAP−, PTAP−YP− and Δp6, that is, they are arrested. The higher angle of Gag 
incorporation for HIV-1 R3A Δp6 suggests that the p6 subdomain may have additional 
role(s) in HIV biogenesis, including regulation of the HIV assembly process, possibly 
through other biochemical modifications. 
 
4.2.2 Preparation of infectious mutant viruses  
In Chapter 3, Figure 3.13, I showed that when HIV-1 R3A PTAP−and Δp6 proviruses 
were introduced into primary macrophages by electroporation and analysed by WB, 
virus release was inhibited, suggesting that the mutants could produce arrested budding 
intermediates for the study of HIV assembly in macrophages. However, about half of 
the cells did not survive electroporation. Initial morphological studies, where MDM 
from three different blood donors were electroporated with the mutants and examined 
by IF to assess the distribution of mutant viruses were, extremely challenging to do, 
with <1% of cells expressing the virus (see Chapter 5). To overcome these difficulties, I 
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the mutants are budding arrested and therefore cannot produce mature infectious 
particles. Therefore, I tested different strategies to rescue the arrested virus in producer 
cells by co-expressing the mutants with either ALIX or wild-type Gag plasmids.  
 
4.2.2.1 ALIX-mediated rescue of HIV-1 PTAP−  
As a first approach to produce infectious provirus mutants, I tested reports that when 
ALIX is overexpressed it can support efficient release of an HIV-1 PTAP− mutant 
(Fisher et al., 2007; Usami et al., 2007; Carlton et al., 2008). The PTAP−YP− and Δp6 
mutants cannot be rescued by co-expression with ALIX, because the ALIX recruiting 
motif of PTAP−YP− is inactivated by mutagenesis whilst the Δp6 mutant does not 
express the two motifs that wild-type HIV uses to recruit the ESCRT machinery. HEK 
293T cells were co-transfected with HIV-1 R3A PTAP−, and either haemagglutinin-
tagged ALIX (HA-ALIX), or ALIX tagged with monomeric Cherry (mCh-ALIX) 
(Carlton and Martin-Serrano, 2007; Carlton et al., 2008). Different amounts of ALIX 
plasmid DNA (0.25 or 0.75 µg) were used with 3 µg of HIV-1 R3A plasmid. The 
transfected cells were incubated for 24 hrs before harvesting virus from the medium.  
Biochemical analysis of cell lysates showed that equal amounts of p55 were expressed 
for all transfections, except where 0.75 µg of mCh-ALIX plasmid was used (Figure 
4.6A). Using 0.25 µg of either HA-ALIX or mCh-ALIX plasmids did not increase the 
amount of released virus, compared to transfections with HIV-1 R3A PTAP− only. A 3-
fold increase in the concentration of HA-ALIX plasmid resulted in modest increase in 
virus release; therefore, I proceeded with this plasmid. A similar increase in the amount 
of mCh-ALIX appeared inhibitory to Gag synthesis or toxic to the cells, as noted from 
the low expression level of cell-associated Gag and the loading control.  
 
To determine whether increasing HA-ALIX input in the rescue experiments would 
result in a further increase in the amount of rescued virus, 0.75 and 2.25 µg of the 
plasmid was used.  However, increasing the input of HA-ALIX by 3x did not increase 
the amount of rescued virus, suggesting that the system was probably saturated (Figure 
4.6B). Overall, these results show that rescue with ALIX is not efficient. Moreover, 
ALIX would not rescue the PTAP−YP− double mutants. Therefore an alternative 
approach for rescuing the virus was required. 




Figure 4.6: Rescue of Tsg101-binding site mutant virus by overexpressing ALIX.  
(A) HEK 293T cells (1.4 x 105 cells/mL in 3 mL medium, on 6-well plate) were transfected with 
WT, or PTAP− plus one of the indicated ALIX plasmids at two concentrations. Total DNA was 
normalised to 3.75 µg with an empty pEGFP vector. Cells were incubated for 24 hrs. Pelleted 
virus and cells were lysed in sample buffer. Cell- and virion-associated Gag were analysed by 
WB. (B) HEK 293T cells were transfected with the indicated plasmids. Total DNA was 
normalised to 5.25 µg with empty pEGFP plasmid. Cultures were treated as in A.  
 
4.2.2.2 Gag WT rescues the release defective PTAP− and PTAP−YP− mutants 
As an alternative approach, I exploited the codon-optimised Gag WT that is released 
efficiently from HEK 293T cells (Chapter 3, Figure 3.7), to rescue the HIV-1 R3A 
PTAP− and PTAP−YP− mutants. HEK 293T cells were co-transfected with pNL4.3-R3A 
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increasing concentrations pCMVGag WT were used to determine the amount required 
to achieve optimal rescue of the HIV-1 R3A PTAP− virions. Cell lysates and virions 
were harvested and analysed by WB (Figure 4.7A). The blot for virion-associated Gag 
shows that p24 levels decreased with increasing Gag WT input, suggesting that a small 
amount of the Gag WT plasmid was sufficient to recruit the ESCRT machinery and 
allow the release and subsequent maturation of virions.  
 
To quantify the amount of released mature virus from the co-transfected cells, p24 
levels were measured. These were compared to the amount of p24 (100%) from cultures 
that were transfected with HIV-1 R3A WT. Although the p24 level in cells co-
transfected with 0.25 µg Gag WT plasmid was 84.5 ± 27.6% (Figure 4.7B), higher 
concentrations of the Gag WT plasmid in the co-transfections reduced the levels of p24 
released. At 0.75 and 2.25 µg Gag WT plasmid, the p24 levels were 52.5 ± 13.4 and 
21.5 ± 6.4%, respectively. These data show that Gag WT can efficiently rescue the 
HIV-1 R3A PTAP− viruses, and low concentrations of Gag WT were required to 
optimally achieve this. The optimal plasmid ratio of Gag WT : HIV-1 R3A PTAP− 
plasmid was 1:12 for efficient rescue.  
 
To produce stocks of the HIV-1 R3A PTAP− or PTAP−YP− viruses, the 1:12 ratio for 
GagWT : provirus plasmids was used to scale up virus production (see Materials and 
Methods, Section 2.10). Virus titres were determined by infecting TZM-bl cells (see 
Materials and Methods, Section 2.3.2), which shows that infectivity is also rescued 
(Figure 4.7C). 
 
Taken together, these data show that viruses defective in ESCRT recruitment, and thus 
release, can be rescued by co-expression with Gag WT, and that these viruses were 
infectious as determined on TZM-bl cells. Therefore, the HIV-1 R3A mutant viruses 
can be used to infect macrophages where virus budding intermediates will be arrested at 
all sites assembly sites, allowing for quantitative analysis of HIV assembly in 
macrophages.  
 





Figure 4.7: Gag WT-mediated rescue of release defective HIV-1 mutants.  
(A) HEK 293T cells were transfected with pNL4.3-R3A WT, PTAP− alone, or PTAP− plus 
increasing concentrations of the vector expressing pCMV Gag WT. Cells were incubated for 24 
hrs. Virus production and Gag expression levels were compared by WB with anti-p24/55 
antibodies.  (B) Quantitative analysis of p24 levels ± SD for the rescued HIV-1 R3A PTAP− 
virions in two independent experiments. (C) A typical graph showing virus titres for the HIV-1 
R3A WT and mutants (e.g. PTAP−) as determined on TZM-bl cells. 
 
 Discussion 4.3
The ESCRT pathway is essential for the release of HIV-1 from infected cells (Sundquist 
and Krausslich, 2012). ESCRT proteins are recruited by Gag to the plasma membrane, 
where HIV-1 assembles in different cell types, including primary macrophages. In 
macrophages the virus mainly uses the internally sequestered plasma membrane 
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clear whether assembly also occurs at the cell surface. In order to study HIV assembly 
in MDM, I needed to generate and characterise mutants that would be defective in 
release. To this end, provirus mutants (HIV-1 R3A PTAP−, PTAP−YP− and Δp6) were 
generated from the dual tropic provirus HIV-1 R3A and characterised by WB in 
Chapter 3. In this chapter, the mutants were further characterised by morphological 
methods. Analysis of these mutants by IF revealed virus unable to undergo PR-
mediated proteolysis at the plasma membrane of HEK 293T cells. Furthermore, ultra-
structural analysis by EM showed the accumulation of immature viruses and buds at the 
cell surface, thereby confirming that these mutants are indeed budding arrested. 
Introducing the mutants into MDM by electroporation revealed that the procedure was 
toxic to the cells. Therefore, infectious stocks of mutant viruses were produced by 
rescuing production in HEK 293T cells, so that MDM could subsequently be infected 
with the release-defective mutants. 
 
Immunofluorescence was used to examine the morphology of the viruses in HEK 293T 
cells transfected with the HIV-1 R3A PTAP− and Δp6 mutants. Puncta of p24/55 
staining, presumably assembling virus particles, were seen at the cell surface.  Notably, 
these puncta were not labelled with 4C9 anti-p17, suggesting lack of processing of MA, 
and consistent with an immature virus phenotype (Figure 4.1). In agreement, some 
punta co-staining with p24/55 and p17 were seen at the surface of WT expressing cells. 
Occasional cells that had very high expression of the mutants, indicated by stronger 
p24/55 labelling, tended to also have a continuous layer of p17 labelling the plasma 
membrane, suggesting premature protease activation (Carlson et al., 2010). To directly 
verify the structure of HIV particles at the surface of HEK 293T cells, I used EM, the 
only technique that has the resolution to show the fine structure of the particles. Both 
immuno-EM and Epon EM techniques were used. For immuno-EM, ultrathin cryo-
sections of HEK 293T cells, transfected with plasmids for HIV-1 R3A WT and the 
mutants (PTAP−, Δp6), were labelled with either anti-p24/55 or -p17 and protein A gold 
(Figure 4.2). Gold labelling helps in locating rare structures and aids in the 
identification of structures even if not oriented optimally in the section. Mature particles 
produced by R3A WT were labelled with anti-p24/55 and -p17, consistent with 
labelling for mature HIV-1 (Deneka et al., 2007; Pelchen-Matthews et al., 2012). As 
these were the same antibodies used for IF, similar specificities of the antibodies were 
Morphology	  of	  HIV-­‐1	  Clones	  Defective	  in	  ESCRT	  Recruitment	   Chapter	  4	  
 
 118 
observed, that is, anti-p24/55 labelled both the mature and immature viruses, whilst 
anti-p17 only labelled the mature particles.  
 
When Epon-EM was used to further characterise the morphology of the HIV-1 R3A 
PTAP−, PTAP−YP− and Δp6 mutants, budding arrested HIV-1 profiles were seen 
decorating the surfaces of HEK 293T cells (Figure 4.3 B, D). This was consistent with 
previous studies, where the ultra-structural analysis of budding arrested HIV-1 was 
mainly conducted on plastic embedded specimens (Garrus et al., 2001; Pornillos et al., 
2003; von Schwedler et al., 2003). The clearer morphology of the HIV-1 buds made it 
easy to recognise some subtle differences in phenotypes produced by HIV-1 R3A 
PTAP− or PTAP−YP− and Δp6. For the PTAP− and PTAP−YP− mutants, a large number 
of more shallow buds, mostly half complete Gag shells (~180° Gag incorporation), were 
observed. The virus shells for the Δp6 were more complete (on average three-quarters, 
~270° Gag incorporation) (Figure 4.7). The Δp6 virus profiles, in agreement, had 
narrow membrane stalks (~75 nm). It is possible that the thinner stalks might be sheared 
off more easily, perhaps explaining the release of some p55 virion-associated Gag into 
the medium as seen in the WB (Chapter 3, Figure 3.13). 
 
It is not clear what causes these differences in bud completeness of the HIV-1 R3A 
PTAP−YP− or PTAP− and Δp6, though it is tempting to speculate that the p6 portion of 
Gag may regulate HIV-1 assembly. Both HIV-1 R3A PTAP−YP− and Δp6 do not recruit 
ESCRT, including VPS4. On the other hand HIV-1 R3A PTAP− can recruit ALIX, 
although endogenous levels of ALIX do not overcome the PTAP− defect to mediate 
virus release in HEK 293T cells. Two recent studies has suggested that VPS4 may be 
involved early in HIV particle biogenesis and the formation of intralumenal vesicles in 
MVBs, in addition to acting late to depolymerise and recycle the ESCRT components 
(Adell et al., 2014; Cashikar et al., 2014). However, as both the HIV-1 R3A PTAP−YP− 
and Δp6 cannot recruit the ESCRT-III, and ultimately VPS4 complexes, the average 
differences in bud morphology may not be explained in terms of VPS4. Furthermore, in 
preliminary studies with J. Burden, we have observed cells co-transfected with 
dominant negative VPS4 and R3A WT had virus budding profiles that were even 
shallower, with on average 149.5° of Gag incorporation (Apendix, Figure 7.2). 
Morphology	  of	  HIV-­‐1	  Clones	  Defective	  in	  ESCRT	  Recruitment	   Chapter	  4	  
 
 119 
Therefore, the function(s) of VPS4 in membrane fission events require more 
investigations to clarify how it interacts with other ESCRT components. 
 
As the mutants were producing arrested budding structures in HEK 293T cells, the 
potential to rescue infectious viruses was investigated. To this end, two approaches 
were tested in HEK 293T cells, which involved co-expressing the mutants with either 
ALIX or Gag WT. Previous studies have demonstrated that when ALIX is 
overexpressed, it can rescue HIV-1 PTAP− viruses (Fisher et al., 2007; Usami et al., 
2007; Carlton et al., 2008). However, when I used ALIX to rescue the PTAP− mutant, 
there was only a minimal effect on virus release (Figure 4.6). In parallel, I tested rescue 
with Gag WT as an alternative, with promising results. Using Gag WT also offered the 
advantage of rescuing the R3A PTAP−YP− that lacks the ALIX binding motif. The 
concentrations of Gag WT and R3A PTAP− plasmids required for optimal rescue were 
obtained by performing titrations (Figure 4.7). Surprisingly, higher concentrations of 
Gag WT plasmid sometimes reduced the levels of mature virus. These higher 
concentrations of the Gag WT plasmid in the co-transfections may have favoured the 
production of VLPs over infectious virions. A full molecular clone of HIV-1 produces 
one GagPol molecule for every 20 Gag molecules (Jacks et al., 1988; Pettit et al., 2005; 
Bell and Lever, 2013). Therefore, a higher input of the Gag WT plasmid might upset 
this 20:1 ratio of Gag:GagPol in the cell. This could result in the competitive exclusion 
of some GagPol during virus assembly, which may affect auto-activation of the viral 
protease. Therefore, the resulting released particles would not mature and would not be 
infectious. The optimal plasmid concentrations were then scaled up to produce 
infectious virus stocks.   
 
In conclusion, to investigate HIV assembly in macrophages, I need to infect rather than 
electroporate MDM, as electroporation damages the cells. Therefore, a full molecular 
virus clone, HIV-1 R3A, was used to generate proviruses lacking ESCRT interaction 
motifs. The mutants were characterised on HEK 293T cells by WB and a range of light 
and electron microscopy techniques, and then rescued to generate infectious virus 
stocks. The infectious mutants have been used to infect MDM and study HIV assembly, 
as described in Chapter 5.  
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HIV-1 targets key cells in the immune system, such as CD4+ T cells and macrophages. 
In T cells, HIV-1 assembly occurs at the cell surface, whilst in macrophages the virus 
accumulates in intracellular compartments, and budding structures have been seen on 
the limiting membrane of these compartments, which suggests that HIV assembles at 
these sites (Gartner et al., 1986; Deneka et al., 2007; Welsch et al., 2007; Pelchen-
Matthews et al., 2012). Following the initial observation that HIV-1 assembly in 
macrophages may be different to T cells, understanding the nature of these 
compartments has been growing. The current view is that these are intracellular plasma 
membrane-connected compartments (IPMCs) (see General introduction, Section 1.6.2). 
 
The IPMCs where HIV assembles in macrophages are morphologically heterogeneous. 
They can have complicated structures, with various interconnected internal membranes 
(Deneka et al., 2007; Bennett et al., 2009; Welsch et al., 2011; Pelchen-Matthews et al., 
2012). The cytoplasmic face of the IPMCs can have thick flat coats that contain integrin 
adhesion complex proteins (Pelchen-Matthews et al., 2012). This complex, as well as 
the actin cytoskeleton, maintains the integrity of the IPMCs (Gaudin et al., 2012; 
Pelchen-Matthews et al., 2012; Mlcochova et al., 2013). Although HIV accumulates at 
the IPMCs and budding structures have been seen on the limiting membranes of the 
IPMCs, it is not clear whether the IPMCs are sites where the virus assembles, as viruses 
budding from the cell surface would be lost.  
  
The aim of this chapter was to address whether the IPMC is the main site selectively 
targeted by the virus for assembly in MDM, compared to the exposed cell surface. To 
achieve this, primary human MDM were infected with HIV-1 mutants defective in 
release, thereby capturing budding intermediates at all sites where HIV-1 assembles. 
The infected cells were then examined by IF and EM. For the IF studies, the plasma 
membrane marker CD44 was used to identify cell surfaces and IPMCs, whilst Gag 
staining was used to visualise the virus. This allowed for (i) an estimation of virus 
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distribution, and (ii) the quantitation of Gag fluorescence at the two plasma membrane 
domains, the IPMC and cell surface. EM allowed direct counting of the numbers of 
virus buds or particles at the different sites, while two-dimensional (2D) stereology was 
used to estimate the relative areas of plasma membrane at the cell surface and in the 
IPMCs. These studies showed that HIV-1 predominantly (>90%) assembled at the 
IPMCs in primary human macrophages. 
 
 Results 5.2
5.2.1 Morphology of MDM infected with R3A WT and rescued late domain 
mutants 
Analysis of the HIV-1 R3A late domain mutants, PTAP− and Δp6 showed that their 
release from MDM was inhibited, suggesting that they were arrested, as observed in 
HEK 293T cells (Chapter 4, Figure 4.2 and 4.3). To verify how the rescued HIV-1 R3A 
PTAP−YP− mutant virus behaves in MDM, cells were infected with HIV-1 R3A 
PTAP−YP−, or HIV-1 R3A WT for comparison. Cells were incubated for 7 days, fixed 
and then immuno-labelled with antibodies against the PM marker CD44 and viral 
proteins p24/55 and p17.  The p24/55 antibody recognises immature and mature forms 
of HIV-1 Gag, whilst monoclonal anti-p17 (4C9) binds the proteolytically cleaved p17 
subdomain of Gag and can therefore discriminate between the two virus forms by 
labelling mature virions only (see Chapter 4, Section 4.2.1.1). The fluorescence was 
examined by confocal microscopy. 
 
In MDM infected with HIV-1 R3A WT, clumps of strong p24/p55 labelling were 
associated with the intracellular CD44 staining for the IPMCs (Figure 5.1 A to C). For 
the PTAP−YP− mutant, the p24/55 labelling was weaker and exhibited scattered 
punctate staining on the IPMCs (Figure 5.1D, E). This suggested low expression of the 
PTAP−YP− compared to the WT.  
 
The p17 staining was examined in the HIV-1 R3A WT- and mutant-infected MDM. 
Cells infected with the WT had strong p17 labelling that co-localised with the p24/55 
stain at the IPMCs. Conversely, very weak p17 staining was observed on the 
PTAP−YP−, where the majority of p24/55 puncta did not label with p17. Therefore, 
HIV-1 R3A PTAP−YP− shows little processing of Gag polyprotein by the viral protease, 
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suggesting an immature arrested phenotype, similar to that observed when the mutant 
was characterised in HEK 293T cells (Chapter 4, Figure 4.1).  
 
 
Figure 5.1: Morphology of infected MDM. 
Seven-day old MDM were infected with HIV-1 R3A WT (A to C) or the rescued release-defective 
virus, HIV-1 R3A PTAP−YP− (D, E). Cultures were incubated for 7 more days, fixed and immuno-
labelled with antibodies against p24/55 (Kal-1), p17 (4C9) and CD44 (MEM-85), and examined by 
confocal microscopy. Representative images of cells shown here are single confocal sections. See 
the enclosed CD with movies showing 3D image of cells shown in B and E (Appendix, Section 8.3).  
Mature and immature viruses were found at IPMCs with diverse morphologies. Scale bars = 10 µm. 
 
The detailed morphologies of the IPMCs on the infected cells were examined. Labelling 
with CD44 showed that the IPMCs had a wide range of morphologies: a few examples 
are shown (Figure 5.1). In Figure 5.1A, the virus-containing compartment is at the 
centre of the syncytium and surrounded by nuclei. The reverse of this arrangement can 
be seen in Figure 5.1B (cell with asterisk), where the IPMC encircles the nucleus. 
Clumps of seemingly compact IPMC were also observed in some cells (Figure 5.1C). In 
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Figure 5.1D, an ovoid cell has a mass of similarly ovoid IPMCs. The macrophage in 
Figure 5.1E, shows a complex IPMC occupying most of the cytosolic space (with 
morphology akin to raw cotton). Markedly, some cells were multinucleated, referred to 
as syncytia. A syncytium forms when viral Env proteins in infected cells bind CD4 and 
co-receptors of neighbouring cells(s), culminating in fusion and the generation of giant 
cells with several nuclei. Cells with more that 100 nuclei have been reported for 
macrophages infected with HIV-1 (Gartner et al., 1986). The IPMCs were very diverse 
in size and morphology, in agreement with previous reports (Gaudin et al., 2013a; 
Mlcochova et al., 2013). 
 
Notably, for MDM infected with either HIV-1 R3A WT or mutants, the virus staining 
was on the CD44-labelled IPMCs. Moreover, the fact that immature virus was found at 
the IPMCs implies that HIV-1 assembles at this plasma membrane domain.  
	  
5.2.2 Analysis of the distribution of HIV-1 in MDM by IF 
To evaluate the distribution of HIV-1 R3A in MDM, cells from eight blood donors were 
electroporated or infected with either the single mutant PTAP−, or the double mutant 
PTAP−YP−. Electroporation experiments were performed initially, prior to the 
development of the rescued mutants in HEK 293T cells, which could be used to infect 
MDM. The cells were immuno-stained with antibodies against CD44 and viral proteins 
p24/55 as well as a monoclonal antibody against p17. The cells were then analysed by 
confocal microscopy to assess the distribution of viral proteins. Qualitative analysis of 
the p24/55 staining pattern on CD44-labelled membranes revealed a diverse set of 
morphologies that were scored into one of three categories. There were cells where 
virus was at the IPMC only, or cells with virus at the cell surface. Notably these latter 
cells lacked the IPMCs. In a few cells, virus was seen at both the IPMC and the cell 
surface. To document infected cells, random fields were imaged using the same settings, 
on z-stack mode with the confocal microscope to capture 3D images of the cells. The 
images were acquired in four channels comprising the nucleus, CD44, p24/55 and p17. 
Representative images of cells infected with the HIV-1 R3A WT and PTAP−YP− 
mutant are shown in Figures 5.2A to D, illustrating cells within the three categories 
described above. Movies for the 3D images are on CD (Appendix, Section 8.3). 




Figure 5.2: The distribution of HIV-1 R3A WT and PTAP−YP− in MDM.  
MDM were immuno-stained with antibodies against p24/55 (Kal-1), p17 (4C9), and CD44. Images 
were acquired with the z-stack mode of the confocal microscope. The numbers on the merged image 
panels indicate the position of the sections in the z-stack, shown from the top to the bottom of the cell 
(See movies on CD, Appendix, Section 8.3). Arrows (magenta) on CD44 images (far left) point to the 
IPMC on the selected cell sections. (A) HIV-1 R3A WT virus only in IPMCs. The cell is 
multinucleated with a compact IPMC near the nuclei. Scale bar, 20 µm.  
The figure continues on the next pages. 



















HIV-­‐1	  Assembly	  in	  Macrophages	   Chapter	  5	  
 
 125 
Figure 5.2 continues 
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Figure 5.2 continues 
 
(C) HIV-1 R3A PTAP−YP− assembly at the cell surface only. Note that CD44 shows this cell 
lacks an IPMC. Scale bar, 10 µm 
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Figure 5.2 Continued 
 
(D) HIV-1 R3A PTAP−YP− distributed to the IPMC and cell surface. Scale bar, 10 µm 
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To quantitatively analyse the virus distributions in MDMs, coverslips were scanned in a 
rasterised manner, and the cells were carefully observed and scored into the three 
categories described above. A total of 1,120 random cells (448 for R3A WT, and 662 
for R3A PTAP− and PTAP−YP−) were analysed (Figure 5.3). For all viruses, there were 
a high proportion of cells with virus staining at the IPMCs only (brown bars), although 
this was variable from donor to donor, ranging from 43 to 100% (Figure 5.3A). Since 
electroporated cells had low transfection efficiencies (<1%), all cells expressing Gag 
were included in the analysis. The lowest numbers of transfected cells were for D383, 
and here the entire Gag staining for the WT and mutant was at the IPMCs. Although 
electroporation with provirus resulted in few virus-expressing cells, the data was 
comparable to that obtained for cells inoculated with infectious virus (Figure 5.3B). On 
average, 66 and 77% of cells expressing the WT and mutants, respectively, showed 
virus at the IPMCs only (Figure 5.3C). In a small proportion of cells, virus staining was 
found at both the IPMC and cell surface: 10% and 5% for the WT and mutants, 
respectively. Furthermore, virus staining was observed at the surface of cells that lacked 
IPMCs, representing 24% of cells with WT infection, and 18% of cells with the 
mutants. Taken together, these results suggest that HIV-1 is primarily distributed to the 
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Figure 5.3: HIV-1 mainly distributes to the IPMC in MDM.  
(A) Cells from eight blood donors were either electroporated or infected with the indicated viruses. 
Immunolabelled cells were examined by confocal microscopy and scored into three categories, as 
illustrated above the graph (see z-stacks images in Figures 5.2). For each donor, the proportions of cells in 
each category were determined. (B) Averages are shown according to the method used to express the 
virus in MDM. (C) A summary, comparing the WT and mutants for all the treatments, shows that the virus 
was predominantly located in IPMCs. (All treatments = electroporation and infection methods). 
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5.2.3 Quantitation of virus fluorescence intensities in infected cells 
During the analysis of virus distribution in MDM, it was evident that most cells had 
virus in the IPMCs only, and a small percentage of cells (5%, PTAP− and PTAP−YP−; 
10%, WT) had virus at both the cell surface and IPMCs. Also, the p17 staining on the 
mutants was generally weaker than on the WT.  To determine how much virus staining 
there was at the IPMCs and the cell surfaces, Gag (p24/55 and p17) fluorescence 
intensities were quantified on randomly imaged MDM from two blood donors: 88 and 
39 MDM from D435, expressing HIV-1 R3A WT and PTAP−YP−, respectively; and 55 
MDM from D429, expressing PTAP−YP−.  Using CD44 as a maker for the cell surface 
and IPMC, detailed examination of z-stack images was performed, employing “3-D 
Viewer” and “Orthogonal Views” features of ImageJ software (Figure 5.4A, B) to 
dissect the locations of the Gag p24/55 and p17 fluorescence.  The “3D Object Counter” 
plugin (Bolte and Cordelieres, 2006; Cordelieres, 2009) was used to quantify Gag 
fluorescence associated with each site, as illustrated in Figure 5.4C and D for a 
macrophage from D429 infected with the PTAP−YP− mutant. 
 
Initially, the total fluorescence intensities for p24/55 and p17 were determined on the 
imaged cells. The average fluorescence intensities of p24/55 on WT virus in the D435 
MDM was 2.6 x 106 arbitrary units (A.U.), compared to 1.1 x 106 A.U. of p24/55 on the 
PTAP−YP−-expressing MDM from the same donor (Figure 5.5A). This shows a 2-fold 
difference that is consistent with the lower expression levels of the mutant, although not 
statistically significant (P value = 0.1638).  Additionally, fluorescence intensities for 
p17 were estimated on the same D435 cells. On average, the fluorescence intensities of 
p17 for the WT and PTAP−YP− were 3.6 x 106 and 0.49 x 106 A.U., respectively (Figure 
5.5B), representing a 7-fold difference, which is statistically significant (P value = 
0.0017). To account for the lower expression of the PTAP−YP− mutant, ratios of the 
p24/55 to p17 were calculated for the D435 cells infected with the WT and mutant 
viruses, and they were 1.38 and 0.45 respectively, showing 3-fold decrease in the p17 
fluorescence. Furthermore, a comparison was made between the average fluorescence 
intensities of either p24/55 or p17 for the PTAP−YP− expressing MDM from D435 and 
D429. The differences between the averages were not statistically significant (p24/55 
averages, P value = 0.1230; p17 averages, P value = 0.4484). Collectively, these data 
support the notion that the PTAP−YP− virus is scission-impaired. 




Figure 5.4: Quantitation of fluorescence intensity for Gag p24/55 and p17.  
(A) Orthogonal views and, (B) 3D views of the cell, to identify plasma membrane domains and 
Gag at these domains. (C) The p24/55 staining channel (so-called image object) for estimating 
fluorescence intensity using the 3D Object counter plugin in ImageJ software. First, a threshold 
was set on the image, resulting in a binarised image. The software then runs a 2-pass analysis 
on this binarised image. The first pass involves scanning the image objects (for instance, HIV-1 
p24 fluorescence staining in C) from the top left corner to the lower right corner. (D) During this 
pass, tags (numbers) are assigned to the object’s pixels. To resolve any ambiguities, the 
software performs a second pass. For example, a U-shaped image object that has been 
scanned and assigned separate tags at the beginning of the z-stack (i.e. the top part of the U-
shape) would be resolved by replacing the higher tags with the lowest tags on the whole image. 
(Note that all tags are not shown on the zoom, as these would have been shown on previous z-
stack slices). Fluorescence intensity was calculated as an integrated density (in arbitrary units), 
which is the sum of all the intensities of the object’s voxels. A voxel is a volume element that 
represents pixels in a 3-D space. Scale bar = 20 µm. (See also videos on the enclosed CD, 
Appendix, Section 8.3) 
p55/24A













Figure 5.5: Quantitative analysis of Gag fluorescence intensity on MDM.  
MDM from blood donors, D435 and D429, were infected with HIV-1 R3A WT or PTAP−YP−, and 
double stained with antibodies against p24/55 and p17, and CD44 to identify IPMCs. Using 
confocal microscopy, random whole-cell images were acquired in z-stack mode. (A, B) 
Quantitation of fluorescence intensity for p24/55 and p17 staining was analysed on 3-D images 
using ImageJ software as in Figure 5.4. Graphs show p24/55 (A) and p17 (B) fluorescence 
intensities per cell. For statistical analysis, an unpaired t-test was performed to compare the 












































 ns (P = 0.1638)









































4.9 x 105 3.3 x 105
 ** (P = 0.0017)
 ns (P = 0.4484)
n = 88 n = 39 n = 55
A. 
B. 
HIV-­‐1	  Assembly	  in	  Macrophages	   Chapter	  5	  
 
 133 
Next, I sought to determine the proportion of Gag p24/55 found at the IPMC and the 
cell surface in those cells that had viruses at the cell surface and IPMCs. Whole cell 
images of infected MDM from D435 and D429 were sorted into the three categories 
described in Figure 5.3, and the results are shown in Table 5.1. In agreement with the 
data obtained by scanning slides of cells and then scoring them at the microscope, there 
were more cells with virus at the IPMCs only: 85.2% WT and 89.7% PTAP−YP− for 
D435; and 74.5% PTAP−YP− for D429. A small percentage of cells showed virus at 
both PM domains: 11.4% WT and 7.7% PTAP−YP− for D435; and 18.2% PTAP−YP− 
for D429 (Table 5.1). 
 
Table 5.1: Categorising cell images from D435 and D429, according to virus distribution. 
Cells categories according to 
site for p24/55 fluorescence 
  Number of cells  (%) 
 D435  D429 
 R3A WT  R3A PTAP−YP−  R3A PTAP−YP− 
1. Cell surface (no IPMC)  3 (3.4)  1 (2.6)  4 (7.3) 
2. IPMC  75 (85.2)  35 (89.7)  41 (74.5) 
3. IPMC and cell surface   10 (11.4)  3 (7.7)  10 (18.2) 
      (a) analysed  6   3   9  
      (b) not analysed  4   n/a   1  
TOTAL   88 (100)   39 (100)   55 (100) 
 
 
As shown in Table 5.1, 4/10 cells expressing the WT (for D435) and 1/13 expressing 
the PTAP−YP− (for D435 and D429) could not be analysed because it was difficult to 
accurately resolve the IPMCs and cell surface. This could be attributed to the IPMCs 
being in close proximity to the cell surface. To estimate the proportion of virus at the 
IPMCs, p24/55 fluorescence at the IPMC was divided by the total p24/55 fluorescence 
in the cell (Figure 5.6A). On average, the PTAP−YP− mutant showed 96.1% and 92.1% 
of virus in the IPMCs, for D435 and D429, respectively. The WT-expressing cells had 
81.3% of the virus in the IPMCs. However, the averages between the WT and the 
mutants were not statistically different (P value = 0.3096). These data show that even in 
cells that have virus at the IPMCs and cell surface, the IPMC is the main PM domain 
where the virus is found.  
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Figure 5.6: Gag fluorescence is predominantely at the IPMC in MDM. 
(A) For cells with Gag p24/55 at both the IPMC and cell surface, the proportion of p24/p55 at 
the IPMC was estimated using the equation. (B) Estimates for MDM from the two donors were 
graphed as shown, including the arithmetic mean for each group of cells.  
 
 
Together, these immunofluorescence data on the distribution of virus in MDM showed 
more than 90% of the virus located in the IPMC of cells infected with the HIV-1 R3A 
PTAP−YP− mutant, and more than 80% in the WT-infected cells. The WT was slightly 
lower, possibly due to stronger infection, resulting in the virus redirecting to the cell 
surface when the IPMC is full, or some virus being released from the IPMC and 
remaining bound to PM. These data strongly suggest that HIV-1 predominantly 
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5.2.4 EM analysis of IPMC ultra-structure and HIV budding  
Immunofluorescence studies of macrophages infected with HIV-1 R3A WT and PTAP− 
or PTAP−YP− showed that the virus distributes mainly to the IPMCs. To follow up on 
these IF observations, the ultrastructure of infected macrophages was investigated using 
EM, and the data was analysed qualitatively and quantitatively.  
 
5.2.4.1 IF screening of semi-thin sections of infected MDM 
The analysis of whole MDM revealed that cells expressing the HIV-1 R3A mutants 
were rare and virus expression levels in the cells were also weak. In addition, infection 
was variable from donor-to-donor. Therefore, in order to assess infection levels prior to 
EM, semi-thin sections of MDM infected with R3A WT or PTAP−YP− were immuno-
labelled with antibodies against p24/55 and p17. For each specimen, three or four 
random images of stained sections were acquired at low power magnification (40x) by 
fluorescence microscopy (Figure 5.7A, B). Individual cells were imaged at higher 
magnification. Figure 5.7C and D shows examples of MDM infected with the WT and 
PTAP−YP− viruses. Cells infected with the WT had high expression level of p24/55, 
which was frequently seen as large aggregates, compared to the punctate staining of the 
PTAP−YP− mutant. Similar to the observations made on whole cells, the p17 staining 
was weaker on the PTAP−YP− compared to WT. This systematic screening of semi-thin 
sections, allowed for the identification of MDM with relatively high PTAP−YP− 
infection levels, to stain specimens for EM.  
 
The number of cell profiles labelled with p24/55 were counted on each field (at 40x) 
and averaged to estimate infection levels. The data in Figure 5.8 show a ranking of 
infection levels for MDM expressing the HIV-1 R3A WT or the PTAP−YP− mutant. 
Cells infected with HIV-1 R3A WT had higher infection levels compared to the mutant-
infected cells. Based on data in Figure 5.8, cells from donors D429, D428, D435 and 
D432 were chosen for the EM studies. Also included in these studies were MDM from 
D415, infected with the PTAP− single mutant.  
 




Figure 5.7: Determination of infection levels by IF analysis of MDM.  
Semi-thin cryo-sections of MDM infected with the indicated viruses were double stained with antibodies 
against p24/55 (38:96K and EF7) and p17 (4C9). (A, B) An overview of a stained section. Infection levels 
were 43% and 28%, for the WT and PTAP−YP−, respectively. The top panels show merged images of the 
p24/55 (green) and p17 (red) channels. The p24/55 (green) labels WT- and PTAP−YP−-infected cells. 
Phase images are shown in the middle panels. Fluorescence and phase images have been overlaid in the 
lower panel. (C, D)  Higher power magnification of stained cell sections. Scale bars: A and B, 50 µm, C 
and D, 10 µm. 




Figure 5.8: Estimation of the number of infected MDM.  
Semi-thin sections stained with anti-p24 were analysed by IF to assess infection. Stained cell profiled 
were counted to estimate the number of infected cells per 40x field of view.  
 
5.2.4.2 Correlative light and electron microscopy (CLEM) to identify infected 
cells 
Given that fewer infected cells were observed for MDM infected with HIV-1 R3A 
PTAP−YP− it was apparent that surveying specimens to find cells infected with mutants 
at the EM would be a challenge. To address this problem, a different approach that 
combines IF and EM was used, termed correlative light and electron microscopy 
(CLEM). This procedure takes advantage of the fact that IF can be used to screen large 
areas of a sample at relatively low resolution, to identify areas of interest that can then 
be found again at the electron microscope to obtain ultra-structural details. 
 
H6 finder grids with letters (Figure 5.9A) were used to support specimens that would be 
analysed using CLEM. An example of CLEM data output is shown in Figure 5.9B to G. 
In this example, MDM infected with R3A PTAP−YP− were immuno-stained with anti-
p24/55 and PAG on a finder grid. The nuclei were visualised by labelling with Hoechst. 
Specimens were examined by IF to identify infected cells labelled with the anti-p24/55 
(Figure 5.9B). A cluster of p24/55 puncta near a nucleus, suggestive of an IPMC, was 
observed (Figure 5.9C). Grid bars and letters, as well as the cells’ nuclei were visualised 
during imaging in order to locate structures at the electron microscope. Thus, the 
fluorescence in Figure 5.9C coincided with the ultra-structural features on the overview 
micrograph in Figure 5.9D. When the area with p24/55 fluorescence was examined 
using EM at higher magnification (Figure 5.9E), virus profiles with immature 





Immunofluorescence of macrophages infected with HIV-1 R3A WT and PTAP− or 
PTAP−YP− showed that the virus distributes mainly to the IPMCs. To follow up on 
these IF observations, the ultrastructure of infected macrophages was investigated using 
EM, and the data was analysed qualitatively and quantitatively.  
 
5.2.4.1 IF!screening!of!semiEthin!sections!of!infected!MDM!
The analysis of whole cells revealed that cells expressing the R3A mutants were rare 
and expression levels in the cells was also weak. Also, expression was variable from 
donor-to-donor. Therefore, in order to assess infection levels prior to EM, semi-thin 
sections of MDM infected with R3A WT and PTAP−YP− cells were immuno-labelled 
with antibodies against p24/55 and p17. For each specimen, three or four random 
images of stained sections were acquired at low power magnification (40x) by epi-
fluorescence microscopy (Figure 5.11A, B). The cell profiles labelled with p24/55 were 
counted on each image and averaged to estimate infection levels. The data in Figure 
5.10 show ranking of infection levels for MDM expressing the R3A WT and 
PTAP−YP− mutant. Cells infected with the R3A WT had higher infection levels 
compared to the mutant-infected cells. 
 
 
Figure 5.10: Estimation of the number of infected MDM.  
Semi-thin sections stained with anti-p24 were analysed by IF to assess infection. Stained cell 




























































































Figure 5.9: Using CLEM to localize and image infected cells. 
(A) Image of an H6 finder grid used to support specimens. (B) IF overview showing part of the finder grid 
mesh: ultra-thin sections of MDM infected with HIV R3A PTAP−YP− for 7 days were labelled with anti-
p24/55, rabitt anti-mouse Alexa-488 antibody and 10-nm PAG. Hoechst was used to visualise the nuclei 
(pink). Fluorescence micrographs were stitched together or aligned to display part of the finder grid 
(containing the letter O). [Note the Hexagon O1 (bump)]. Overviews like this were used to locate infected 
cells during EM imaging. (C) The fluorescence corresponds with electron dense features in the EM 
overview shown in (D). (E) Higher-magnification EM image of the boxed area shown in D, revealing the 
ultra-structure of the MDM.  (F, G) Immature virus profiles were labelled with 10-nm PAG for the p24/55 on 
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The results show that the procedure can be used reliably to identify infected cells when 
infection levels are low. Furthermore, the data demonstrate directly that the R3A 
PTAP−YP− produces an arrested virus phenotype in the IPMC.  
 
5.2.4.3 The ultra-structure of HIV assembly in the IPMC 
To study the morphology of assembling HIV in the IPMCs, MDM infected with HIV-1 
R3A WT were examined. Cryo-sections of infected cells were either labelled with 
antibodies against CD44 or p24/55 and Protein A-gold (PAG). Initially, CD44 was used 
as a marker for the IPMCs.  Various intracellular PM domains were labelled, even on 
cell profiles that did not contain virus particles (Figure 5.10). These IPMCs had varying 
morphologies, ranging from the large loose vacuoles seen in Figure 5.10A, to others 
with convoluted tightly apposed membranes (Figure 5.10 C, D).   On infected MDM, 
the IPMCs were densely packed with mature virus particles (Figure 5.11A).  At higher 
power, the electron-dense cores of the viral capsid could be identified (Figure 5.11B-D; 
black arrows). In addition, immature particles characterised by electron dense shells, 
were sporadically found in the IPMCs (Figure 5.13B and E-G; white arrows). Both the 
mature virus particles and the immature profiles labelled strongly for p24/p55 (Figure 
5.11 E, F).  Moreover, other features noted on the IPMCs included clathrin-coated pits 
and thick flat coats on cytoplasmic face of the PM (Figure 5.11G, H), as previously 
reported (Welsch et al., 2007; Pelchen-Matthews et al., 2012). 
 
To study the ultra-structure of MDM infected with HIV-1 R3A PTAP− or PTAP−YP− 
mutants, infected MDMs had to be located using CLEM. In the first study, ultra-thin 
sections of MDM infected with the PTAP− mutant were labelled with antibodies against 
p24/55 and PAG, located by CLEM and examined at the EM. A virus-containing 
compartment with immature virus profiles is shown in Figure 5.12A. This IPMC 
appeared loosely filled with particles with similar electron-dense shells noted for 
immature HIV-1 R3A WT (Figure 5.11). At high magnification, these profiles were 
labelled specifically with anti-p24/55 visualised with immunogold (Figure 5.12B, C). 
Other features of the IPMCs, such as tightly apposed membranes that appear to connect 
separate pockets of the compartments were also observed (Figure 5.12C). Examination 
of the surface of this cell profile did not reveal any budding virus profiles at this 
location. These observations show that, as in HEK 293T cells, the HIV-1 R3A PTAP− 
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Figure 5.10: Morphology of IPMC on cell profiles without virus.  
Ultra-thin cryo-sections were labelled with CD44 and 10-nm PAG. (A) CD44 labelling showed 
vacuole-like IPMC structures that were dispersed in the cytoplasm. The arrow points to a 
clathrin coated pit on the IPMC. (B) CD44 labelling at the cell surface. (C) A complex IPMC with 
convoluted interconnected tightly apposed membranes. The cell surface has numerous 
microvilli (MV) that are also labelled for CD44. (D) Higher power view of the area marked in C. 
Clathrin-coated vesicles/pits are indicated by black arrows. Scale bars: A and B, 200 nm; C, 1 
µm; D, 500 nm. 
 
 




Figure 5.11: Ultra-structure of HIV-1 R3A WT virions in the IPMCs.  
MDM infected with the HIV-1 R3A WT were immunolabelled with anti-CD44 (MEM-85) in A to D, 
or anti-p24 in E to H. (A) Overview of a large IPMC, densely packed with mature virus particles. 
(B-D) Enlarged views showing mature particles (black arrows) and immature figures (white 
arrows). (E) Overview of an IPMC containing mature and immature virus profiles. White arrows 
point to immature virus profiles.  (G) Part of the IPMC, showing a clathrin coated pit (black 
asteriks), and an immature virus figure (white arrow). (H) Arrowheads point to electron dense 
flat coats that sometimes decorate parts of IPMCs. Scale bars: A, 500 nm; B-D, 200 nm; E, 500 
nm; F-G, 100 nm.  
 




Figure 5.12: Ultra-structure of HIV-1 R3A PTAP− virions in an IPMC.  
Primary human MDM were infected with HIV-1 R3A PTAP− for 7 days. Ultra-thin sections of the 
cells were immunolabelled with anti-p24/55 and 10-nm PAG. (A) An overview of an IPMC 
(located by CLEM) with immature virus profiles, characterised by electron dense shells. (B, C) 
Higher-magnification views of virus profiles shows that they label with 10-nm gold particles, that 
is, contain the HIV-1 Gag protein. In C, arrowheads point to closely apposed membranes 
connecting pockets of the IPMC. Scale bars: A, 1 µm; B & C, 200 nm. 
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5.2.4.4 Analysis of PTAP−YP−-infected MDM by CLEM 
The ultra-structure of the IPMCs was also analysed in the context of the R3A PTAP− 
YP− mutants. A large number of cell profiles with associated virus buds were located 
using CLEM.  As described below, the infected cell profiles showed a variety of IPMC 
morphologies, ranging from loose IPMCs close to the cell surface (Figure 5.13) and 
structures with sponge-like interconnected membranes (Figure 5.14) to apparent 
vacuoles filled with immature particles (Figure 5.15). Cell profiles were analysed in 
detail, photographed, and the locations of the virus buds recorded. 
 
In Figure 5.13, a loose IPMC (on cell A) was observed near the cell surface. The IPMC 
opened up to the extra-cellular space in close proximity to another cell (cell B). Tunnels 
of closely apposed membranes connected some parts of the IPMC (Figure 5.13C), and 
were lined with thick flat coats of integrins CD18/CD11b,c (Pelchen-Matthews et al., 
2012). This structure suggests that Cell A may be in the process of transferring virus to 
Cell B, as has been described (Gousset et al., 2008).  On this cell, 94 virus profiles were 
seen in the IPMC, whilst only three were at the cell surface. Some virus buds had 
visible connections to the IPMC (Figure 5.13E, F). Notably, all observed virus profiles 
had immature morphology. 
 
Some IPMCs containing viruses were sponge-like in appearance (Figure 5.14). 
Different sizes of the sponge-like IPMC have been observed. The cell in Figure 5.14 A, 
B had a small sponge-like IPMC with few virus profiles in a labyrinth of membranes 
that appeared to form individual pockets of IPMC. On 2D images, these may appear 
isolated (Deneka et al., 2007), but it is known from 3D image reconstructions that these 
are likely to be connected (Welsch et al., 2011). There were 12 immature virus profiles 
in the IPMC, and none on the cell surface. A much larger sponge-like IPMC with an 
extensive maze of membranes containing budding profiles of R3A PTAP− YP− is shown 
in Figure 5.14 C to G. Some of the membranes formed vacuole-like enclosures 
containing budding viruses. In addition, several narrow tunnels and rings of membranes 
were also found in the IPMC network (Figure 5.14G). Furthermore, there were arrested 
virus particles that double labelled with anti-p24/55 (5-nm gold) and anti-Env (10-nm 
gold) (Figure 5.14E, F). The labelling with anti-Env indicates that these were likely to 
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be infectious viruses. Virus profiles were enumerated; 255 were seen in the IPMC and 
none were found at the cell surface. 
 
 
Figure 5.13: Loose IPMC near cell surface.  
Ultra-thin cryo-sections from MDM infected with HIV R3A PTAP−YP− for 7 days were stained with p24/55 
(10-nm PAG). (A) The approximate boundaries for two adjecent cells is indicated by a red dashed line. B-F 
show a higher magnification from cell B (C) Arrowheads identify the thick integrin coat that lines parts of 
the IPMC. (D) One of the three virus buds found at the cell surface among microvilli. (E, F) Immature virus 
profiles in the IPMC. Membrane stalks linking virions to the IPMC were visible, as indicated by black 
arrows. Scale bars: A, 1 µm; B, 200 nm; C-D, 100 nm. 




Figure 5.14. Sponge-like IPMCs in MDM.  
MDM infected with HIV-1 R3A PTAP−YP− were labelled with indicated antibodies and PAG. (A) 
An overview of a cell with a small IPMC (boxed). (B) MDM specimens were single labelled with 
p24/55 and detected with 10-nm PAG. (C) An overview of MDM with a large IPMC (boxed). 
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Figure is continued from the previous page. 
 
Figure 5.14: Sponge-like IPMCs in MDM.  
(D) An alignment of IPMC images at high magnification. (E, F) Arrested PTAP−YP− budding 
intermediates at the IPMC, double labelled with p24/55 (5-nm PAG) and Env (10-nm PAG). 
Black arrows point at membrane necks connecting virus profiles to the PM. (G) A ring of closely 
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The third type of IPMC observed was a loose vacuole-like compartment. Here, budding 
profiles appeared enclosed in a continuous limiting membrane that may have connection 
to the cell surface in another plane (Figure 5.15A, B). The IPMC was deep within the 
cell and contained immature virus figures that were labelled with antibodies against 
p24/55 and Env viral proteins. In total, 69 virus profiles were found in two pockets of 
the IPMC in this cell, while there were no virus profiles on the cell surface. Together, 
these data show immature viruses in IPMCs with diverse morphologies. Notably, only 
few virus profiles were observed on the cell surface.  
 
To quantitatively assess the distribution of virus on EM micrographs in addition to the 
cells described above, virus profiles were counted on 29 cell profiles expressing either 
HIV-1 R3A PTAP− or PTAP−YP− (Table 5.2). For these cell profiles, 19/29 (66%) and 
9/19 (31%) had HIV-1 at the IPMC, and IPMC plus cell surface, respectively. Notably, 
only 1/29 (3%) of the cells examined had all virions only at the cell surface, though it is 
not clear whether this cell would have an IPMC in a different plane, or whether it is one 
of the MDMs lacking the IPMC (see also Section 5.2.2). Collectively, 3003/3089 (97%) 
virus profiles were observed associated with IPMCs, and 86/3089 (3%) were at the cell 
surface (Table 5.3). These results support the IF data and indicate that most virus and 
virus assembly is associated with IPMCs.  
 




Figure 5.15: Tight vacuole-like IPMC in MDM 
(A) Ultra-thin cryo-section of MDM infected with HIV-1 R3A PTAP−YP−. The dark spots 
(arrowheads) in A represent lipid droplets. (B) Immature virus profiles in a vacuole-like 
compartment double labelled with antibodies against p24/55 (5-nm PAG) and Env (10-nm 
PAG). Scale bars: 2 µm; 200 nm. 
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Table 5.2: Direct bud counts: numbers of virus profiles associated with IPMCs and the 
cell surface of MDM infected with HIV-1 R3A PTAP− or PTAP−YP−.  
Cells profiles where buds were seen at both IPMCs and the cell surface are in bold font, whilst 
the cell with virus at the cell surface only is in italics. The data in regular font refers to cell 
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Total	  (or	  sum)	   	  	   3003	   	  	   86	  
Proportion	  (%)	   	  	   97.2	   	  	   2.8	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5.2.4.5 Morphometric analysis of MDM infected with HIV R3A PTAP−YP− 
The analysis of number of virus profiles on EM cell profile images revealed that 97% of 
the budding-arrested virions were found at the IPMC. Because a lot of membrane is 
folded up in the IPMCs, virus may simply be budding at the most abundant membrane 
surface. Therefore, I wanted to estimate the area of membrane at the cell surface or in 
the IPMCs on cells with budding arrested particles. Relative membranes areas were 
measured on EM images using standard stereological methods (West, 2012).  
 
Segmentation of the plasma membrane at the IPMC and cell surface was performed on 
highly magnified EM images (23,000x or 30,000x), by manually tracing the relevant 
compartments (Figure 5.19-5.21). Straight lines, 1-cm apart, were then superimposed on 
the images. Points were counted where the lines intercepted the segmentation lines 
(Figures 5.19).  Using the number of intercepts, the surface areas covered by the 
membranes were estimated using the mathematical relationship below (Figure 5.18).  
 
 
Figure 5.16: Morphometric analysis of biological samples or objects. 
Diagram showing the mathematical relationships between 3D structural features of objects (left) 
and the interaction of the line probe/interceptor with features of the object apparent in section. 
 
For these estimates, the cells with complete membranes covering both the cell surface 
and IPMC were chosen. These profiles were analysed using the above stereology 
procedure, to estimate membrane surface areas, at the IPMC and cell surface in arbitrary 
units (A.U.) (Table 5.3). The data shows that Cell 16 had similar amounts of membrane 
area at the IPMC and cell surface. The cell surface area of Cell 19 was about 28-fold 
more than that of the IPMC, whilst cell 21 had about twice the amount of membrane at 
the cell surface than at the IPMC. The ratios of virus profiles to membranes were 
calculated and are presented in Table 5.3. The results indicate that targeting of the virus 
to any particular site did not depend on the amount of membrane present at either the 
IPMC or cell surface, as all the virus was predominantly at the IPMC for the three 
profiles analysed.  VV. One stipulates that the relationships hold “on average,” because this may not be so for any one
sample, but will approach the true value as the amount of sampling is increased.
These relationship equations are not recent developments. The proof of the relationship VV = AA
was described more than 150 years ago (Delesse 1847). The VV = LL relationship was ﬁrst described
more than 100 years ago (Rosiwal 1898), and the VV = PP relationship is more than 80 years old
(Thomson 1930).
Mathematical relationships also exist between speciﬁc probes and the other structural parameters
(Fig. 4). As indicated in the second line of Figure 4, surfaces appear as lines in sections. The interaction
between line probes and the linear representation of the surface in the section results in intercepts, I.
There is a well-deﬁned relationship between the number of intercepts, per length of probe, and the
amount of surface per volume sampled. Two times the number of intercepts, per length of probe, 2IL,
is, on average, the surface area per unit volume, SV (Smith and Guttman 1953; Baddeley et al. 1986). It
is also possible to use the ratio of the length of the border of the sectional proﬁle of a 3D surface feature
B (border) to the area of the section sampled A to estimate the surface per unit volume, SV, that is, SV
= 4/pi × BA. Note that it is not possible to use point probes to measure linear features (Fig. 4, line 3).
Points do not interact with lines, because neither mathematical lines nor points have width. The
chance that a point falls onto a line is therefore inﬁnitely small.
As pointed out above, length and surface area are direction-sensitive parameters. As a result, this
relationship is only valid if one ensures an isotropic interaction between probe and feature. Because
one wants to avoid making any assumptions regarding the orientation of linear features (to avoid
biases in the estimate), onemust either cut the tissue or orient the probes in amanner that ensures that
this happens.
The third cardinal structural feature, length, can only be analyzed with area probes (Fig. 4, line 3).
Linear features appear on sections as cross sections or points that have no dimensions. As a conse-
quence, linear features interact with neither point nor line probes. Although the derivation of the
relationship between intercepts per unit area of sections QA and length per volume LV is somewhat
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FIGURE 4. Diagram showing the mathematical rela-
tionships between 3D structural features of objects
(left column) and the interaction of probes of various
dimensions, with features of the object apparent in
sections. (Lower right) A table showing the dimensions
of the probes that can be related to structural param-
eters of varying dimensions: (V ) Volume, (A) area, (L)
length, (P) points, (S) surface, (B) boundary, (I ) inter-
cepts, (Q) cross sections, (N ) number. (Redrawn from
West 1993.)
846 Cite this article as Cold Spring Harb Protoc; 2012; doi:10.1101/pdb.top070623
M.J. West
 Cold Spring Harbor Laboratory Press
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Figure 5.17: 2D Stereology for cell No. 16 in Table 5.2.  
High-magnification images (DON319-DON321) of the cell were aligned to assemble the entire cell 
profile. The montage was printed on A3 paper and segmented manually using pens with different 
colours for the IPMC and cell surface. Points of interception of the straight line probes and 
segmentation lines (red and blue) were counted and scored as shown on the right side of the image.  
(Note that this is the same cell shown in Figure 5.12) 




Figure 5.18: Segmentation of cell No. 19 in Table 5.2.  
(A) An alignment of multiple high-magnification images, to assemble the cell profile. (B) The 
segmentation of plasma membrane (red) and IPMC (blue), here done by adding brush lines in 
Photoshop CS.  




Figure 5.19: Segmentation of cell No. 21 in Table 5.2.  
(A) An alignment of multiple high-magnification images, to assemble the cell profile. (B) The 
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Table 5.3: Estimations of virus relative to membranes at the IPMC and cell surface.  





	  	   Cell	  profiles	  
	   	   No.	  16	   	  	   No.	  19	   	  	   No.	  21	  
IPMC	  
	   SV	  (A.U.)	   	   306	   	   30	   	   404	  
	   Virus	  profiles	   	   281	   	   62	   	   255	  
	   Profiles/SV	   	   0.918	   	   2.067	   	   0.631	  
Cell	  surface	  
	   SV	  (A.U.)	   	   320	   	   828	   	   754	  
	   Virus	  profiles	   	   3	   	   1	   	   0	  
	  	   Profiles/SV	   	  	   0.009	   	  	   0.001	   	  	   0.000	  
 
In conclusion, my analysis of IF data for the HIV-1 R3A mutant revealed that more than 
90% of Gag labelling was found at the IPMCs. Then when individual viruses were 
identified and counted at higher resolution using EM, 97% of the viruses were in the 
IPMCs. If the virus was budding at the cell surface and later phagocytosed, as suggested 
by some reports (Jouvenet et al., 2006; Bennett et al., 2009; Chu et al., 2012a), then I 
would not have found barely 3% of arrested viruses at the cell surface. Estimations of 
the amount of membrane at the IPMC and cell surface in infected cells showed that the 
virus was enriched in IPMCs, suggesting specific targeting.  Taken together, these data 
provide the first conclusive evidence that the IPMC is the principal site for HIV-1 
assembly in primary human macrophages.  
 
 Discussion 5.3
Since it was discovered that in primary human macrophages HIV-1 accumulates in 
intracellular compartments (Gartner et al., 1986), understanding the nature of these 
structures has been growing over the years, with the current view being that they are 
internally sequestered plasma membrane domains. Different names all referring to the 
same structures have been used in the literature: for example, the internal plasma 
membrane-connected compartments (IPMCs) (Pelchen-Matthews et al., 2012; 
Mlcochova et al., 2013; Giese and Marsh, 2014) and virus containing compartments 
(VCC) (Chu et al., 2012b; Gaudin et al., 2013a; Duncan et al., 2014; Mariani et al., 
2014). As the former name suggests, connections of these compartments to the cell 
surfaces have been observed (Deneka et al., 2007; Bennett et al., 2009; Welsch et al., 
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2011; Pelchen-Matthews et al., 2012). These compartments have also been seen in 
uninfected macrophages, and clearly are not formed/induced as a consequence of 
infection (Welsch et al., 2011; Pelchen-Matthews et al., 2012; Berre et al., 2013; Giese 
and Marsh, 2014). Therefore, we have opted to call them IPMCs. Although HIV-1 
accumulates in IPMCs and budding viruses have been found on the limiting membranes 
of IPMCs, it is still controversial whether IPMCs are the main site for HIV-1 assembly 
in primary human macrophages (Jouvenet et al., 2006; Chu et al., 2012a). Since HIV-1 
recruits the ESCRT machinery to mediate scission of the membrane stalk that links new 
virions to their producer cell, HIV-1 mutants defective in ESCRT recruitment were 
generated to inhibit membrane fission. Rescued mutants were used to infect MDM, and 
analysed by IF and EM. Quantitation of IF data showed that, on average more than 90% 
of the viral antigens were located in the IPMCs of infected cells. Furthermore, EM was 
used to directly identify and analyse the distribution of individual virus particles, and 
estimate the amount of membrane at each cell surface and IPMC. The data revealed the 
enrichment of virus in the IPMCs.  
 
The IPMCs where HIV-1 assembles in macrophages vary in size and morphology. For 
IF analysis, immuno-staining of MDM with the plasma membrane marker CD44 was 
used to identify the cell surface and IPMC. The CD44-containing membrane structures 
were variable from cell-to-cell, ranging from simple to very complex (Figures 5.1 and 
5.3), consistent with recent reports (Berre et al., 2013; Mlcochova et al., 2013). 
Although in some cases the compartments would appear as individual structures in a 
single confocal section, in the majority of cases these were inter-connected when whole 
cells imaged in z-series were reconstructed into 3D images.  This agrees with similar 
reconstructions of 3D EM image series (Bennett et al., 2009; Welsch et al., 2011). By 
immunofluorescence staining for the HIV-1 structural proteins, Gag p24/55 and p17, 
the virus was found mostly in these diverse and complex IPMCs. Notably, for MDMs 
infected with HIV-1 WT or the PTAP− or PTAP−YP− mutants, virus staining was 
observed mainly in the IPMCs. 
 
Analysis of infection levels by IF showed there were fewer macrophages infected with 
the mutants, and Gag was poorly expressed in the infected cells, compared to the WT 
(Figures 5.1 and 5.8). There was some donor-to-donor variation in infection levels, as 
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reported before (Bol et al., 2009). For the HIV-1 R3A WT, infectious particles are 
released from the infected MDM, allowing a spreading infection in the cultures, while 
the budding-arrested mutants are not able to establish a spreading infection. This 
probably explains why infection levels were low for the mutants, even though higher 
titres were used to infect the MDM. Moreover, earlier reports had suggested that 
mutations in the L domain of HIV-1 reduces the replication kinetics of VSV-G 
pseudotyped viruses used to infect different cell lines and primary cells including MDM 
(Demirov et al., 2002b; Fujii et al., 2009). In these studies, the kinetics of the L domain 
mutants were determined by monitoring reverse transcriptase (RT) activity. In most 
cases, the RT activity of the mutants began to rise above baseline on the sixth day post 
infection. Therefore, these published observations may explain the low expression 
levels of mutants in the current study. Because the L domain mutations do not overlap 
with the open reading frame of RT, it is not clear how they would influence RT activity.  
Quantitation of the IF data revealed that HIV-1 was mainly found at the IPMC (Figure 
5.3). Overall, in 66% and 77% of cells expressing HIV-1 R3A WT or the mutants, 
respectively, HIV staining was seen at the IPMC only. For cells with virus at both the 
IPMC and cell surface, more that 90% of virus fluorescence was associated with 
IPMCs. However, one limitation with quantifying virus fluorescence is the low 
resolution of confocal microscopy, which made it difficult or even impossible in some 
cases to separate the IPMC from the cell surface when the two membrane domains were 
in close proximity.  
 
There is currently no specific marker for the IPMC. Therefore, fluorescence studies of 
the IPMC have relied on markers that recognise both IPMCs and the cell surface, such 
as CD9, CD81 and CD44 (Deneka et al., 2007; Welsch et al., 2007). Furthermore, using 
CD44 as a surrogate marker for the IPMC and cell surface PM in quantitative IF is not 
always reliable as the staining for this molecule at IPMCs can be reduced in cells 
containing a large amount of virus, presumably due to its incorporation into virions 
(Lawn and Butera, 2000; Lawn et al., 2000; Chertova et al., 2006). EM was used in 
order to identify individual viruses and quantify membranes. Immature viruses were 
observed primarily at the IPMC of infected macrophages expressing HIV-1 PTAP− and 
PTAP−YP− mutants (Figure 5.12 and 5.15; Table 5.2). The appearance of these buds 
was very similar to that of the few immature buds in MDM infected with HIV-1 WT 
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(Figure 5.11). They typically contained an electron-dense layer of Gag beneath the 
membrane and an electron-lucent centre, consistent with the reported morphologies of 
the budding arrested HIV particles (Garrus et al., 2001; von Schwedler et al., 2003). 
More than 95% of viruses counted were in the IPMCs with diverse morphologies and 
sizes. The type of morphologies observed included IPMCs that were loose or compact, 
some more vacuole-like and others sponge-like, as described before (Deneka et al., 
2007; Welsch et al., 2011; Pelchen-Matthews et al., 2012). The predominance of buds 
in the IPMCs may simply be due to the large amount of membrane in these structures. 
Therefore, 2D stereology was used to determine the number of buds per unit membrane 
for particles at the IPMC or at the cell surface.  This showed that the amount of 
membrane in the IPMCs is not very much greater than that at the cell surface (Table 
5.3). For example, for cell profile 16 there was a similar amount of membrane at both 
the IPMC and cell surface, giving an enrichment of virus buds in the IPMC of over 
100x, while virus targeting to the IPMCs was even greater for the other two cells 
analysed. This clearly defines this site as the target for HIV assembly in macrophages, 
in support of earlier reports (Deneka et al., 2007; Welsch et al., 2007). Furthermore, a 
recent study using live-cell imaging has shown HIV-1 Gag fluorescence accumulation 
in the IPMCs of infected macrophages (Berre et al., 2013), suggesting assembly is 
initially targeted to the IPMCs. Collectively, the live-cell imaging study and the current 
study, provide convincing evidence that IPMCs are indeed directly targeted for HIV 
assembly in macrophages.  
 
In this chapter, I have shown systematically, using various morphological techniques 
and quantitative analysis, that the IPMC is indeed the main plasma membrane domain 
for HIV-1 assembly in macrophages. This suggests that Gag is specifically targeted to 
IPMCs in macrophages. The mechanism of this targeting is not clear.  A study from our 
group showed that the pleckstrin homology domain of phospholipase Cδ fused to GFP, 
which specifically binds PI(4,5)P2, was targeted to both the IPMC and cell surface 
plasma membranes (Mlcochova et al., 2013). This suggested that PI(4,5)P2, which is 
important for targeting myristoylated Gag to the plasma membrane (Ono et al., 2004; 
Saad et al., 2006a), may be equally abundant at both the IPMC and cell surface 
membranes. Therefore, there are possibly other aspects of the membrane composition 
that influence HIV assembly at the IPMCs in macrophages. In vitro model studies using 
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liposomes have shown that increase in cholesterol content increases binding efficiency 
of Gag (Dick et al., 2012). Similarly, increasing the concentration of phosphatidylserine 
(PS) increases the binding of Gag to the liposome. In addition, HIV-1 MA could also 
bind, directly to liposomes made up of phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) with varying lengths of acyl chains, independently of 
myristoylation (Vlach and Saad, 2013). These are interesting studies that should be 
extended to intact cells to try and understand if there are differences in the composition 
of the membrane domains of macrophages where HIV-1 assembles. 
 
In conclusion, I have taken advantage of the cellular ESCRT machinery that HIV 
recruits to bud from cells, and disrupted its engagement with the virus. This allowed for 
the infection of MDMs and generation of stable HIV-1 budding intermediates. By 
analysing the distribution of these arrested assembly intermediates, the IPMC was 
identified as the principal site for HIV assembly in macrophages. Because macrophages 
are found in all body tissues, and they are long-lived, they represent an important viral 
reservoir that may impact on HIV-1 pathogenesis. The virus in the IPMC is concealed 
from immune surveillance, and can be transferred to uninfected cells through cell-to-
cell contacts (Giese and Marsh, 2014).  With a better understanding of HIV-1 assembly 
in the IPMCs of macrophages, efforts can be made to therapeutically target this viral 
niche, to further reduce the HIV/AIDS disease burden.  
 
“… i f  i t wasn't for those f i rst few fa i lures, the future successes would never 
have happened.”  
R ichard Branson, Founder of Virg in Group. 
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6. General Discussion 
Macrophages are amongst the key immune cells that HIV infects in vivo and in vitro. 
Numerous studies have demonstrated that HIV assembles and accumulates in internal 
compartments of primary human monocyte-derived macrophages cultured in vitro. 
Initially, the nature of this compartment was unclear, but now there is compelling 
evidence from different research groups that these structures are internal plasma 
membrane-connected compartments (IPMCs), and that they are not induced by HIV 
infection (see Introduction, Section 1.6.3) 
 
Although the majority of HIV seen in infected macrophages is associated with IPMCs, 
there has been concern that some virus particles may assemble at the cell surface. To 
address this question, I set out to establish an experimental system to determine whether 
HIV does assemble at the surface of infected cells and, if so, what proportion. As the 
ESCRT machinery is required for HIV budding in many cell systems, I disrupted the 
recruitment of this machinery, and first investigated its requirement for virus release in 
macrophages, since this has not been studied to any great extent in these cells. Using 
siRNA, ALIX and Tsg101 were depleted efficiently. Although the effects on virus 
release were minimal, Tsg101 had a greater effect than ALIX for HIV release in MDM. 
In the second approach I generated mutants (HIV-1 PTAP−, YP−, PTAP−YP−, Δp6) 
defective in recruiting the ESCRT machinery by mutating the sequences that bind 
Tsg101 and ALIX. The mutants were characterised in HEK 293T cells, and the release 
of PTAP−, PTAP−YP− and Δp6 was inhibited. EM analysis showed that the mutants 
produced arrested budding profiles. As the mutants are defective in release, I developed 
a method to rescue HIV-1 PTAP− and PTAP−YP− viruses for infecting MDM. I infected 
MDM with the rescued mutants and used IF and EM to analyse the specimens. In the 
vast majority of cells (77%), the virus was found at the IPMCs. Analysis by EM showed 
immature viruses predominantly (97%) in the IPMCs. Using morphometric analysis to 
estimate the area of PM at the cell surface and IPMC, I discovered that HIV was 
enriched in the IPMCs, suggesting specific targeting of viral components to the IPMC 
membrane. This thesis therefore provides the first conclusive quantitative evidence that 
the IPMCs are the main sites for HIV assembly in primary MDM. The implications of 
these findings for HIV pathogenesis and future directions are discussed below.  
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 The ESCRT machinery is required for HIV assembly in 6.1
primary macrophages 
The ESCRT machinery mediates topologically equivalent membrane fission processes, 
such as HIV release, abscission and MVB intralumenal vesicles formation (see General 
introduction, Section 1.5.5). I investigated the requirement of the ESCRT machinery for 
HIV assembly in macrophages. Specifically, Tsgl01 and ALIX were efficiently depleted 
in infected MDM using siRNA. However, I observed limited effects on virus release 
(Figure 3.1 to 3.3). Two recent studies reported efficient inhibition of virus release in 
macrophages depleted of Tsg101 (Gaudin et al., 2012; Berre et al., 2013). In these 
studies, VSV G-pseudotyped HIV was used to infect macrophages to achieve almost 
100% infection, whilst I used a replication-competent macrophage-tropic virus strain, 
HIV-1 BaL, to infect MDM. The level of infection achieved in the two studies cited 
above is difficult to achieve when emulating physiological conditions, which involve 
HIV-1 gp120 binding to CD4 and CCR5/CXCR4 on target cells (see General 
introduction, Section 1.4.1), and certainly CD4 levels are lower on MDMs. It is possible 
that cells that were infected in this thesis escaped siRNA transfection. Macrophages are 
more restrictive to productive HIV replication than T cells, and the restriction can occur 
at different stages of replication. Recently identified restriction factors in macrophages 
include SAMHD1, which depletes the dNTP pool required for reverse transcription 
(Laguette et al., 2011); and interferon-inducible protein 16 (IFI16) that senses and binds 
pathogen DNA, to stimulate innate immunity through the stimulator of interferon genes 
(STING) pathway (Jakobsen et al., 2013; Bhat and Fitzgerald, 2014). Therefore, I 
speculate that when macrophages are infected with VSV G-pseudotyped HIV, more 
virus particles will be taken up and the virus DNA generated may overwhelm the DNA 
sensing machinery, and therefore escape innate immunity. This may partially explain 
why Berre et al. (2013) and Gaudin et al. (2012) observed efficient virus inhibition 
when I did not. However, I chose not to use VSV-G pseudotyped viruses to avoid 
possible artefacts generated by infection through non-gp120/41 mediated entry. 
 
Whilst optimising knockdown protocols, I found that Tsgl01 was depleted to lower 
levels on day 6 compared to day 3 after siRNA transfections (see Materials and 
Methods, Section 2.5). Therefore, I infected MDM and transfected them with siRNA 
oligonucleotides 24 hrs later. Cultures were incubated for 6 days after the siRNA 
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transfections (that is 7 days post-infection [dpi]), and then harvested for biochemical 
analysis. By contrast, Berre et al. (2013) and Gaudin et al. (2012) transfected MDM 
with siRNA oligonucleotides 8 hrs after infection. Their cultures were incubated 4 dpi, 
and then harvested for biochemical analysis (Gaudin et al., 2012). It is possible that 
Gaudin and colleagues (2012) used macrophages with less developed IPMCs. However, 
for their morphological experiments, where visualising the IPMCs was important, they 
harvested their cultures 7 dpi. IPMCs become more prominent as macrophages mature 
in tissue culture, as determined by following CD18 and CD44 expression (Pelchen-
Matthews et al., 2012). Therefore, it is possible that in my experiments, the virus was 
able to accumulate in the developed IPMCs before the level of Tsg101 and ALIX were 
sufficiently low to inhibit budding. Although RNAi experiments had a limited effect on 
virus release, overall, Tsg101 had a greater effect than ALIX for virus release in 
macrophages, as in other cell types reported elsewhere (Garrus et al., 2001; Pornillos et 
al., 2003; Fujii et al., 2009).  
 
To avoid the problems of balancing siRNA knockdown with infection, I generated HIV-
1 R3A mutants defective in recruiting Tsg101 and ALIX, which were expressed in 
MDM and analysed by western blotting (Figure 3.13). The inhibition of virus release 
from MDM expressing HIV-1 R3A PTAP− and Δp6 was greater than that of YP−, 
further demonstrating that Tsg101 is more important than ALIX for virus release in 
MDM.  
 
I also looked in detail at the morphologies of the PTAP−, PTAP−YP− and Δp6 mutants 
in HEK 293T cells using EM. On average PTAP− and PTAP−YP− exhibited half 
complete budding profiles (representing an early stage during assembly), whilst the Δp6 
profiles were typically three-quarters complete (late stage during assembly) (Figure 
4.5). The commonalities between these viruses are that (1) PTAP−YP− and PTAP− have 
a full-length Gag polyprotein, and (2) PTAP−YP− and Δp6 cannot recruit the ESCRT 
machinery. These data suggest that the p6 subdomain may be involved in regulating 
HIV assembly. Furthermore, I co-transfected HEK 293T cells with dominant negative 
(DN) GFP-VPS4 EQ and HIV-1 R3A WT, and used correlative light and electron 
microscopy (CLEM) to examine the cells. The virus profiles were on average shallower 
than those for the PTAP− and PTAP−YP− (Appendix, Figure 8.2), suggesting arrest at a 
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much earlier stage during assembly. This is in contrast to a previous report showing that 
DN VPS4 arrested viruses on HEK 293T cells at a later stage during assembly (von 
Schwedler et al., 2003).  
 
Recently, two independent studies have suggested that VPS4 may be involved early in 
membrane fission processes, such as HIV assembly and MVB biogenesis (Adell et al., 
2014; Cashikar et al., 2014). Cashikar and co-workers used siRNA to deplete VPS4 in 
HeLa cells, and the cells were unroofed to analyse the cytoplasmic surface of the 
plasma membrane using EM (Cashikar et al., 2014). Conical spirals that labelled with 
ESCRT-III antibodies were observed. These studies were extended to study HIV VLP 
assembly in HEK 293T cells by knocking down VPS4 in Gag transfected cells, and the 
researchers observed shallow Gag shells with fewer ESCRT-III filaments, compared to 
the deep exvaginations of Gag shell with tight spirals of ESCRT-III filaments in control 
cells. These data suggest similarity to my observations of shallow HIV-1 budding 
profiles when DN VPS4 was expressed. What makes these two independent 
observations interesting is the fact that Cashikar et al. (2014) depleted VPS4, whilst I 
overexpressed a dominant negative form of VPS4, but we have similar observations, 
suggesting an earlier involvement of ESCT-III and VPS4 in membrane remodelling.  
Other reports have shown that that VPS4 is recruited late and transiently during HIV 
assembly (Jouvenet et al., 2011; Bleck et al., 2014). It is possible that VPS4 has dual 
roles in HIV budding, similar to the dual role of dynamin in the formation of clathrin-
coated vesicles (Mettlen et al., 2009; Grove et al., 2014).  Furthermore, when Cashikar 
and co-workers used a GagΔp6 in their studies, they did not observe ESCRT-III 
filaments. However, they have not commented on the extent of exvagination for the Gag 
assemblies. The study also lacks quantitative characterisation of the observed structures, 
such as estimating the diameters of the VLP structures, which would have been more 
informative for comparisons.  
 
Reconciling these two VPS4 studies [Cashikar et al. (2014) and my observations] with 
the data on mutants is not easy because neither the PTAP−YP− nor the Δp6 recruit 
ESCRT components, but they have different degrees of bud completeness, suggesting 
that the p6 subdomain itself may modulate HIV assembly. The p6 subdomain might 
recruit additional cellular factors that influence assembly, thus giving different 
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phenotypes for full length Gag and GagΔp6. Maybe VPS4 is needed to remove these 
components for ESCRT binding, hence flatter profiles were seen with DN VPS4 or 
siRNA VPS4.  
  
The ESCRT machinery is involved in vital membrane fission processes such as 
cytokinesis, plasma membrane repair, receptor recycling to modulate signalling, and 
microvesicle release into immunological synapses (see General introduction, Section 
1.5.5). Enveloped viruses such as HIV have evolved to hijack this key cellular 
machinery whose components cannot be therapeutically targeted directly as that would 
be detrimental to cells. It seems that ESCRT machinery components are not viable drug 
targets, leaving the viral components as attractive targets. This has been tried before, 
where a cyclic peptide targeting Gag-Tsg101 inhibited VLP release without adverse 
effects on the cells (Tavassoli et al., 2008), although the mechanism is not clear. I 
obtained the cyclic-peptide and was unable to reproduce the data, and to the best of my 
knowledge there is no publication that repeated the work published in 2008.   
 
 HIV is targeted to IPMCs in primary macrophages 6.2
Several reports have shown that in macrophages, HIV-1 predominantly assembles in 
IPMCs. To investigate HIV assembly in macrophages, I infected MDM from eight 
blood donors with rescued release-defective HIV (PTAP− and PTAP−YP− mutants) and 
analysed the distribution of the mutants by IF (Figure 5.2 and 5.3). In the majority of 
cells (77%), Gag staining was found in the IPMCs only. In situations where the virus 
was found at the IPMCs and cell surface, more than 90% of the staining was at the 
IPMCs, which is highly significant. Furthermore, 29 cell profiles were examined using 
EM, to directly identify and count individual budding profiles, and a very significant 
number of immature viruses (97%) were found in the IPMC. These data strongly 
suggest that IPMCs are the main sites for HIV assembly, consistent with published 
work from our group and others (see General introduction, Section 1.6.2). However, as 
the notion of virus assembly in internal compartments was evolving, there was a 
proposal that HIV initially assembles at the cell surface and some of it is internalised by 
endocytosis or phagocytosis (Jouvenet et al., 2006). In their study, Jouvenet and 
colleagues transfected 7-day old cultures post monocyte isolation with GagGFP, and 
analysed expression after 24 hrs. Since IPMCs develop as macrophages mature in tissue 
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culture (Pelchen-Matthews et al., 2012), it is not surprising that GagGFP was found at 
the cell surface of these young macrophages. In this thesis, I have found that when HIV-
expressing macrophages do not have IPMCs, the virus assembles at the cell surface. 
Furthermore, where I performed transfections (electroporation) of macrophages with 
HIV, but on 14- not 7-day old cultures (post monocyte isolation), the distributions of the 
virus in transfected cells was very similar to that in infected cells (Figure 5.2), showing 
that the IPMCs are indeed the main site for HIV assembly in macrophages.  
 
It is currently not clear how IPMCs are formed. However, a recent study has suggested 
that in macrophages the viral restriction factor, tetherin, is involved in the formation of 
IPMCs (Chu et al., 2012a). In their investigations, Chu and colleagues (2012a) found 
tetherin localised to the IPMCs and trans-Golgi network, but not at the cell surface. 
However, our group found tetherin at the cell surface, trans-Golgi network, as well as 
IPMCs, without any apparent enrichment (Giese and Marsh, 2014). Giese and Marsh 
state that tetherin antibodies have reduced binding to aldehyde-fixed cells, thus they 
labelled live cells on ice before fixation. Chu et al. labelled fixed cells, and this might 
explain the different staining patterns observed in the two studies, and therefore the data 
interpretation. The study by Giese and Marsh is consistent with the previous reports that 
HIV does not induce IPMC formation (Welsch et al., 2011; Pelchen-Matthews et al., 
2012; Berre et al., 2013; Mlcochova et al., 2013), and my data affirm earlier findings 
that the IPMCs are the principal target sites for HIV assembly.  
 
In this study, I have also shown enrichment of virus at the IPMCs by estimating the area 
of plasma membrane at the IPMCs and cell surface. The assembly of HIV at the IPMCs 
was independent of the amount of membrane at this site, suggesting specific targeting 
and enrichment of the virus to the IPMCs. It is not clear what viral or host factors 
determine this enrichment. It is possible that the lipid content of the membranes plays a 
role. As discussed in Chapter 5, studies with in vitro liposome models suggest that 
different compositions of lipids, other than PI(4,5)P2, may influence Gag targeting.  
 
 Functions of the IPMCs 6.3
IPMCs are heterogeneous and dynamic structures that can have one or several 
connections to the cell surface (Mlcochova et al., 2013). IPMCs can be very complex 
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with an array of membranes that are sponge-like or that form swirls (Figures 5.10 to 
5.15), consistent with previous reports (Deneka et al., 2007; Welsch et al., 2007; Welsch 
et al., 2011; Pelchen-Matthews et al., 2012). Morphologically similar compartments 
have been implicated in artherosclerosis, where macrophages take up aggregated low 
density lipoproteins (agLDL) into surface connected compartments (SCCs), and release 
lysosomal enzymes to digest the agLDL (Kruth et al., 1995; Zhang et al., 1997; Haka et 
al., 2009; Haka et al., 2013). To determine the connection of these compartments that 
sequester agLDL to the cell surface, ruthenium red was used to stain the cell. 
Interestingly, SCCs can be induced by the agLDL particles in culture medium (Kruth et 
al., 1995; Tan and Sattentau, 2013), but IPMCs are an intrinsic feature of mature 
primary MDM. Therefore, the relationship between these morphologically similar 
compartments is unclear.  
 
HIV-containing compartments, similar to the MDM’s IPMCs, have been seen in mature 
and immature DCs (Garcia et al., 2005; Garcia et al., 2008). Immature DCs are more 
efficiently infected by HIV than mature DCs (Shimauchi and Piguet, 2014). The virus-
containing compartments (VCCs) in DCs are connected to the cell surface, and enriched 
in tetraspanins the CD81, CD82 and CD9 (Garcia et al., 2005; Garcia et al., 2008), 
similar to the compartments in MDM. Whilst the infected immature DCs can transfer 
the viruses they produce, both the mature and immature DCs use the C-type lectin DC-
SIGN molecules on their cell surface to capture viruses and concentrate them in VCCs, 
from where they can be transferred through cell-to-cell contacts to target T cells in a 
process termed trans-infection (Shimauchi and Piguet, 2014).  The VCCs of DCs that 
have captured virions from the extracellular milieu (trans-infection) are devoid of the 
tetraspanin CD63, whilst DCs that are productively infected (cis-infection) have 
moderate levels of CD63 (Garcia et al., 2008). In MDM, CD63 accumulates in the 
IPMCs during virus assembly (Deneka et al., 2007), probably as it is incorporated into 
virus particles during assembly. 
 
Although IPMCs, and sequestered intracellular virus, have been observed in MDM 
maintained in tissue culture, it has remained unclear whether similar structures are 
present in macrophages in vivo. Intracellular HIV has been found in cells on lymph 
nodes and brain biopsies (Meyenhofer et al., 1987; Orenstein et al., 1988; Orenstein, 
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2007), suggesting that IPMCs may be present in vivo. Nevertheless, the nature of the 
cells and the compartment has not been unequivocally established. The existence of 
IPMCs in vivo has also been suggested by a recent study, where HIV was introduced 
into mice engrafted with human immune cells to investigate infection in the gut-
associated lymphoid tissue (Ladinsky et al., 2014). The study shows sporadic pictures 
of macrophages with pools of intracellular viruses identified and interpreted as IPMCs, 
similar to what has been observed in tissue cultures of primary human macrophages. 
Although the study did not use any cell markers to definitively characterise the 
identified cells and compartments, the findings are very important because they show 
similar compartments to what has been described in this thesis and elsewhere.  
 
The enrichment of HIV in the IPMCs as shown in this thesis (Figure 5.3) may offer the 
virus some reproductive advantages over cell surface assembly observed in T cells, such 
as efficient transfer through cell-to-cell contacts; concealing the virus from direct 
immune attack by neutralising antibodies, as the intricate structures of the IPMCs 
(Figures 5.10 to 5.15) can make it difficult for neutralising antibodies to access the 
IPMCs (Chu et al., 2012b; Koppensteiner et al., 2012a); limiting the exposure of viral 
structures on the macrophage surface, thereby protecting against virus-specific immune 
responses including CD8+ cytotoxic T-lymphocyte, and antibody-dependent cellular 
cytotoxicity (ADCC). 
 
In the current study, immature HIV profiles were found predominantly in IPMCs of 
infected macrophages, with a very small proportion (3%) at the cell surface. 
Concentrating HIV in the IPMCs may have effects on virus transfer to other cells in 
vivo. Virus transfer between cells occurs by two modes: cell-free virus or cell-to-cell 
transfer (Waki and Freed, 2010; Schiffner et al., 2013). Cell-to-cell transfer occurs 
through intimate contacts between donor and target cells, the so-called virological 
synapses (VS), where HIV appropriates some of the molecules (ICAM-1 and LAF-1) 
used by the antigen presentation machinery (see General introduction, Section 1.6.3). 
Infected macrophages can directly transfer HIV to CD4+ T cells in clusters (Giese and 
Marsh, 2014), and the transfer is inhibited by antibodies against gp120, ICAM-1 and 
LAF-1, the structural components of VS (Duncan et al., 2014). Using live-cell imaging, 
Duncan and colleagues provided direct evidence for transfer of GFP-tagged HIV-1 from 
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IPMCs of infected macrophages to T cells in co-cultures, and demonstrated that the 
macrophage-T cell contacts were transient, lasting 30-40 min. The transfer of HIV from 
macrophages to T cells is estimated to be 20- to 250-fold more efficient than cell-free 
transfer (Duncan et al., 2014). These in vitro studies show that IPMCs in macrophages 
may provide an efficient system of infecting other cells in vivo. It is also possible that 
the release of virions in the IPMCs is regulated, such that release of multiple particles 
coincides with the activation of T cells upon interaction with infected macrophages.  
 
It is not clear what stimulates the release of the HIV from IPMCs. Nonetheless, recent 
studies that examined how IPMCs are maintained provide some clues (Gaudin et al., 
2012; Pelchen-Matthews et al., 2012; Mlcochova et al., 2013). The three studies 
identified different components of the cytoskeleton that maintain the IPMCs. A study 
by our group suggested that focal adhesion complexes, often seen on closely apposed 
membranes adjacent to the plasma membrane, may regulate HIV release, as knocking 
down the β2 integrin CD18 disrupted IPMCs, making them smaller and more dispersed 
(Pelchen-Matthews et al., 2012). Another study showed that the kinesin KIF3A drives 
the transport of IPMCs on microtubules towards the cell surface, as depleting KIF3A 
reduced virus release from the MDM (Gaudin et al., 2012). The most recent 
investigation, also by our group, showed that disrupting the actin cytoskeleton causes 
dispersal of IPMCs, resulting in increased virus release (Mlcochova et al., 2013). It is 
likely that intra- and extra-cellular signals impacting on the cytoskeleton in 
macrophages may regulate virus release.   
 
 Future directions 6.4
It has emerged from my analysis of HIV budding profiles that, on average, the Δp6 
mutant buds were two-thirds complete, whilst the PTAP− and PTAP−YP− mutants were 
half complete virus shells. In addition to recruiting the ESCRT machinery for HIV 
assembly, it seems the p6 subdomain of Gag may also regulate HIV assembly in other 
ways, possibly by interacting with other host molecules(s), or even viral protein(s) such 
as Vpr that interact with the p6 subdomain. The role of p6 could be investigated by 
generating HIV-1 Δp6 mutant with a fluorescent tag, expressing it in cells, and then 
performing live-cell super-resolution microscopy to assess assembly dynamics of the 
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mutant, compared to HIV-1 WT. This may shed light on other potential role(s) for the 
p6 in HIV biogenesis. 
 
Studies demonstrating the existence of IPMCs in vivo are still lacking. In vivo, myeloid 
lineage cells are infected with HIV-1 at two stages of differentiation: (1) as monocytes 
in the blood; and (2) as mature macrophages in tissues. Only a small proportion of 
circulating monocytes (5%) is susceptible to HIV infection and can harbour the virus 
without productive replication. Since monocytes migrate to different tissues or anatomic 
sites including the brain, kidneys, lungs and the gut-associated lymphoid tissues 
(GALT), where they differentiate into macrophages, they can disseminate and establish 
HIV infection in different tissues. Monocytes can cross the blood-brain barrier, which 
explains how the brain is infected with HIV. Therefore, studies using animal models 
will be important in identifying infected macrophages in vivo, and identifying the 
presence or not of IPMCs. This would give medical merit to conceiving new therapeutic 
strategies targeting virus in IPMCs, such as the use of nanoparticles to deliver drugs to 
the IPMCs. Furthermore, antibodies against the scavenger receptor CD36, can block 
virus release by tethering viruses within IPMCs, and this has been proposed as a 
possible therapeutic strategy that could prevent virus release from IPMCs (Berre et al., 
2013). 
 
HIV-infected macrophages may play a role in kidney nephropathies such as focal 
segmental glomerulosclerosis (FSGS). FSGS involves injury to podocytes and scarring 
of the glomeruli, and these may have several causes including HIV infection (Kopp and 
Winkler, 2003). Macrophages are the main inflammatory cells in the kidneys (Duffield, 
2010), which may afford them the opportunity to promote nephropathies if infected 
with HIV. The pathology of HIV may alter the physiological functions of macrophages 
in many tissues including kidneys. There are reports suggesting that HIV-infected 
macrophages have impaired phagocytic function (Mazzolini et al., 2010; Jambo et al., 
2014). It is reasonable to speculate that the role of HIV infected macrophages in kidney 
diseases may be underestimated due to limited studies on this subject. Therefore, more 
studies are required in the context of macrophage involvement in FSGS.  
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The data presented in this study show enrichment of HIV at the IPMCs. It is not clear 
what host factors could be mediating this specific targeting to this plasma membrane 
compartment. One possibility is that the lipid composition of the membranes that can 
influence targeting (see Section 5.3 Discussion). Currently, marker(s) specific for the 
IPMC have not been identified. So more investigations need to be conducted into the 
properties of the IPMCs that influence targeting of HIV to this site. Laurdan, a 
fluorescent dye that detects changes in membrane phase properties, has been used to 
study the properties of host cell-derived membranes on HIV particles (Lorizate et al., 
2009), and the effect of HIV Nef on the properties of mouse macrophage cell lines (N7 
and RAW 264.7) (Cui et al., 2012). If used to label macrophages, this dye may yield 
some interesting data about the difference(s) between the IPMC and cell surface plasma 
membrane of MDM.  
 
Estimates from UNAIDS show a decline in the mortalities attributed to HIV/AIDS, and 
an increase in HIV prevalence (UNAIDS, November 2013). Currently, guidelines for 
HIV treatment indicate that individuals with CD4+ T cell count of ≤350 copies/mm3 or 
with AIDS defining illnesses should be put on therapy. However, treating individuals 
with established infection, when the virus has already spread to anatomic sites that 
cannot be reached/penetrated by ART, such as the brain, means it will be difficult to 
eradicate the virus in these areas. Furthermore, HIV-associated neurological disorders 
(HAND) will increase, as there is already some evidence that about half of adults living 
with HIV have varying degrees of HAND. This could become a new public health 
problem as more people now live with chronic HIV infection. This may call for a 
revision of UNAIDS/WHO guidelines on when to initiate therapy. Currently, there have 
been debates to adopt the “test-and-treat” strategy for mitigating HIV infections in high-
risk populations (Novitsky et al., 2010a; Kretzschmar et al., 2013). This would require 
regular testing of the high-risk populations, and putting them on ART if HIV infected, 
regardless of their CD4+ T cell status or clinical conditions. Macrophages and their 
potential impact on the epidemic are overlooked in rationalising this strategy. Starting 
treatment early may reduce the establishment of viral sanctuaries that are difficult to 
purge, such as in the brain, or at least delay the onset of HAND. Therefore, the “test-
and-treat” strategy may be appealing in the context of curbing HIV infections, 
especially of the brain. Although, expensive for most developing countries in Africa, 
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which unfortunately are the hardest hit by the HIV pandemic, this may seem like an 
alternative approach to evade conditions such as HAND and HIV-associated 
nephropathies, and could be done in parallel with searching for new and less toxic ARV 
drugs. The cost-effectiveness of all these approaches will have to be carefully evaluated 
to come up with comprehensive strategies/policies. 
 
In HIV infection and pathology, the role of macrophages has been largely 
overshadowed by the role played by T cells. Whilst T cells are highly permissive to 
HIV, they have a short lifespan compared to macrophages, due to their susceptibility to 
cytopathic effects of HIV. Although T cells may provide quantity hosts/substrates in 
term of reproductive rate, macrophages are quality hosts/substrates. Macrophages may 
compensate for their low virus reproductive rate by outliving T cells, archiving the virus 
in IPMCs, and making numerous contacts with uninfected T cells to inoculate them 
with virions released from IPMCs, hence fuelling infection in the host.  
 
Despite numerous reports supporting the notion of HIV on intracellular membranes in 
macrophages, there has been on-going debate as to whether IPMCs are the only, or even 
the main, site of HIV assembly (Chu et al., 2012a; Tan and Sattentau, 2013; Giese and 
Marsh, 2014). My thesis has provided the first conclusive data that the IPMCs are 
unequivocally the main site for HIV assembly in macrophages. Probably what is 
limiting the work on tissue macrophages is the invasive nature of acquiring samples 
(biopsies) from patients. Nevertheless, more investigations are required at the molecular 
level to better understand macrophages in tissues. Tissue macrophages such as alveolar 
macrophages can be obtained from HIV patients, and could well be included in clinical 
parameters used to monitor HAART. Currently, individuals on HAART have scheduled 
tests to evaluate blood viral load, CD4+ T cell counts to evaluate immune recovery, and 
blood chemistry to monitor drug toxicities. Although, blood viral load is routinely used 
to monitor HAART, it does not reflect the viral load (and virus diversity if sequenced) 
of different anatomical sites, where macrophages may have a major role to play in HIV 
pathogenesis. Therefore, it is important to also identify surrogate marker(s) for HIV 
pathology in macrophages, so that the effect of HAART can be assessed more closely. 
Efforts to eradicate HIV-1 would be fruitless without increased research quality and 
funding devoted to investigations on HIV-macrophage interactions. 






“…at the forefront of research there are so many diff icu lt ies that depress ion 
and low motivat ion are a constant danger . …s ince the pursu it of good sc ience 
was so dif f icu lt , i t was essent ia l that the problem being studied was an 
important one to just i fy the effort expended.”  
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 Analysis of GagBaL in different vector backgrounds 8.1
To test whether the lack of expression of the native GagBaL was due to the expression 
vector, I subcloned GagBaL from the pRK5 background into two alternative vectors, 
pcDNA3.1 and pcDNA3. The new constructs were tested in HEK 293T cells and 
analysed by WB. The pRK5GagBaL WT was used as a positive control for this 
experiment. Although the pRK5GagBaL was expressed efficiently, I could only see very 
weak bands of cell-associated GagBaL in pcDNA3.1 and pcDNA3; band intensities for 
the cell lysates were barely above background, even after over-exposure of the WB, and 
no bands were seen for the VLPs (Figure 7.1). Taken together, these data demonstrate 
that plasmid vector background does impact on the expression of native GagBaL, in 
addition to the AU content that makes Gag transcripts unstable.  
 
 
Figure 8.1: Biochemical analysis of GagBaL in different expression vectors.  
HEK 293T cells were transfected with the indicated GagBaL plasmids, harbouring either WT or 
mutant Gag sequences. Transfected cells were incubated 24 hrs, harvested by pelleting VLPs 
through sucrose cushions and lysing cells in sample buffer. VLPs and cell lysates were 
analysed by WB. Membranes were incubated with anti-p24/55 or the loading control, adaptin-γ. 
Gag band signals for pCDNA3.1Gag and pCDNA3Gag were barely above background, after 
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 Analysis of HIV-1 budding profiles in HEK 293T cells 8.2
 
 
Figure 8.2: Comparison of budding profiles on HEK 293T cells.  
The cells were transfected with the indicated HIV-1 R3A mutants or co-transfected with HIV-1 
R3A WT and VPS4 EQ expression vectors. The average angles of Gag incorporation are 
shown below the graph.  
 
The quantitative analysis of budding profiles for HIV-1 R3A mutants revealed that 
HIV-1 R3A PTAP−YP− and PTAP− had shallower profiles compared to HIV-1 R3A 
Δp6 (Figure 4.5). As the dominant negative VPS4 EQ has been reported to disrupt virus 
release and produce arrested budding viruses (Garrus et al., 2001; von Schwedler et al., 
2003), I wanted to examine the wild-type virus morphologies in the presence of VPS4 
EQ, and compare them to morphologies for mutant viruses. To this end, HIV-1 R3A 
WT was co-expressed with GFP-VPS4 EQ in HEK 293T cells growing on gridded 
cover slips. Cells expressing GFP-VPS4 were located using light microscopy, and cover 
slip coordinates for the cells were recorded, so the same cells could be found at the 
electron microscope, and be assessed for HIV expression. Cells with the virus were 
imaged, and the morphologies of HIV-1 budding profiles were analysed as shown in 
Materials and Methods, Figure 2.7. These preliminary data show that, on average, 
budding profiles generated when HIV-1 R3A WT is co-expressed with VPS4 EQ are 
shallower than those for the mutants (PTAP−YP−, PTAP−, Δp6) (Figure 7.2), suggesting 
that VPS4 may be involved early in the biogenesis of HIV particles. 




















n = 123 n = 75n = 58 n = 40
180.3 176.3 266.9 149.5Average (°):
Same as Figure 4.5
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 Analysis of virus distribution in MDM: videos for IF 8.3
data 
 
Table 8.1: A list of videos on the enclosed CD.  
The movies are on PowerPoint slides. 
Video  Reference figures 
in Chapter 5 
 Description 
1  5.1B  HIV-1 R3A WT virus in IPMC only 
2  5.1E  HIV-1 R3A PTAP−YP− virus in IPMC only 
3  5.2A  HIV-1 R3A WT virus in IPMC only 
4  5.2B  HIV-1 R3A PTAP−YP− virus in IPMC only 
5  5.2C  HIV-1 R3A PTAP−YP− virus on the cell surface 
6  5.2D  HIV-1 R3A PTAP−YP− virus at the cell surface and IPMC 
7-9  5.4  Using “3D Object Counter” to estimate fluorescence intensity 
 
 
 
